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INTRODUCTION AND OVERVIEW OF THIS THESIS 

Inroduction and overview 
Angiographic restenosis occurs in up to 60% of cases after balloon angioplasty (BA). 
Restenosis after BA occurs due to elastic recoil of the artery, vascular remodeling 
with vessel shrinkage and neointimal hyperplasia. Neointimal hyperplasia develops by 
migration and proliferation of smooth muscle cells (SMCs) and myofibroblasts after 
balloon-induced trauma of the arterial wall and by deposition of an extracellular matrix 
by the SMCs. By preventing elastic recoil and negative remodeling stent implantation 
has resolved many of the problems created by balloon angioplasty. However, a new 
problem has been created - that of in-stent restenosis, which is caused by neointimal 
hyperplasia. This entity occurs in 9-30% of cases after stent implantation. In the 
USA this equates to some 125,000 cases per year. Conventional treatment for in-stent 
restenosis (balloon angioplasty and debulking) has been unsuccessful with 50-80% of 
cases suffering from further restenosis. 
Alternative treatment modalities were clearly required. Since radiotherapy had proven 
to be effective in treating the exuberant fibroelasticity of keloid scar formation and 
other non-malignant process such as ocular pterygia, it was assumed that this adjunctive 
therapy may also inhibit coronary restenosis. 
Principles ofradiation 
In the process of radioactive decay or disintegration atomic nuclei change their 
configuration and energy content to reach a stable state. This process is usually 
associated with the emission of (J. or ~ radiation. Alpha particles are heavyweight 
charged particles that can travel very short distances within tissue. Beta particles are 
lightweight high-energy electrons with either a positive or negative charge. A third type 
of emission originates from the nucleus, known as y - emission or photon emission takes 
the form of electromagnetic radiation. An alternate way for an unstable nucleus to reach 
a stable state is to capture an electron orbiting just outside the nucleus. This process 
called electron capture makes the outer shell where the electrons are orbiting unstable. 
To fill the void of captured electrons other electrons from nearby orbits jump to the 
innermost orbit which leads to the emission of photons, called X-rays, which take the 
form of electromagnetic waves. Gamma and X-rays are high - energy photons without 
charge or mass. The only distinction between gamma and X-rays lies in their origins: 
y-rays are emitted by the nucleus whereas the X-rays emanate from electrons jumping 
to innermost orbits. Most often an unstable nucleus will emit an alpha or beta particle 
followed by y radiation. Only a few isotopes, for example 32p, emit only ~-particles, 
without y-radiation. 
The process of radioactive decay is a spontaneous random event. In a sample with a 
large number of atoms the decay follows exponential behaviour. The radioactivity of a 
sample is defined as the number of disintegrations per unit time. The units in which 
radioactivity has been conventionally measured are: 
13 
Radiation and the Stent 
1 bequerel (Bq)=disintegration per second 
1 curie (Ci)=3.7*101O Bq 
1 millicurie=3.7*IO' Bq 
As the nnclei of radioactive material disintegrate the number of nuclei available for 
decay decreases. The rate of decrease varies among radioisotopes. This value is unique 
to each isotope. This rate of decay follows the exponential formula: 
A(t)=A(0)e·o.693·1IT!l2 where A(O) is the known activity at time zero; A(t) is the activity 
remaining at time t and TII2 is the half-life. 
Tissue damage induced by radiation and effective dose. 
When radiation is absorbed in a tissue it can either cause direct damage to a critical 
target by ionization or it can indirectly damage a critical target by interacting with 
other molecules to produce free radicles, which will subsequently damage the critical 
target. Approximately 80% of the radiation damage is caused by these free radicles. 
The most critical target that could be damaged by radiation is DNA. The consequence 
of this is chromosomal damage, where the cell loses the ability to proliferate, which 
will ultimately lead to its death. This mode of cell death leads to a dose - response 
relationship where the fraction of cells surviving (S) is a linear-quadratic function of the 
dose (D): 
S = e""" - ~'D2 where a and ~ are constants that are a characteristic of a given cell type. 
At low doses the linear component dominates, but at higher doses (such as the single 
doses that are used in catheter - based radiation) the quadratic dominates. Theoretically 
a single acute dose of 12 to 20 Gy would result in a depopulation of SMCs of about 10.3 
to 10"". These surviving cells would need to double between 12 to 20 times to produce 
sufficient progeny to block the artery. Considering that SMCs are not malignant and 
therefore do not have the capacity to proliferate indefinitely, it may be that a dose of this 
magnitude will result in a permanent inhibition of restenosis. 
Target Tissue 
Experimental models have suggested that myofibroblasts in the adventitia proliferate 
after angioplasty and may migrate into the intima where they appear as smooth muscle 
actin-containing cells. The effect of radiation on myofibroblast proliferation in the 
adventitia as well as on vessel remodeling has been recently reported. Endovascular 
radiation after balloon overstretch injury of porcine arteries significantly reduced the 
number of proliferating cells in the adventitia and medial wall compared to controls at 
a dose of 14 to 28 Gy prescribed at 2 mm into the vessel wall. The 28Gy dose resulted 
in a much greater inhibition of cell proliferation in the adventitia compared to 14Gy. In 
the same study a significant reduction in the extent of adventitial a-actin staining was 
observed in the irradiated cells compared to controls. This suggests an inhibition of 
adventitial fibrosis by the irradiation treatment, leading to a significant increase in the 
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vessel perimeter (inhibition of constrictive vascular remodeling). These findings support 
the concept that the adventitia is the target tissue of iutracoronary radiotherapy. 
Radiation Therapy Systems 
Radiation therapy can be delivered to the coronary arteries by external beam radiation, 
by brachytberapy methods usiug catheter - based systems or by radiaoactive stents. This 
thesis focuses on the latter two modalities only. Catheter - based systems can use both 
~ or yemitters, which can deliver the prescribed dose at either a high or a low dose rate. 
Table: Isotopes currently used for intraluminal brachytherapy: 
Isotope Emission Maximum energy (MeV) Average energy (MeV) Half life 
192 Ir Gamma 0.6 0.37 74 days 
32 P Beta 1.7 0.60 14 days 
90 Sr Beta 0.5 0.20 28 years 
90Y Beta 2.3 0.90 64 hours 
188 Re Beta 2.2 0.79 17 hours 
l88W Beta 0.5 0.17 60 days 
Radioactive stents 
The radioactive stent was first conceptualized iu the late 1980s. Animal experiments 
followed iu the early and mid 1990s, demonstratiug efficacy iu the porciue and rabbit 
model at activities as low as 0.14f.lCi. Human trials followed. 
Radioactive stents utilize mainly ~-emitters at a low dose rate. Low-dose beta-particle 
radiation iuhibits smooth-muscle proliferation and migration through the stent struts. 
This process has been described as an 'electron beam fence' . 
The dosimetry of the 32p stent has been previously described. Janicki characterized 
the near field dose of a 1.0f.lCi 15mm length Palmaz -Schatz usiug a modification of 
the dose-poiut-kemel method. Modification of the dose-distribution around a uniform 
cyliuder of P32 to account for the geometry of a tubular slotted Palmaz - Schatz stent 
with mathematical modeliug allowed construction of 3-D dose maps. For a 1.0f.lCi 
15mm length 32p stent at a distance of O.lmm dose values of 2500cGy are delivered 
at the strut wires (peaks) and 800 cGy between the wires (valleys) over one half-life 
(14.3 days). The non-uniformity of dosiug reflective of the stent geometry decreases at 
distances of 1 - 2mm from the surface. The dosimetry predicted by the dose calculations 
correlated well with measured dose usiug photochromic film. While these data provide 
an iu-vitro analysis of dosiug from a radioactive stent the actual dose distribution will be 
affected by variations iu atherosclerotic plaque morphology and the symmetry of stent 
expansion. 
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This thesis evaluates the results of two modalities of intracoronary radiation: catheter -
based radiation and radioactive stenting. In part I important predictors of restenosis after 
conventional stenting are evaluated. Part II considers methodological issues important 
in the assessment oflesions that have undergone intracoronary radiation. These include 
relocation of the minimum lumen diameter and geographical miss. In Part III we 
discuss the evolution of radioactive stents through their initial human trials to later 
studies describing different stent configurations. Part IV explores aspects common to 
both radioactive stenting and catheter - based stenting and radiation. This includes 
a mechanistic approach to evaluating remodeling and restenosis using very powerful 
3-dimensional rvus technology. In part V we analyze the complications and interesting 
observations made during the application of this technology. 
Part I 
Important predictors of restenosis 
I 
I 
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Chapter 1 
Peri procedural quantitative coronary 
angiography after Palmaz-Schatz stent 
implantation predicts the restenosis rate at six 
months: results of a meta-analysis of the BElgian 
NEtherlands Stent study (BENESTENT) I, BENESTENT 
1\ Pilot, BENESTENT II and MUSIC trials. 
J Am Call Cordial. 79990ct;34(4):7067-74. 
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Periprocedural Qgantitative 
Coronary Angiography After 
Palrnaz-Schatz Stent Implantation 
Predicts the Restenosis Rate at Six Months 
Results of a Meta-analysis of the 
Belgian Netherlands Stent Study (BENESTENT) I, 
BENESTENT II Pilot, BENESTENT II and MUSIC Trials 
Patrick W. Serruys, MD, PHD, FACC, 1. Patrick Kay, ME, CHB, Clemens Disco, MSc,' 
Niteen V. Deshpande, MD, DM, DNB, Pim J. de Feyter, MD, PHD, FACC, on behalf of the 
BENESTENT I, BENESTENT II Pilot, BENESTENT II and MUSIC Study Groups 
Rotterdam, The Netherlands 
OBiECTlVES We aimed to identifY periprocedural quantitative coronary angiograpbic (QCA) variables that 
have predictive value on long~term angiogtapbic results and to construct multivariate models 
using these variables for postprocedural prognosis. 
BACKGROUND Coronary stent implantation has reduced the restenosis tate significandy as compared with 
balloon angioplasty in short de novo lesions in coronary arteries> 3 rom in size. Although the 
postprocedural rninimalluminal diameter (MLD) is known to have significant bearing on 
long-term angiograpbic results, no practically useful model exists for prediction of angio-
graphic outcome based on the penprocedural QCA variables. 
MErHODS The QCA data from patients who underwent Palmaz-Schatz stent implantation for short 
«15 mm) de novo lesions in coronary arteries >3 mm and completed six months of 
angiographic follow-up in the fuur prospective clinical trials (BENESTENT 1, BENE-
STENT n pilot, BENESTENT n and rvruSIC) were pooled. Multiple models were 
constructed using multivariate analysis. The Hosmer-Lemeshow goodness-of-fit test was 
used to identify the model ofbest fit, and this model was used to construct a reference chart 
for prediction of angiographic outcome on the basis of penprocedural QCA variables. 
RESULtS Univariate analysis performed using QCA variables revealed that vessel size, MLD before and 
after the procedure, reference area before and after the procedure, rninimalluminal cross-sectional 
area before and after the procedure, diameter stenosis after the procedure, area of plaque after the 
procedure and area stenosis after the procedure were significant predictors of angiographic 
outcome. Using multivariate analysis, the Hosmer-Lemeshow goodness-of-fit test showed. that 
the model containing percent diameter stenosis after the procedure and vessel size best fit the dam. 
A reference chart was then developed to calculate the expected restenosis rate. 
CONCLUSIONS Restenosis rate after stent implantation for short lesions can be predicted using the variables 
percent diameter stenosis after the procedure and vessel size. This meta-analysis indicates that 
the concept of "the bigger the better" holds true for coronaI)' stent implantation. Applicability 
of the model beyond short lesions should be tested. (J Am Coll Cardiol1999;34:1067-74) © 
1999 by the American College of Cardiology 
Introduction of coronary stenting into the armamentarium 
of intervenrional cardiology marks a distinct milestone in 
the history of coronary angioplasty. Although first concep-
From the Department of Intaventional C:trdioiogy, Tho=ta, Academisch 
Ziekenhuis, Rcttetd:un, ruld 'C:u:dialysis, Rotterd=, The Nethetlands. Dr. Kay ill 
rupported by the National Heart Foundntion of New Zealand. The rutisticl support 
provided by Clemens Disco w:u; ma,dc possible through a grant supplied by Cordis 
Eutopa NY, The Netherland ... 
:Manuscript rcccivedAugw.'t 18, 1998; m>ised =uscript received Apri122,1999, 
accepted June 10, 1999. 
tualized by Charles Dotter in 1964 (1), it became a reality 
when Jacques Puel (2), followed shordy by Ulrich Sigwart 
(3), perfonned the first human implantations in 1986. The 
initial multicenter study by Schatz et al. (4) demonstrated 
the safety and efficacy of the implantation of the Palmaz-
Schatz (P-S) coronary stent. This was soon followed by two 
randomized trials: BElgian NEtherlands STENT study 
(BENESTENT I) (5) and ST ent REStenosis Study 
(STRESS) (6) that compared the P-S stent with balloon 
ang;oplasty. Since the landmark BENESTENT I trial we 
21 
Chapter 7 
Abbreviations and Acronyms 
AVID ::: Angiography Versus Intr:lVasculnr 
Ultr:lSound Directed Coronary Stent 
Placement 
BENESTENT ::: BElgian NEtherlands STENT study 
CAAS IT = Cardiovascular Angiography Analysis 
CI 
DS 
IVUS 
MLD 
MUSIC 
P-S 
QCA 
RD 
STRESS 
System n 
::: confidence intervul 
== diameter stcnosi~ 
"" intravascular ultr:lsound 
::: mlnimallumcn diameter 
::: Multicenter illtr:lsound Stent In 
Coronaries study 
::: Prumaz-Schatz 
::: quantitative coronruy angiogr:tphy, 
angiographic 
::: reference diameter 
::: ST ent REStenosis Study 
have accumulated enormous data on the use of the P-S 
intracoronary stent. Over the years the practice of coronary 
stenting has evolved progressively through improvements in 
stent design and characteristics as well as in techniques of 
optimal deployment. The postprocedural management has 
also improved and the problem of stent thrombosis has been 
solved to a great extent. However, the problem of restenosis, 
although reduced, still exists despite this evolution. Various 
factors like use of multiple stents (7-9), stenting of long 
lesions (10), total occlusions (7) and small vessels <3 mm 
(7,8), diabetes mellitus (9) and stenting of restenotic lesions 
(7,11) have been considered to be the predictors of resten-
osis. We hypothesized that in the cohort ofBENESTEhT'[ 
type lesions, the periprocedural quantitative coronary angio-
plasty (QCA) variables alone, after implantation of the P-S 
stent, could predict the restenosis rate at six months. This 
meta-analysis of the BENESTENT J, BENESTENT II 
pilot, BENESTENT n and Multicenter Ultrasound Stent 
In Coronaries (MUSIC) trials was done to venry this idea. 
The aims of this analysis were to 
1. identifY periprocedural QCA variables that have a pre-
dictive value on long-tenn angiographic results, specifi-
cally the restenosis rate based on a categoric criterion of 
diameter stenosis (US) >50%; 
2. construct a variety of multivariate models using these 
variables for the prediction of long-tenn angiographic 
outcome; 
3. select the model with best fit based on the Hosmer-
Lemeshow goodness-of-fit test; and 
4. obtain the most practical model for periprocedural guid-
ance or for postprocedural prognosis, or both. 
These trials have been considered together because their 
angiographic outcomes have been analyzed using identical 
methods of analysis and definitions of the variables in the 
same core laboratory. 
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METHODS 
Four clinical trials (BENESTENT 1[5], BENESTENT II 
pilot [12], BENESTENT II [13,14] and MUSIC [15]) 
that used the P-S intracoronary stent over a period of seven 
years were considered for this meta-analysis. These four 
studies were considered together because of their common 
design features. Of the four studies, two were prospective 
randomized studies and two were prospective observational 
studies for new treatment strategies. Only patients with 
stable angina pectoris were enrolled in the BENESTENT I 
and MUSIC studies, whereas the BENESTENT II pilot 
and BENESTENT n trials also recruited patients with 
unstable angina. Coronary angioplasty was perfonned with 
stent implantation of native coronary artery lesions <15 mm in 
length (only BENESTENT II included le~ons <18 mm) in 
vessels >3 mm that supplied viable myocardium. Patients 
with an ostial lesion, a bifurcation lesion or a lesion in a 
previously grafted vessel were excluded. Balloon angioplasty 
followed by stent implantation was perfonned according to 
standard clinical practice by the femoral approach. The 
post-stenting anticoagulation regimen varied as a result of 
changes in concepts over time, but all patients received 
aspirin. after stenting. Use of on-line quantitative angiogra-
phy to optimize stent placement was encouraged in the 
BENESTENT II pilot study, and the use increased pro-
gressively during the course of the study. In the l\1USIC 
study, systematic use of intravascular ultrasound (IVUS) 
guidance was undertaken to optimize the results. All pa-
tients had clinical follow-up after one, three and six months 
and a follow-up angiogram was obtained at six months. 
Angiographic analysis. Three angiograms were obtained 
per patient, one immediately before the intervention, one 
immediately after and one at follow-up. The off-line anal-
ysis of all angiograms was done at the core laboratory 
(Cardialysis, Rotterdam, The Netherlands) using the Car-
diovascular Angiography Analysis System II (CAAS II) 
(pie Medical, Maastricht, The Netherlands), which has 
been validated previously (16). For each patient, multiple 
matched angiographic views were acquired after intracoro-
nary administration of nitrates. Patients with an unsuccess-
ful procedure or without angiographic follow-up were ex-
cluded from the final analysis. For patients having 
multilesion percutaneous transluminal coronary angioplasty, 
all lesions were analyzed and each was considered indepen-
dent. To standardize the method of data acquisition and to 
ensure exact reproducibility of the angiograms perfonned 
after the intervention and at follow-up, measurements were 
made as described earlier (17). The catheter calibration was 
based on dimensions of the catheters not filled with contrast 
medium (18). A dual type of quantitative analysis was used: 
vessel analysis and stent analysis (12). Vessel analysis was 
applied to the segment located between two side branches, 
and stent analysis was applied to the part actually stented. 
This was considered necessary, because most of the vessels 
Periprocedural QCA Predicts Six-month Stent Restenosis 
Table 1. Baseline Patient Chamcteristics 
BENESTENT BENESTENfIT BENESTENT 
I Pilot IT MUSIC 
Ag' (yr) 57 ± 9 S&:±: 10 59 :t 11 60 ± 9 
Mol, gond" (%) 80 84 77 82 
CCS class ill or IV 54 46 24 43 
"'gina (%) 
Diabetes mellitus (%) 7 8 13 11 
Previous MI (%) 20 23 25 25 
Previous CAJ3G (%) 0 3 2 2 
Previous PTCA (%) 2 6 7 9 
BENESTTh'T - BElgian l\'Ethcrl:mds STEm lltIldy; CABG - COfe>naI)' artery bypaoi groft surgery; CCS - C=d.ian 
Grdiovuscular Society; MI '" myocurdiru infhrction; MUSIC'" Multicenter Ultl'mKlund Stcn! In Coro=ies study; PTeA '" 
pcn:utUlcOU6 tr:ms1umirull coronary angioplatlty. 
taper and as a consequence minimal luminal diameter 
(MLD) was found out of the stented area. In each analyzed 
segment, mean diameter, MLD and reference interpolated 
diameter were detcrrn.illcd. New lesions that developed in 
the vessel beyond the stented segments were excluded from 
the analysis. 
Definitions. The reference diameter (RD) was the diam-
eter obtained by an interpolated method, and the lesion 
length was defined by the curvature anolys~ (19,20). Diam-
eter stenosis after stenting was defined as the MLD within 
the stent related to the interpolated diameter measured over 
the length of the stent. Plaque area was derived from the 
reconstructed boundaries. The luminal area measurements 
were obtained by a videodensitometric method (21,22) and 
included minimal luminal cross-sectional area and percent 
area stenosis. To describe negative stenosis where it was 
present, mean stent diameter was expressed relative to the 
interpolated RD. 
Statistical methods. The statistical analysis was done using 
the SAS sofuvare package (SAS Institute, Cary, North 
Carolina). Continuous variables were compared using the 
Student t test and the categoric variables by the Fisher exact 
test. Multiple QCA variables were tested using univariate 
analysis to determine the predictors of long-term angio-
graphic outcome. Using multivariate analysis, multiple 
models containing the QCA variables relating to long-term 
angiograpruc outcome were constructed. Considering this 
pragmatic approach indexes such as acute gain and late loss 
were not included in the models. Also variables accounting 
for the dilferences in the studies were not included in the 
models. The models were then tested using the Hosmer-
Lemeshow goodness-of.fit test to choose the most appro-
priate model. In the Hosmer-Lemeshow goodness-of-fit 
test, an estimated event probability is calculated from the 
observations using a model. These observations are then 
sorted in order of their estimated event probability and 
divided in approximately 10 groups (g) of about equal size. 
The Hosmer-Lemeshow goodness-of-fit statistic is ob-
tained by calculating the Pearson chi-square test from the 
2 X g table of the observed and the expected frequencies. 
The greater the p value (smaller the chi-square number) the 
better the model fits the data. 
Ethical issues. The study was carried out according to the 
principles of the declaration of Helsinki. Written informed 
consent according to local practice was obtained from every 
patient. 
RESULTS 
A total of775 patients who underwent coronary angioplasty 
with P-S stent implantation and who completed six-month 
angiographic follow-up were considered for the meta-
analysis. The baseline characteristics of these patients are 
summarized in Table 1. The length of stent used was 
15 rnrn except ill BENESTENT II study where 10-rnrn and 
20-mm stents were also used. The stents implanted in 
the BENESTENT II pilot and BENESTENf IT studies 
were heparin-coated. The pharmacotherapy after stenting 
consisted of oral vitamin-K antagonist with aspirin in 
BEl'.'ESTENf I and the first three phases ofBEl'.'ESTEl'.'T 
II pilot tria1. In phase IV of the BENESTENf II pilot and 
BENESTENT IT main study, all patients wore treated with a 
combination of aspirin and ticlopidine, whereas in the MUSIC 
study patients meeting the NUS criteria of optimal stent 
deployment received only aspirin. Online QCA was not used 
ill the BENESTENf I tria1. During the BENESTENf II 
pilot trial, its use increased progressively from 53% to 68% 
from phase I to phase IV. In addition NUS guidance for 
stenting was also used in a minority of the patients in 
BENESTENT IT (12%, 8%, 20% and 8% ill phase I to IV, 
respectively). In the BENESTENT IT main study, on-line 
QCA was performed for 5?OAl of lesions. In the MUSIC 
trial, systematic use ofIVUS guidance was made to optimize 
stent deployment. The mean balloon pressure used for final 
stent deploymenr was 10 ± 8 aon ill BENESTENT I. 
Inflation pressures> 12 attn for dilation after stenting were 
applied in 43%, 71%, 67% and 82% of patients, respectively, 
from phase I to IV of the BENESTENT IT pilot study. The 
mean pressures used for final stent deployment in the 
BENESTENT IT and MUSIC studies were 15 ± 3 and 
15.8 ± 3.3 arm, respectively. The pooled mean RD was 
23 
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Table 2. Quantitative Coronary Angiographic Results by Edge-Detection Method 
Pooled 
BENESTENT BENESTENT BENESTENT M"", 25th 75th Median 
I II-Pilot n MUSIC Value Percentile Percentile Value 
RD pre (rom) 2.99 3.16 2.96 3.09 3.04 2.72 3.33 2.99 
1<ngth (mm) 7.03 8.37 8.20 8.19 7.89 6.25 9.22 7.66 
MLD pre (mm) 1.08 1.12 1.08 1.13 1.10 0.91 127 1.06 
MLD PO" (mm) 2.49 2.77 2.69 2.90 2.69 2.42 2.97 2.68 
DS pre (%) 64 64 63 63 63.6 58.0 70.00 64.00 
DS po" (%) 21 18 16 15 17.7 12.50 22.00 16.6 
Stent-artery ratio (%) -126 -3.82 -6.08 -3.52 -10.02 3.58 -2.69 
Restenosis tate (%) 21 12 16 10 
Columns 2 to 5 show the IDClIl vrulle of each variable in the individuru [<rudy. Column 6 rcpr=ts the pooled mc::m for each v:tri:!.ble. Column 9 shoWl< the median vnlue for 
each v:triable in the pooled dnlll. Negative values fur stent-artety ntio indk:i.te ~!e:r m= rlttnt di:u:neta' th:i.n ref=nce dlam=. 
DS '" diruncte:r stenOSL'!i MLD '" minima1lumen diruneter; RD '" reference diameter; pre '" kforc procedure; po~t '" after p=dure; other abbmiatiolUl ru! in T llhlc 1. 
3.04 mm and the mean RD in the individual trials ranged 
from 2.99 rom (BENESTENT I) to 3.16 rom (BENE-
STENT IT pilot). The mean length of the lesions dilated 
was 8.19 rom. PrepIocedural MLD measured 1.10 mm, and 
the preprocedural DS was 63.6%. The mean MLD imme-
diately after the procedure increased to 2.69 rom and DS 
decreased to 17.7%. The comparative data from the indi-
vidual trials and the pooled mean values are presented in 
Table 2. The corresponding measurements calculated by 
videodensitometry are sho'Wll in the Table 3. Mean area 
stenosis decreased from 85% to 7%, and the mean minimal 
luminal area improved from 1.15 to 6.28 mm2 • The maxi-
mal nominal balloon size used increased gradually (3.40 ± 
0.40 rom in BENESTENT I to 3.65 ± 0.37 rom in 
MUSIC), as did the maximal inflation pressures (10.0 ± 
8.0 atm in BENESTENT I to 15.8 ± 3.3 atm in MUSIC). 
The mean MLD achieved after the procedure progres-
sively improved from smallest in BENESTENT I to largest 
in MUSIC (2.49 rom vs. 2.90 rom, respectively). A corre-
sponding fall in the restenosis rate from 21% to 10% was 
observed in these trials. When the mean MLD was com-
pared with the restenosis rate in each trial, a potential linear 
relation between the two variables emerged (Fig. 1). Uni-
variate analysis performed using the angiographic variables 
to determine the predictor(s) of restenosis revealed that 
vessel size, MLD before and after the procedure, reference 
area before and after the procedure, minima1luminal cross-
sectional area before and after the procedure, DS after the 
procedure, area of plaque before the procedure and area 
stenosis after the procedure were significant predictors of 
restenosis (Table 4). However, left anterior descending 
coronary artery location, stent-artery ratio, maximal balloon 
inflation pressure, lesion length, area stenosis and DS before 
the procedure were not related significantly to long-term 
angiographic outcome. Multiple models were constructed 
using the QCA variables in multivariate analysis (Table 5). 
Using the Hosmer-Lemeshow goodness-of-fit test, two 
appropriate models emerged-one with one variable (MLD 
after the procedure) and the other with two variables (vessel 
size and percent DS after the proeed",e) (Table 5). As 
MLD after the procedure is a more direct and practical 
measurement than percent DS after the procedure, a third 
model was constructed replacing percent stenosis with 
MLD after the procedure in model II. When tested using 
the Hosmer-Lemeshow goodness-of-fit test, this model 
showed a lower probability value than the second model, 
thereby indicating its inferiority. The observed and expected 
restenosis rate on the basis of model II is depicted in Figure 
2. 
Reference chart. Using the be" fit model ofDS after the 
procedure and vessel size (model IT), a chart was developed 
Table 3. QIantitative Coronary Angiograpbic Results by Videodensitometry 
BENESTENT BENESTENT BENESTENT PooI«l 25th 75th Median 
I II Pilot II MUSIC Mean Value Percentile Percentile Value 
RAp" (nun') 721 8.00 7.11 7.72 7.47 5.87 8.76 7.06 
RApost (rom') 8.03 9.12 8.13 9.25 8.55 6.93 9.88 835 
MLCA pre (mm') 0.87 1.37 1.13 1.32 1.15 0.55 1.59 0.93 
MLCA po" (mm') 4.72 7.07 6.54 7.41 628 4.80 7.61 6.10 
AS pre (%) 88.0 83.0 84.0 82.0 84.7 79.00 92.00 86.50 
AS Po" (%) 41.0 23.0 20.0 20.0 272 153 37.5 25.00 
Col\Ull1l5 2 to 5 :!how the mean value of each variable in the indlviduru study. Column 6 represents the pooled mean value for eacll variable. Column 9 shows the median value 
for each variable in the pooled d:ltI.. 
AS = = stenosis; MLCA = minim:U lumen <:ross-sectioruU tU'ca; RA "" reference tU'ca; other :ilibreviations :tS in T:ililes 1 and 2. 
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FIgUre 1. Potential linear relation between MLD after the proce-
dure and observed restenosis rate in the four trials. 
(Table 6 and Fig. 3) that can be used as a ready reference to 
estimate expected restenosis rates using immediate postpro-
cedure angiographic variables. The range of the two vari-
ables was divided into 10 groups each. The expected 
restenosis rate using model n for the median value of each 
range was calculated along with the 95% confidence inter-
vals (CIs) for this particular value. The expected restenosis 
rate is given at the top in each cell, and the CI is indicated 
at the bottom. For example, for a vessel size of 1.83 to 
2.14 rom and postprocedural percent DS of19.1 % to 23.5%, 
the expected restenosis rate is 0.44% or 44% (95% CI 32% 
to 56%), The cells in the chart marked by an asterisk and 
figures in italics indicate that there were no observations in 
that range in the actual data set, and the figures mentioned 
there are calculated by e.xtrapolation from the model 
Table 4. (hlantitative Coronary Angiographic Variables-
Univariate Analysis of Predictors for Long-Term Outcome 
Variable p Value 
Vessel size 
MLD post 
RAp" 
RA post 
MLCApost 
MLCApre 
MLDpre 
DS post 
Plaque area pre 
AS PO" 
LAD location 
Stent-artety ratio 
Lesion length 
Plaque area post 
Maximal balloon inflation pressure 
AS pre 
DS pre 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0.001 
0.002 
0.006 
0.015 
0.035 
0.160 
0.172 
0.220 
0.452 
0.474 
0.812 
0.917 
LAD "" left: :1l1.terior descending coronary :Irtcr)': RA = refcren~ mea; other 
abbreviations ~ in TablOi 2:1l1.d 3, 
Table 5. Multivariate Models Using QIantitative Coronary 
Angiographic Variables 
Variable Coefficient SE p Value 
ModdI 
Intercept 2.67 
MLD po" -1.68 028 <0.001 
Hosmer-Lemeshow goodness-of-fit statistic 10.328; 
p = 0243. 
ModdIT 
Intercept 1.32 
Vessel me -1.34 0.25 
% DS Po" 0.05 0.001 
Hosmer-Lemeshow goodness-of-fit statistic 8.705; 
p = 0.368. 
Model III 
Intercept 3.45 
Vessel me . -0.59 026 
MLD post -1.31 0.30 
Hosmer-Lemeshow goodness-of-fit statistic 13.970; 
p = 0.083. 
SE - st:tndnrd error; other abbreviatiolUl as in Table 2. 
<0,001 
<0.001 
0.025 
<0.001 
Caution must be exercised while using the reference chart in 
these ranges. 
DISCUSSION 
The multivariate analysis of QCA variables pooled from the 
four trials of P-S stent implantation for short de novo 
lesions in coronary arteries >3.0 mm revealed that MLD 
after the procedure, vessel size and percent DS after the 
procedure procedure were the strongest predictors of the 
long-term angiographic outcome. The model containing 
vessel size and percent DS after the procedure provide the 
be" fit to the data, thus highlighting the importance of early 
results. 
ModdH- Vesselsizeand % diameter stenosis 
30 
" 
H ·Observed I 
oExpected I 
:111 Im-Il 
4 10 
Bosmer-Lemeshow groups 
F".gure 2. Observed and expected restenosis rate calculated using 
model II in the 10 patient groups on the basis of the Hosmer-
Lemeshow goodness-of-fit test. 
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Table 6. Reference Chart Generated Using Mood n 
Percent Diameter Stenosis After Procedure 
Vessel size 
(mm) 1.5--5.9 5.9-10.3 10.3-14.7 14.7-19.1 19.1-23.5 23.5--27.9 27.9-32.3 32.3-30.7 36.7-41.1 41.1-45.5 
1.83-2.14 0.24' 0.28 0.33 0.38 0.44 0.49 0.55 0.61 0.66' 0.71" 
0.15-0.36 0.19-0.40 023-0.45 028-0.50 0.32-0.56 0.37-0.62 0.41-0.69 0.44-0.75 0.48-0.80 0.51-0.85 
2.14-2.45 0.17 0.21 025 0.29 0.34 0.39 0.45 0.50 0.56 0.62* 
0.11-0.26 0.14-0.28 0.18-0.32 0.22-0.37 0.26-0.42 0.30-0.49 0.34-0.57 0.37-0.64 0.40-0.71 0.43-0.78 
2.45-2.76 0.12 0.15 0.18 0.21 025 0.3{) 0.35 0.40 0.46 0.51' 
0.08-0.18 0.11-0.20 0.14-022 0.17-0.26 0.2l-D.30 024-0.37 0.27-0.44 029-0.52 0.32-0.61 0.35-0.68 
2.76-3.07 0.08 0.10 0.12 0.15 0.18 0.22 0.26 0.31 0.36 0.41 
0.05-0.12 0.07-0.14 0.10-0.16 0.13-0.18 0.15-0.22 0.18-0.27 0.20-0.33 0.22-0.41 024-0.49 0.26-0.58 
3.07-3.38 0.06 0.07 0.09 0.11 0.13 0.16 0.19 0.23 0.27 0.32 
0.03-0.09 0.05-0.10 0.06-0.11 0.08-D.13 0.10-0.16 0.12-0.20 0.14-0.25 0.15-0.32 0.17-0.39 0.19-0.48 
3.38-3.69 0.04 0.05 0.06 0.07 0.09 0.11 0.13 0.16 0.20 0.23 
0.02-0.07 0.03-0.07 0.04-0.09 0.05-0.10 0.06-0.12 0.08-0.15 0.09-0.19 0.10-025 0.12-0.31 0.13-0.38 
3.69-4.00 0.03 0.03 0.04 0.05 0.06 0.07 0.09 0.11 0.14 0.17 
0.0l-D.05 0.02-0.06 0.02-0.07 0.03-0.08 0.04-0.10 0.05-0.12 0.05-0.15 0.06-0.19 0.07-0.24 0.08-0.30 
4.0H.31 a.o:!' 0.02 0.03 0.03 0.04 0.05 0.06 0.08 0.11! 0.12' 
0.01-0.04 O.ot-o.04 0.0l-D.05 0.02-0.06 0.02-0.08 0.03-0.09 0.03-0.12 0.04-0.15 0.05-0.19 0.05-0.24 
4.31-4.62 0.01' 0.01' 0.02' 0.02' 0.03 0.03 0.04 0.0S' o.or 0.0!! 
0.00-0.03 0.01-0.03 0.01-0.04 0.01-0.05 O.ot-o.06 0.02-0.07 0.02-0.09 0.02-0.12 0.03-0.15 0.03-0.19 
4.62-4.93 0.01" 0.01' o.or 0.01' 0.02 0.02' 0.0J" O.D4' 0.1)4" 0.0S' 
0.00-0.02 0.00-0.03 0.00-0.03 0.01-0.04 0.01-0.05 0.01-0.06 0.01-0.07 0.01-0.09 0.02-0.11 0.02-0.15 
The ccl1; nwkcd with numbw in itilics nnd an asterisk indicutc the rnnge without uctu:J1 obsav:i.tions in the datl, :let. Cdls with bold numhQ'S indicate the rnnge with ncruru 
ob,;erw.tioru;, 
The <lliferenee between BENESTENT I and MUSIC. 
The most conspicuous observation emerging from these 
trials is the improvement in MLD after the procedure 
(2.49 rom in BENESTENT I and 2.90 rom in MUSIC) 
and the reduction in the restenosis rate from 21% in 
BENESTENT I to 10% in MUSIC, thus supporting the 
concept "the bigger the better" in a very homogeneous 
population treated with intracoronary stent implantation. 
Introduction of on-line QCA and NUS guidance are 
potentially responsible for this improvement. Heparin coat-
" ResIeriosis 
,,_post VessaI Size 
Figure 3. Three-dimensional bar diagram representing the refer-
ence chart. The lower the vessel size and the higher the DS after 
the procedure, the higher the expected restenosis rate. 
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ing of the $tents was tried in the BENESTENT IT pilot and 
the BENESTENT IT study to circumvent the problem of 
subacute stent thrombosis, which emerged as the main 
hurdle to overcome in coronary stent implantation since the 
BENESTENT I and STRESS studies. Analysis of both 
these studies made it clear that although heparin coating did 
reduce the subacute thrombosis rate significantly, it had no 
etfect on long-term outcome and restenosis rate (12,14). 
Applicability of "the bigger the better." Kuntz et al. (23) 
first introduced this concept and demonstrated that it holds 
true irrespective of the device used for coronary angioplasty 
(24). They also suggested that a variety of other factors 
independenrly modulate restenosis superimposed on the 
platform of early results. However, there is significant 
evidence suggesting that this concept is device-speci£c and 
does not hold true for debulking techniques such as direc-
tional coronary atherectomy and excimer laser therapy 
(25,26). 
Reasons for the difference. Three factors may have led to 
superior results, including the use of online QCA, high 
pressure dilation and lVUS guidance. Online digital auto-
mated edge detection QCA systems decrease measurement 
variability in comparison with visual assessment of coronary 
artery dimensions or band-held callipers (27,28). Accurate 
Periprocedural QCA Predicts Six-month Stent Restenosis 
assessment of dimensions is important to guide sizing of 
balloon and other devices. Note that online QCA was not 
used during the BENESTENT I study but was used increas-
ingly during the COUlSe of the BENESTENT II pilot study. 
The concept of optimal stent deployment using high 
pressure dilation was proposed by Colombo et al. (29-33). 
Using IVUS they demonstrated that most of the angio-
graphically satisfactory stent deployments were in fact far 
from being optimal and proposed. the use of high pressure 
intrastent dilation and the use of IVUS to optimize stent 
placement. It was also noted that high pressure dilation with 
an appropriately sized balloon was better than using an 
oversized balloon, because the rate of complications like 
coronary rupture was higher with oversized balloons. The 
stent deployment strategy used in the BENESTENT I trial 
was according to the strategy in vogue (4), and only 
moderate pressure inflations were used for postdilation of 
the stents. The use ofbigh pressure intrastent dilations became 
routine during subsequent trials. Although the debate about 
benefits of high pressure intrastent dilations bas continued 
(34), a recent retrospective study by Goldbetg et al (33) has 
shown that the aggressive stent implantation techniques were 
not associated with increased late loss or resrenosis and the 
above meta-analysis oonfinns this. Baut'" et al (35) have also 
demonstrated that high pressure inflation in the P-S stentwas 
an independent predictor of lower late lumen loss. The results 
of this meta-analysis indicare that in the MUSIC study high 
pressure dilation was one of the factors associated with a 
reduction in the restenosis rate. 
The role of IVUS imaging in the era of high pressure 
stent deployment remains to be clearly established. A recent 
study by Akiyama et al (36) showed that, despire high 
pressure dilation, 33% of the lesions required additional 
treatment when assessed by IVUS. The preli.roinary results 
of the Angiography Versus Intravascular Ultrnsound Directed 
Cororuuy Stent Placement (AVID) study (37) also support 
this; however, the long-term implications of this finding have 
yet to be estlblished. The present study indicates that IVUS-
guided optimal stent deployment was one of the important 
factors responsible for the improved results. 
Left anterior descending coronat)'" artexy location. Phil-
lips et al (38) and Wong et al (39) have demoost<ated that 
stent implantation in the proximal left anterior descending 
coronary artery is associated with a greater reduction in the 
restenosis rate as compared with implantation elsewhere in 
the coronary tree. In contrast, Bauters et al (35) and the 
current univariate analysis support the notion that after stent 
implantation, left anterior descending coronary artery loca-
tion ceases to be a predictor of restenosis. 
Can we equate the results of oll'line QCA with on-line 
QCA? In the present study the results of ofBine QCA were 
used to construct the multivariate models, whereas the 
best-fit model, which was used to build the reference chart, 
used the variables of percent DS after the procedure and 
vessel size. Previous studies (40) have demonstrated that the 
geometric variables of :MID and obstruction diameter, as 
measured by off-line and on-line QCA systems, respec-
tively, show good correlation. The correlation between 
interpolated and relative variables, like interpolated RD and 
percent DS, although acceptable, was lower (r = 0.76) than 
that of the geometric variables. The difference in the derived 
variables was due to the fact that the two systems use 
different definitions to calculate the relative variables. Avail-
ability of second-generation QCA systems like CAAS II, 
which can be used both online and offline, should resolve 
this problem. Other second-generation QCA systems like 
CMS, QANSAD, AWOS, Cardio 500 ",d Angioimage 
have been shown to be more precise than the first-
generation systems and were validated in vitro by Hausleiter 
et al. (41). However, intersystem variability needs to be 
established before these results from CAAS II can be 
extrapolated to other systems. 
Can the results be generalized? The multivariate models 
were developed using the data obtained by the use of the 
P-S stent, and the applicability of the same to other stents 
is not clear. Several ongoing or recently completed multi-
center randomized trials comparing stents like GR II (42) 
(seoond-generation), AVE Micro (43) (SMART [Study of 
AVE Micro Stent ability to limit Restenosis Trial]), Cardiocoil 
(RACE), ACS Multilink (ASCENT [ACS Multilink Clini-
cal Equivalence Trial]), NIR (NIRVANA [NIR vs. Palrnaz-
Schatz]), Radius (SCORES [Stent Comparative Restenosis 
Trial]) and Wallstent to the P-S stent will tell us about the 
equivalence of these stents to the P-S stent. Meanwhile, it 
would be interesting to apply the reference chart to the data 
from the WEST (Western European Stent Trial) I (44) and 
WEST II (45) trials (MULTI-LINK stent implanred under 
IVUS guidance) to find out the applicability of this type of 
reference chart. The current model is based on the implan-
tation of srents in short de novo lesions in native coronary 
arteries >3 mm in diameter, and its applicability remains to 
be tested in cohorts outside this restricted framework 
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of the Relocation of the Minimal Luminal 
Diameter After Intracoronary Radiation Therapy 
ManeI Sabate, MD," Marco A. Costa, MD,'" Ken Kozuma, MD,* I. Patrick Kay, MBCHB,* 
Connie J. van der Wie~ MSc,t Vitali Verin, MD, PHD,* William Wijns, MD, PHD,§ 
Patrick W. Serruys, MD, PHD, FESC, FACC,' on behalf of the DOSE FiNDING STUDY GROUP 
Rotterdam, The Netherlands; Geneva, Switzerland; and Aals!) Belgium 
OBJECTIVES The aims of the study were to determine the incidence of relocation of the rninimalluminal 
diameter (MLD) after beta-radiation therapy following balloon angioplasty (BA) and to 
describe a new Olethodologic:li approach to define the effect of brachytherapy on treated 
coronary stenoses. 
BACKGROUND Luminal diameter of coronary lesions rru.y increase over time following angiopIasty and 
irradiatation. &, a result, the MLD at follow-up m:ly be relocated from its location 
preintervention, which may induce misleading results when a restricted definition of the 
target segment by quantitative coronary angiography (QCA) is performed. 
METHODS Patients treated with BA followed by intr:a.coronary brachytherapy according to the Dose-
Fmding Study constituted the study population. A historical cohort of patients treated with 
BA was used as control group. To be included in the analysis, an accurnte angiogrnphic 
documentation of all instrwnentations during the procedure was mandatory. In the irradiated 
patients, four regions were defined by QCA: vessel segment (VS), target segment (TS), 
injured segment (INS), and irradiated segment (IRS). 
RESULlS Sixty-five patients from the Dosc-Fmding Study and 179 control patients were included. At 
follow-up, MLD was relocated more often in the radiation group (78.5% vs. 26.3%; P < 
0.0001). The rate of >50% diameter stenosis differed among the four predefined regions: 
3.1% in the TS; 7.7% in the INS; 9.2% in the IRS and 13.8% in the VS. 
CONCLUSJONS Relocation of the MLD is commonly demonstrated after BA and brachytherapy, and it 
should be taken into account during the analysis of the results of radiation clinical trials. a 
Am Coil CardioI2000;36:1536-41) © 2000 by the American College of Cardiology 
During the past 10 years the efficacy of percutaneous 
interventions in preventing restenosis has been assessed by 
the use of quantitative coronary angiography (QCA) (1-4). 
This technique of analysis has become the gold standard for 
the assessment of coronary angiograms in the context of 
scientific research due to its superior accuracy and objectivity 
as compared to visual and hand-held caliper measurements; 
in addition, it possesses a better inter- and intra-observer 
variability (5,6). Consequently, the percent diameter steno-
sis has become the usual output of this analysis, and the 
value of 50% has gained widespread acceptance to define the 
presence of restenosis in the treated coronary segment (7). 
Intravascular ultrasound (IVUS) studies demonstrated that 
restenosis after balloon angioplasty (BA) is mainly due to 
neointimal hyperplasia and vessel shrinkage at the site of the 
injmy (8-10). 
follow-up, rather than decrease (11). Three-dimensional 
IVUS analysis has shown that this phenomenon is induced 
by positive remodeling of the vessel wall at the site of the 
irradiated segment (IRS) (12). fu a result, the minimal 
luminal diameter (MLD) of coronary segments treated with 
brachytherapy following percutaneous interventions may be 
relocated at follow-up from its location pre-intervention. A 
restricted definition of the target segment by QCA could 
induce misleading results and make any comparison to 
previous nonradiation studies unfair. This study was in-
tended to 1) determine the incidence of the relocation of the 
MLD after beta-radiation therapy following successful BA 
and 2) to describe a new methodological approach to 
analyze and report accurately the effect ofbrachytherapy on 
the treated coronary artery. 
Pioneers in intracoronary radiation therapy have demon-
strated that in a majority of patients the luminal diameter at 
the site of the treated lesion may increase during the 
From the "Thor;ucC<:nter, Acodcmiirl> Zickt:nhuis D~1d.gt, Rotterdam, The 
Nethabnds; tC:trdiaIyllia B.V., Rottadam, The Nethabn&; =l:Uruvasity HO>-plt:ll, 
GO'lo:vu, Switzerbnd; l\!ld §O.L. V. Ho~itll ClItdiov;u;culnr Center, AaIst, Belgium. 
Dr, LP. IGyw:u; !lUpported by the Nntlonal H=t Foundation of New Zeilind. The 
Wenck<:bach Pri1.eW:lll nwnrdcd to P,W. Saruys by the Dutch H=t Foundation for 
brnchyth=py memh in the Cltheterization laboratory, 
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ME11IODS 
Patient selection. Patients eligible for the study were those 
successfully treated with BA followed by intracoronary 
radiation according to the Boston ScientifidSchneider 
Dose-Fmding Study (13). The purpose of this trial was to 
deterrnme the eKect of various doses of beta-irradiation on 
coronary artery restenosis after BA with or without stent 
implantation in patients with single de novo lesions of 
native coronary arteries. The isotope selected was the pure 
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Abbreviation~ and Acronyms 
BA = balloon angioplasty 
Gy "" gray 
IKS = injured segment 
IRS '" irrndiated segment 
NUS = mtr.lvascular ultr:lsOund 
MLD = minimal luminal diruneter 
QCA = quantitative coronary angiography 
TS = target segment 
VS = Ye:1sel segment 
beta-emitting 9Oy, and patients were randorcized to receive 
doses of9, 12, 15 or 18 gray (Gy) at 1 mm tissue depth. The 
delivery of radiation was carried out by the use of the 
Schneider-Sauerwein Intravascular Radiation System (14). 
In brief, this system comprises 1) a fle:6ble coil made of 
titanium-coated pure yttrium affixed at the end of a thrust 
wire between proximal and distal tungsten markers; 2) a 
centering catheter, which is a segmented balloon consisting 
of four interconnected compartments and which allows the 
source lumen to be centered relative to the arterial lumen; 
and 3) a computerized afterloader that allows automated 
advancement and positioning of either the dummy or the 
active source (14). 
QCA analysis and definitions. The QCA analysis was 
performed off-line by an independent core laboratory (Car-
dialysis, Rotterdam, The Netherlands), All angiograms 
were evaluated after intracoronary administration of ni-
trates. Analysis was performed by means of the CAAS II 
analysis system (pie Medical BV, Maastricht, The Nether-
lands). Calibration of the system was based on dimensions 
of the catheters un:filled with contrast medium. This 
method of analysis has been previously validated (4,15,16). 
The area of interest was selected after reviewing all cinefilms 
performed during the index procedure. Any angiographic 
sequence showing the lesion preintervention, positions of 
angioplasty balloon and radiation source can be displayed 
simultaneously on the screen using the Rubo DrCOM 
'Viewer (Rubo Medical Imaging, Uithoom, The Nether-
lands). The electrocardiographic (ECG) tracing is also 
displayed in any angiographic sequence. By selecting frames 
in the same part of the cardiac cycle, we were able to define 
the location of the radiation source and angioplasty balloon 
relative to the origina1lesion. The analyst defined a coronary 
segment bordered by angiographically visible side branches 
that encompassed the original lesion, angioplasty balloon 
and radiation source. This segment was defined as the 
"vessel segment' (VS) (Fig. 1). The MID was determined 
in the VS pre-intervention by edge detection and was 
averaged from the two orthogonal projections. Reference 
diameter was automatically calculated for the VS by the 
interpolated method (4). The percent diameter stenosis was 
calculated from the MLD and the reference diameter (7). 
At the time of the procedure, all angioplasty balloons, 
when deflate~ were filmed in place with contrast injection 
in the same projections as were the VS. Mer successful BA, 
intracoronary brachytherapy was performed. Both the loca-
tion of the centering balloon and the active wire in place 
FIgUre 1. (A) Target: segment (TS) is between proximal and discl margin of the target lesion, automatic:illy defined by the qll:lfltitative coronary 
angiography system. Vesse! segment (VS) is bordered by visible side br:tnches, which eneompass the target segment (TS) and the position of the angiop1asty 
b:illoon and radiation source. (A') Original lesion in the rruddle part of the right coronary artery before intervention. (B) Injured segment (INS) is defined 
as the segment encompassed by the most proxim:ll and most distal marker of the angiop1ru;ty b:illoon. $') Mows indiClte the markers of the dd3.ated 
angioph.~ty b:illoon filmed in place with a contrast injection. (C) The segment encompassed by the inner part of the two tungsten markers of the radiation 
delivery system defined as the irradiated segments (IRS). (e') Arrowr, indicate the inner parts of the radiation source tungsten markers filmed with:r. contrast 
injection. 
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PRE POST FUP 
Subsegment 
analysis 
Computer 
defined 
analysis 
FIgUre 2. (A) SUbSegmCDtal analysis before procedure. Vessel segment (VS) W:lS automatically divided into 5~mm subscgmcnts by the eAAS II system. 
The origirullesion is loclted at segment No.5 preprocedure as the arrow indicates. (A') Computet defined analysis pteprocedure. (B) Subsegmental311:UYSis 
atpostprocedure.11inimum lumen di:uneter is 10000ted at segment No.6 (:u:row). (B') Computer-de£ned analysis postprocedure. (C) Subsegmenwl analysis 
at follow-up.:Minimum lumen diameter is loc:ttcd at segment No.7 (arrow). (C') Computcr-defincd nnalysis at follow-up. 
were filmed in the same projections as performed previously. 
The proximal side branch within the VS was used as an 
index anatomicru landmark. The eAAS software computed 
distances from this proximal sidebra.nch to 1) the inner part 
of the proximal tungsten marker, 2) the proximal marker of 
the angioplasty balloon, 3) the proximal margin of the 
obstruction segment, 4) the distal margin of the obstruction 
segment, 5) the distal marker of the angioplasty balloon, and 
6) the inner part of the distal tungsten marker. The "target 
segment" (TS) was encompassed by the proximal and distal 
margin of the obstructed segment. The segment encom-
passed by the most proximal and most distal marker of the 
angioplasty balloon defined the "injured segment" (INS). 
The segment encompassed by the inner part of the two 
tungsten markers defined the IRS (Fig. 1). All regions of 
interest were superimposed on the pre-, post-procedural and 
follow-up angiograms. "Geographical miss" was defined for 
those cases in which the entire length of the INS was not 
fully covered by the IRS (li). 
Using the software of the CAAS system, the analyst is 
able to perform a subsegmental analysis within the VS. The 
segment is automatically divided into subsegments of equi-
distant length (on average, 5.0 ± 0.3 mm). The subsegment 
containing the MLD was taken as the index segment, and 
this enabled relocation of the MLD to be defined (Fig. 2). 
"Relocation pre-post" was defined as those cases in which 
the MLD of the VS post-treatment was located in a 
different subsegment in the two orthogonal projections from 
that of the index procedure. "Relocation post-fup" was 
defined as those cases in which the MLD of the VS at 
follow-up was located in a different subsegment in the two 
orthogonal projections from that of the post-procedure. 
"Relocation pre-fup" was defined as those cases in which the 
MLD of the VS at follow-up was located in a different 
segment in the two orthogonal projections from that of the 
index procedure (Fig. 2). 
Additionally, the analyst computed the MLD in every 
region of interest and calculated the acute gain, the late loss 
and the frequency of >50% diameter stenosis on a regional 
basis. "Acute gain" was defined as MLD posttreatment 
minus MLD premtenrention. "Late loss" was defined as 
MLD posttreatment minus MLD at follow-up. "Resteno-
sis" was defined as diameter stenosis >50% at follow-up. 
Control group. A historical cohort of consecutive patients 
treated with BA from the BENESTENT II trial (18) and 
presenting with matched views and correct angiographic 
documentation was used as the control group. The VS, TS, 
and relocation of the MLD were defined in this cohort as 
described above. 
Statistical analysis. Data are presented as mean ± SD or 
proportions. To compare qualitative variables, the chi-
square test was carried out. To compare quantitative vari-
ables, the Student t test was performed. All tests were 
two-tailed, and a value of p < 0.05 was considered statis-
tically significant. 
RESULTS 
Baseline characteristics. One hundred and eighty-one pa-
tients were included in the dose-finding study. Of these, 51 
patients received a stent. The remaining 130 patients treated 
with BA alone followed by beta-radiation were eligible for 
the study. By comparing the technician worksheet with the 
angiograms recorded, the analyst was able to identify those 
patients for whom all balloon inflations and source posi-
tioning were £1med and all target views matched. Using this 
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Table 1. Baseline Characteristics 
D~~ 
Fmding Control 
G..up Group 
(n = 65) (n = 179) 
Ago~) 64 ± 9 62 ± 10 
Gender (male) 40 (70.7%) 137 (76.5%) 
Treated :uteI)' 
Left anterior descending 2S (43.1%) 80 (44.7%) 
Left: circum£o:: 7 (10.8%) 22 (12.3%) 
Right coronruy 30 (40.1%) n(43%) 
Coronruy risk meters 
System!c hypertension 35 (53.8%) 89 (49.7%) 
Diabetes mellitus 12 (18.5%) 27 (15%) 
Smoking 33 (66.1%) 123 (68.7%) 
Hypercholesterolemia 38(58$%) 98 (54.7%) 
Frunily history 23 (35.4%) 60 (33.5%) 
Dose 
9 Gy 18 (27.7%) 
12 Gy 11 (16.9%) 
15 Gy 20(30.8%) 
18 Gy 16 (24.6%) 
AJ1 p - :"IS. Gy - grny. 
systematic approach, 65 patients who did not accomplish 
these technical requirements for performing an accurate 
QCA were excluded from the study. Thus, the study 
population comprised the 65 patients presenting with com-
plete and correct angiograpruc documentation. All patients, 
regardless of the dose prescribed (9, 12, 15, or 18 Gy at 
1 mm tissue depth), were pooled together. 
Of 410 patients enrolled in the balloon ann of the 
BENESTENT II trial, 179 presenting with all the above-
mentioned technical requirements constituted the control 
group. Baseline characteristics of both the study population 
and control group are described in Table 1. No differences 
were observed between the tvlo groups. 
Incidence and location of the relocation of the MLD. 
Relocation pre-post of the MLD was defined in 36 patients 
(55.4%) in the dose-finding cohort and in 62 patients 
(34.6%) in the control group (p = 0.005); relocation 
post-fup was defined in 37 patients (56.9%) in the dose-
finding cohort and in 59 patients (33.0%) in the control 
group (p = 0.001); and relocation pre-fup was defined m 51 
patients (78.5%) in the dose-finding cohort and in 47 
patients (26.3%) m the control group (p < 0.0001). Geo-
graphical miss was identified in two patients (3%). At 
Table 3. QCA Data From the Four Prede:6.ned Segments 
MLD pre (mml 
MLD poo(_) 
MLDfup (mm) 
%DS fup 
Acute guin (mm) 
Late loss (mm) 
Rc:stenosis rate, n (%) 
Segment length (mm) 
TS 
1.06 :::!: 0.2 
2.17 :I:: OS 
2.36 ± 0.5 
20.3 ± 11 
1.12:::!: 0.4 
-0.18 ± 0.4 
2 (3.1) 
5.0 ± 0.3 
Table 2. Location of the Relocated MLD 
Within INS-IRS 
Outside INS-IRS 
Within IR5-0utside ~S 
Wtthin lN5-0utside IRS 
(gt:OgrapIDc!l miss) 
Relocation 
P«-p<»< 
(n = 36) 
19 (52.9%) 
9(25%) 
6 (16.6%) 
2 (5.5%) 
INS ~ injUl'l:d ,;egment; IRS - irmdiated ~egment. 
Relocation 
Post-fup 
(n = 37) 
23 (62.2%) 
10 (27%) 
4 (10.8%) 
0(0%) 
Relocation 
Pre-fup 
(n = 51) 
24(47%) 
18 (35.3%) 
8 (15.7%) 
1(2%) 
follow-up, 45 patients (69.2%) presented with an increase in 
the value of MLD at TS, whereas 20 patients (30.8%) 
demonstrated either a decrease (18 patients) or no change (2 
patients) in the value of MLD at TS. The location of the 
MLD in cases of relocation is presented in Table 2. This 
new MLD was most commonly located within the IRS and 
INS, followed by those regions within the VS but outside 
the IRS and the INS. Typically, when the new :MLD was 
located outside the INS and IRS, distal subsegments were 
most often involved rather than the proximal ones (88016 vs. 
12%, respectively). 
Methodological implications of the relocation of the 
MLD. The QCA data derived from the analysis of the 
predefined regions are shown in Table 3. 
DISCUSSION 
Incidence and causes of relocation of the MLD. This 
study demonstrates that the relocation of the MLD is a 
common phenomenon in coronary segments treated with 
BA followed by intracoronary beta-radiation therapy. Al-
though relocation of the MLD at follow-up was signifi-
cantly more frequent in the irradiated group, control pa-
tients treated with "plain old balloon" angioplasty also 
demonstrated. a notable incidence of relocation. This phe-
nomenon was noted after radiation was witnessed in previ-
ous studies showing that the restenosis process affected the 
entire vessel segment, which was dilated, and not just the 
obstructed segment (19,20). To overcome this problem, the 
Total Occlusion Study of Canada (TOSCA) group drnsed 
the concept of "target lesion work length," de£ned as the 
length of contiguous target segment exposed to balloon 
infu:tion (21). In addition, the relocation of the MLD may 
explain the mismatch betvleen good angiograpruc results of 
INS IRS VS 
1.06 ± 02 1.06 ± 02 1.06 ± 02 
1.99 :::!: 0.4 2.00 ± 0.4 1.91 :::!: 0.4 
1.97 ± 0.5 1.97:::!: 0.5 1.84 ± 0,5 
332 ± 11 33.4 ± 11 37.9 ± 10 
0.93 ± 0.4 0.94:::!: 0.4 0.85.:::: 0.4 
0.01.:::: 0.4 0.03:::: 0.4 0.07:::!: 0.3 
5 (7.n 6 (9.2) 9 (13.8) 
18.7:t 42 22.9:t 3,5 36.9 ± 8.4 
DS - diameter stenosu;; /Up - fonow-up; INS '" injw-ed ,;egment; IRS "" irmdiated segment; MLD "" minimru luminal di:uneter; pre - pre-intervention; po~t '" 
poRt-intervention; TS '" wget segment; VS "" ves.cl ,;egment. 
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previous radiation trials and the poor clinical outcome (i.e., 
high target vessel revascularization rates) observed in these 
studies (22). 
Further, because changes in the reference diameter may 
occur during the follow-up period, the use of the percent 
diameter stenosis measurements is questionable as an accu-
rate estimate oflesian severity (19,20). In this regard, two 
thirds of our study population demonstrated an increase in 
the value of the preintcrvention MLD. In the radiation 
group, increase of vessel dimensions at the site of the index 
MLD may play an important role in the relocation of the 
MLD. 
Previous three-dimensional IVUS observations demon-
strated that the vessel wall enlarges after catheter-based 
radiation therapy either following conventional BA or stent 
implantation (12,23). This vessel enlargement was able to 
accommodate the mean increase in plaque volume, resulting 
in a net increase in the irradiated luminal volume at 
follow-up. 
In our study, the MLD was mainly relocated within the 
IRS and the INS and outside the INS and the IRS (typically 
at distal segments). In such regions, the presence of pre-
existing plaques that became angiographically apparent or 
that progressed after the treatment and tapering of the vessel 
may have accounted for the relocation of the MLD. In 
addition to these causes of relocation, we cannot exclude the 
influence of the natural atherosclerotic process on this 
phenomenon in the context of patients with coronary risk 
factors by inducing development of new coronary lesions in 
any of the predefined regions of interest. 
Methodological consequences of relocation. When the 
analysis was restricted to the TS, this lumen gain at 
follow-up resulted in a negative mean late loss and a very 
low restenosis rate (3.1%). The TS represents a region that 
was injured by the balloon and theoretically presented with 
the peak stress and vessel stretch after BA Further, this 
segment was fully covered by the radiation source in all 
cases. Thus, the results of the analysis of the TS may 
demonstrate the effect of brachytherapy under optimal 
conditions. On the other side of the spectrum, when the 
analysis included the entire VS, both the late loss and the 
restenosis rate were significantly higher (Table 3). This 
latter analysis was performed in most of the hlstorical trials 
aimed to detennine effectiveness of new therapeutic agents 
on the restenosis process after BA (24-27). This traditional 
approach is driven by the concern that hemodynamic effects 
(i.e., flow-limiting lesion), symptoms, and outcomes are 
likely related to the location of the new MLD, irrespective 
of precise anatomic concordance with its location pre-
intervention. The meticulous analyses proposed are likely to 
yield new insights on the pathophysiology of this new 
therapy, and we believe that these are highly recommended 
during feasibility in vivo and in vitro studies. In clinical 
radiation trials, the traditional VS approach should be the 
common angiographic end point, and further analyses of the 
above-defined regions of interest may complement the 
results of the study. In this regard, the efficacy of the therapy 
itself would be determined by the results at the TS, whereas 
the effectiveness of the radiation therapy would be defined 
for the entire VS, which includes both the desired (i.e., 
lumen enlargement) and the side effects (i.e., edge resteno-
sis). 
Study limitations. The definition of relocation of the 
MLD depends decisively on the accurate documentation of 
all steps followed during the procedure. This was accom-
plished in only 50% of the cases treated with BA in the dose 
finding study and in 44% of the historical control group. 
The QCA data presented in this study represent only the 
results of the pooled cohort of patients enrolled in the dose 
finding study, and not the entire population. 
Conclusions. Relocation of the MLD is a common phe-
nomenon after successful BA followed by intracoronary 
beta-radiation. This feature may induce controversial results 
related to the methodology used in the QCA analysis and 
should be considered when reporting the results of subse-
quent radiation studies. The new methodological approach 
proposed may be useful to detennine both the potentialities 
and the limitations of this new technique. 
APPENDIX 
The participating centers and investigators of the Dose-
Fmding Study Group are listed along with the number of 
included patients in parentheses. 
University Hospital, Geneva, Switzerland (57): Vitali 
Verin, MD, Touri Popowski, MD, Patrice Delafontaine, 
MD, John Kurtz, MD, Igor Papirov, PhD, Sergey Airiian, 
MD, Philippe Debruyne, MD,Jose Ramos de Oliva}, MD. 
Cardiovascular Center, Onze-Licve-Vrouw Ziekenhuis, 
Aalst. Belgium (54): William Wijns, MD (principallnves-
tigator), Bernard de Bruyne, :MD, Guy Heyndrickx,:MD, 
Luc Verbeke, MD, Marleen Piessens, PhD, Jo De Jans, 
MSc. 
University Hospital, Essen, Germany (26): Dietrich Baum-
gart, :MD, Wolfgang Sauenvein, MD, Raimund Erbel, 
:MD, Clemens von Birgelen, :MD, :Michael Haude, MD. 
University Hospital, Kie4 Germany (22): Mar1.1.lS Lins, 
MD, Simon Ruediger, MD, Gyorgy Kovacs, MD, Thomas 
Marrin, MD, Herrmann Gunhild, MD, Wllhelm Roland, 
MD, Peter Kohl, 1v1D. 
Kings College Hospital, London, United Kingdom (22): 
Thomas Martin, MD, Francis Calman, :MD, Niel Lewis, 
PhD. 
Data monitoring. Thomas Thaler, MD (Boston, Scientif-
ic). 
Angiographic core-laboratory and data analysis. Yvonne 
Teunissen, PhD (Clinical Trial Manager), Astrid Spierings, 
MSc, Connie Van der WIel, MSc, Gitte Kloek, MSc, 
Clemens Disco, PhD. 
Critical Events Committee. Jaap Dekkers MD, Patrick 
Seauys, MD, PhD. 
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Geographic Miss 
A Cause of Treatment Failure in Radio-Oncology Applied to 
Intracoronary Radiation Therapy 
Manel Sabat", MD: Marco A Costa, MD; Ken Kozuma, MD; L Patrick Kay, MBChB: 
Willem J, van der Giessen, MD, PhD; Veronique LMA Coen, MD; Jurgen MK Ligtbart, BSc; 
Pedro Serrano, MD: Peter C. Levendag, MD, PhD; Patrick W. Serruys, MD, PhD 
Backgrountl-A recognized limitation of endovascular .B-radiation therapy is the development of new stenosis at the edges 
of the irradiated area The combination of injury and low-dose radiation may be the precursor of this phenomenon. We 
translated the radio-oncological concept of "geographic miss" to define cases in which the radiation source did not fully 
cover the injured area. The aims of the study were to determine the incidence and causes of geographic miss and evaluate 
the impact of this inadequate treatment on the outcome of patients treated with intracoronary ,B-radiation. 
Methods and Results-We analyzed 50 consecutive patients treated with ,8-radiation after percutaneous coronary 
intervention. The prescribed dose ranged between 12 and 20 Gy at 2 mm from the source axis. By means of quantitative 
coronary angiography, the irradiated segment (IRS) and both edges were studied before and after intervention and at 
6-month follow~up. Edges that were injured during the procedure constituted the geographic miss edges. Twenty~two 
edges were injured during the intervention, mainly because of procedural complications that extended the treatment 
beyond the margins of the IRS. Late loss was significantly higher in geographic miss edges than in IRSs and uninjured 
edges (O.84±O.6 versus O.l5±O.4 and O.09±OA rom. respectively: P<O.OOOl). Similarly. restenosis rate was 
significantly higher in the injured edges (10% within IRS. 40.9% in geographic miss edges. and 1.9% in uninjured edges; 
P<O.OOl). 
Conclusions-These data support the hypothesis that the combination of injury and low-dose j3-radiation induces 
deleterious outcome. (Circukztion. 2000;101:2467~2471.) 
Key Words: geographic miss _ radioisotopes _ balloon _ angioplasty _ stents _ angiography _ restenosis 
Endovascular radiation therapy is a novel technique aimed at preventing restenosis after percutaneous coronary 
intervention.1- 3 Radiation can be delivered to the coronary 
artery by means of catheter~based systems or radioactive 
stents.4 A potential drawback of this treatment is the devel-
opment of new stenotic lesions at both edges of the irradiated 
segment (IRS). This so-called "edge effect" was originally 
described after high-activity (>3 p.Ci) radioactive stent 
implantation.5•6 However. this phenomenon is not exclusive 
to radioactive steats and may also affect coronary segments 
treated by means of catheter~based systems.7 The pathophys~ 
iology of the edge effect may be the result of vessel wall 
injuryS-IO concomitant with low-dose radiation at the edges of 
the irradiated area ll .1Z In radio-oncology. the term to define 
a cause of treatment failure due to low dose was coined by the 
Manchester Clinic as "geographic miss." In such cases. a 
small part of the treatment zone has either escaped radiation 
or been inadequately irradiated because the total volume of 
the turnor was not appreciated and hence an insufficient 
margin was taken. 13 This concept is translated in interven~ 
tional cardiology to define those coronary segments that were 
injured but received low-dose radiation. Typically. this phe-
nomenon occurs when the edges of the IRS. where. by 
definition. the dose is rather low. are injured. 
The aims of the study were (1) to determine the incidence 
and causes of geographic miss in the treatment of patients 
with intracoronary f3-radiation by use of a catheter~based 
system and (2) to evaluate the impact of this inadequate 
treatment on the angiographic outcome of these patients. 
Methods 
Patient Selection 
We retrospectively analyzed 50 consecutive patients treated at our 
institution with catheter~based J3-radiation by means of thc Beta-Cath 
system (Novoste Corp). Patients included in the radiation protocol 
were those with objective signs of ischemia and presence of 
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significant de novo lesions (0=39) or recurrent in·stent rcstcnosis 
(0=11). A detailed description of the radiation system has been 
reported elsewherc,l4 The radiation source train consists of a series 
of 12 cylindrical seeds that contain the radioisotope 9OSrfOY sources 
and is bordered by 2 gold radiopaque markers separated by 30 mm.14 
Procedure 
The medical ethics committee of our institution approved the 
investigational usc of ,B-radiation, and all patients signed :lll in· 
formed consent form. Percutaneous intervention W3S performed 
according to standard clinical practice. Typically, coronary lesions 
were treated initially with balloon angiopbsty (BA). After successful 
BA, the target coronary segment was irradiated. This could be 
followed by additional stent impi:lntatioD when clinically indiC!l.too. 
Lc.~iOD length measured on average IL4:!:4 mm. the mean balloon 
length wus 20.0=!::3 mm, and the number of balloon inflations was 
2.9:::!:1.6. Patient~ received :lSpirin (250 mg) and bepilrin (10 000 ill 
IV) at the initiation of the procedure. and an additional dose of 
heparin was administered to rnaint:Jin the activated clotting time 
>300 seconds. After the procedure. aspirin was continued indcfi~ 
nitely. In patients who also received stcnt implantation, ticlopidine 
was initiated and continued for ~15 days after the procedure. The 
radiation dose was prescribed at 2 mm from the sourcc axis. The 
prescribed dose for the treatment of de novo lesions was randomly 
assigned to 12. 14. or 16 Gy for protocol rcqlrirements. For the 
treatment of in-stent rcstenotic lesions. the prescribed dose was 16 or 
20 Gy if the reference diameter. hy quantitative coronary :mgiogra-
phy (QCA), measured s3.25 mm or >3.25 mm. respectively. The 
mean dwell time to deliver these doses was 143±44 seconds. 
Defmitions 
The IRS was defined as the area encompassed hy the 2 gold markers 
of the radiation source train. It was identified on angiograpby by a 
eontrast injection with the source in place. The edges of the IRS were 
defined as the 5~mm-long segments proximal and distal to the 
angiographie location of the gold markers. The edges that were 
touched by the angioplasty balloon or received new stent implanta-
tion during the procedure were defined as geographic miss edges. 
because they represent injured segments receiving low~dosc radia~ 
tion. Uninjured edges were those that were not traumati7..cd during 
the intervention. To determine whether the edges of the IRS were 
injured. a few steps were followed: during the procedure. every 
balloon inflation or additional stent implantation was filmed in the 
same projection, as was the radiation source. This approach allowed 
us the correct matching of the cine fllrn.s in the offline analysis. 
Either cine loop showing balloon inflation. stent implantation. and 
radiation source may be displayed simultaneously on the screen with 
the Rubo DICOM Viewer (Rubo Medical Imaging). ECG tracing is 
also displayed in either cine loop. By selecting those frames in the 
same part of the cardiac cycle. we were able to definc the 10C;)tion of 
the radiation source relative to the injured area. 
QCA Analysis 
The IRS and both edges were analyzed by QCA before and after 
intervention and at 6~month follow~up. All angiograms were evalu-
ated after intracoronary administration of nitrates. The offline anal~ 
ysis of 2 orthogonal projections was performed by means of the 
CMS II analysis system (pic Medical BY). Calibration of the 
system was based on dimensions of the catheters not filled with 
contrast medium. This method of analysis bas been previously 
validated. I5-17 The following QCA parameters were computed in the 
IRS and both edges: rninimalluminal diameter (MID). which was 
computer defined; reference diameter, which was obt:Jined by an 
interpolated methodL5- 17; and percentage diameter stenosis. Binary 
restenosis was defined in every area as diameter stenosis >50% at 
follow~up. Acute gain was defined as MLD after trC;)tment minus 
MLD before intervention. Late loss was defined as MLD after 
treatment minus MLD at follow-up. Rclative late loss was defmed as 
late loss divided by reference diameter. 1H 
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Statistical Analysis 
To comp:JtC continuous variables between IRS, geographic miss 
edges, and uninjured edges. I-way A...~OVA with post hoc analysis 
for multiple comparisons was peIformed. Unpaired Student's t test 
was peIformed to eomp:JtC continuous variables between proximal 
and distal geographic miss edges and between patients in whom the 
geographic miss was induced by balloon dilatation or stent implan~ 
tation. To comp:JtC the binary restenosis betwecn groups. the K test 
was pcIformed. All tests were 2-tailed, and a value of P<0.05 was 
considered statisticalJy significant 
Results 
Baseline Characteristics 
Fifty irradiated coronary arteries and 100 edges in 50 patients 
were eligible for the study. However. 26 edges were excluded 
because of the ostial location of the proximal end of the 
source in the right coronary artery (n==12) or overlapping of 
1 of the edges with side branches (n==14). Thus. finally, 74 
edge areas and 50 IRSs were studied. Mean age was 55.3=9 
years. and 38 patients (76%) were male. SmOking was the 
most frequent coronary risk factor. involving 33 patients 
(66%). followed by dyslipidemia in 27 patients (54%) and 
hypertension in 24 patients (48%). Eight patients (16%) were 
diabetic. The left anterior descending coronary artery was 
treated in 21 patients. the left circumflex in 10, the right 
coronary artery in 18. and a saphenous vein graft in 1. Twelve 
patients received a stent in a bailout situation. 
Incidence and Causes of Geographic Miss 
Geographic miss was observed in 22 edges (31.9%) induced 
by balloon dilatation (n==13) or additional stent implantation 
(n==9). The remaining 51 edges (68.9%) were defined as 
uninjured edges. The location of the geographic miss was in 
the proximal edge in 11 patients (50%) and in the distal 
margin in 11 patients (50%). The following reasons were 
responsible for this phenomenon: (1) development of proce-
dural complications that extended the treatment beyond the 
margins of the IRS (unexpected geographic miss. n==9): (2) 
lack of availability of a longer radiation source (>30 rrun) in 
patients with diffuse recurrent in~stent restenosis in whom 
radiation was given on a compassionate-use basis (0=8); and 
(3) lack of accurate matching: ie. the injured segment from 
previous balloon inflations was not appropriately covered by 
the source (n==5). An example of a patient with geographic 
miss induced by a balloon dilatation in the proximal margin 
is depicted in Figure 1. 
QCA Analysis 
QCA data are presented in the Table. As expected. IRSs 
demonstrated. on average, a higber acute gain than both 
injured and uninjured edges. However. geographic miss 
edges presented. on average, with significantly higher late 
loss and relative late loss. Restenosis was demonstrated in 5 
cases (10%) within the IRS. in 9 cases (40.9%) in the 
geographic miss edges. and in 1 case (1.9%) in the uninjured 
edges (P<O.OOI). No difference in the pattern of the late loss 
between the 3 areas was observed in de novo lesions 
compared with recurrent in-stent restenotic lesions (Figure 2). 
In the geographic miss edges. 4 edge restenoses (44%) were 
located at the proximal edges. wbereas the other 5 (56%) 
Geographic Miss in Intracoronary Brachytherapy 
were located at the distal edges. Mean relative late loss was 
comparable between those edges. with geographic miss 
located proximal or distal to the IRS (0.31 :to.2 versus 
0.34:!:0.2. respectively: P::::NS). Those edges in which the 
geograpbic miss was due to additional steat implantation 
presented. on average. higher acute gain than those due to 
balloon dilatation (O.70±0.4 versus 0.21=0.3. respectively: 
P=O.005). However. mean late loss and mean relative late 
loss were comparable between both causes of geographic 
miss (O.95±O.9 mm and 0.36±0.3. respectively. after steat 
versus O.77::!:0.3 mm and 0.30±O.1 after ballOQn dilatation: 
both P~NS). 
Discussion 
This study reports on the initial experience of our center with 
the use of intracoronary ,B~radiation. By means of a careful 
QCA Data 
IRS 
(0"50) 
MLD before intervention, mm 1.20:::0.3 
MLD after irrtervention, mm 2.02:::0.4 
MLD at follOW-Up, mm 1.87:::0.5 
Reference diameter, mm 2,69:::0,6 
%DS before intervention, % 54.9:::13 
%DS after intervention, % 28.4:::9 
%DS at follOW-up, % 33.3:::11 
Acute gain, mm 0,81:::0.4 
Late loss, mm 0.15:::0.4 
Relative late loss 0.06=.0.1 
Figure 1. Geographic miss induced by 
balloon dilatation. A, Lesion located in 
proximal segment of left anterior 
descending coronary artery. B, Balloon 
dilatation performed during intervention 
(black arrowheads indicate area injured by 
balloon). C, Radiation source train in 
place. Irradiated area is delimited by gold 
markers (white arrowheads), D, Final 
result: proximal traumatized edge present-
ed a residual type B dissection, E, At 
6-month follow-up: obvious reduction in 
lumen at geographic miss edge, 
retrospective angiographic analysis of all patients treated with 
the same radiation system. we sought to define the effect of 
the injury on those areas located at the margins of the source 
where the delivered dose is potentially rather low, Up to 
31,9% of the patients presented with the predefined technical 
error, called geographic miss. This concept requires the 
concurrence of 2 conditions: low-dose radiation and injury. 
Any other clinical situations that do not include both condi-
tions cannot be called geograpbic miss. For instance. (1) the 
effect of injury on coronary segments not being irradiated 
(proximal or distal to an IRS but in areas in which the 
calculated dose is almost 0) should fall into the category of 
normal restenotic process; (2) the effect of low-dose radiation 
in areas that have not been injured may be defined as the pure 
radiation edge effect. beeause in intracoronary radiation, the 
Geographic Miss Uninjured Edges 
Edges (n=22) (0"52) p 
2.02=.0,6 2.10:::0.6 <0.0001 
2.43:::0.5 2.12:::0.6 0.01 
1.59:::0.6 2.02:::0.5 0.006 
2.50:::0.6 2.55=.0.7 NS 
19.8:::14 17,9:::11 <0.0001 
19.9:::10 20.8:::11 0.0003 
44.3:::22 24.3:::10 <0.0001 
0.41:::0.4 0.Q1:::0.3 <0,0001 
0.84=.0.6 0.09=.0.4 <0.0001 
0.32=.0.2 0.02=.0,1 <0.0001 
%DS indicates diameter stenosis. Data are mean:::SD. 
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Figure 2. O'rt'ference in late loss between IRS, geographic m'ISS 
edges, and uninjured edges. De novo lesions and in~stent reste-
nosis demonstrated same degree of late loss between 3 groups. 
edges of any IRS will always receive low-dose radiation; and 
(3) finally. the effect of a full prescribed dose on segments 
presenting with or Vlithout injury is the situation in which the 
physician may be able to irradiate (with full dose) the entire 
injured segment and include some uninjured margin. A key 
issue in the definition of geographic miss is to define those 
segments receiving a low dose. These may vary between 
systems and sources used. With the Bcta·Cath system, the 
longitudinal distance of the 100% isodose is 26 mm. Because 
the ,s..emitting 9OSrfOY has an acute falloff of dose related to 
the distance.19 the last 2 mrn within the markers of the source 
should be considered as having received a lower than pre-
scribed dose. In fact the dose received at 1 mm from the 
100% isodose is 86% of the prescribed dose. and at 2 mm. 
60% of the prescribed dose (inner part of the gold marker). At 
3 mm, the dose is 30% of the prescribed dose; at 4 mm. 13% 
of the prescribed dose; and at 5 mm. 5% of the prescribed 
dose. We defined the IRS as the segment encompassed by the 
2 gold markers. which included the last 2 mm within the 
markers with a lower than prescribed dose (up to 60% of 
the prescribed dose). By this definition. late loss and reste-
nosis rate were significantly lower than those of the injured 
edges (analyzed from the inner part of the gold marker). 
Furthermore. the 5 cases of restenosis within the IRS were 
located at the site of the initial J\1LD. These results may 
reflect the fact that the dose at these last seeds of the source 
was high enough to avoid the edge effect after the edges had 
probably been injured during the procedure. especially when 
a 20-mm-Iong balloon was used. Thus. the region receiving a 
low dose may be defined. for this system and source. as the 
5-mm-Iong segment located 2 mm farther from the 100% 
isodose boundary. that is. beyond the inner part of the gold 
marker. In this regard. we believe that the injury should be 
completely restricted to the segment of the 100% isodose 
curve of the radiation source (26 mm) and that the last 2 mm 
at both extremities of the source and within the gold markers 
may be considered relatively but probably not completely 
safe. Finally. any injured segment covered by or beyond the 
gold marker (up to 5 mm) must be considered to be at high 
risk of failure at follow-up. 
From the perspective of these findings and future technical 
developments in the field. the following recommendations are 
advisable. Filming every single balloon inflation performed 
during the procedure would allow one to define the injured 
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area. More than ever. tenacious attention to detail in position-
ing the radiation catheter encompassing the entire injured 
area must be mandatory. The development of longer sources 
(>30 mm) would allow one to treat diffuse lesions and 
completely cover those areas in which an extension of the 
treatment was indicated because of procedural complications. 
Equally, the use of online QCA in the decision-making would 
avoid appreciation errors due to visual assessment of the 
target area and subsequent underestimation or overestimation 
of balloon lengths. Finally. the selection of the most suitable 
fluoroscopic projections (eg.less foreshortening. no overlap-
ping) would avoid errors in the quantification of the region of 
interest 
The facts that the locations of most of the restenoses were 
in geographic miss edges and that late loss in those areas was 
unexpectedly high must raise an alarm about the deleterious 
effect of the combination of injury and low-dose radiation. 
This hypothcsis may be supported by the fact that the late loss 
observed in those injured edges is higher than that reported in 
recent clinical trials after either BA or stent implantation20,zl 
and higher than that demonstrated in the uninjured edges. 
Balloon overstretch injury has been used as an experimental 
model to study the restenosis proeess.~-lO The response of the 
vessel wall to injury involves both neointimal hyperplasiaH,q 
and vessel remodeling.10.22.23 The stimulatory effect of low-
dose radiation after BA on smooth muscle cell proliferation 
has been reported previously.ll In the low-dose radiation 
group of this swine model (10 Gy). neointima was composed 
of smooth muscle cells. with a marked increase in inflamma-
tory cells and less medial and intimal fibrosis than in the 
higher-dose groups (15 and 20 Gy) and the control group. It 
was suggested that at low dose. inadequate fibrosis was 
induced to prevent effective smooth muscle cell migration 
and to act as a diffuse barrier for mediators of chemotaxis. 
chemokinesis. and cellular proliferation.1l Similarly. after 
low-activity radioactive stent implantation (1 ,u.Ci) in a 
porcine model. neointimal hyperplasia was significantly 
greater than that after nonradioactive control stents. 12 If 
ongoing intravascular studies reveal that edge restenosis is 
mainly due to plaque increase. the former hypothesis that at a 
low dose. inadequate medial and intimal fibrosis to avoid 
migration and proliferation predominates may become a 
plausible explanation. Conversely. if negative remodeling is 
the main contributor to the lumen loss. the excess of inflam-
matory cells demonstrated at low dose may be responsible for 
subsequent adventitial fibrosis and vessel shrinkagc. The 
development of the so-called "candy wrapper" after radioac-
tive stent implantationS may represent the clinical paradigm 
of the combined deleterious effect of low-dose radiation and 
injury. The latter is secondary to the angioplasty balloon used 
for predilatation and postdilatation of the radioactive stenl In 
this regard. a higher balloon-tOoartery ratio was associated 
with the presence of this phenomenon,s 
Future trials must address the benefit of new technical 
developments in the field (use of square deployment bal-
loons: hot-end. cold-end stents6; longer sources with smaller 
radiation delivery catheters) to minimize the impact of injury 
at the edges after either radioactive stent- or catheter-based 
systems. 
Geographic Miss in Intracoronary Brachytherapy 
Study Limitations 
In this study. only 1 type of radiation delivery catheter using 
the f3-source 9QSrfOY was evaluated. Thus. the effect of either 
other catheter-based systems using centering balloons and 
different sources or the "..radiotherapy on the geographic 
miss edges cannot be extrapolated from our results. 
The actual dose at the margins of the radiation source has 
not been calculated. A low dose at these edges was assumed 
because the isotope 9OSrfOY demonstrates an acute falloff 
related to the distance from the 100% isodose bOundary.l" 
This angiograpbic study was aimed at defining the concept 
and the clinical implications of the geographic miss. To 
define the mechanism of the unexpectedly high late loss and 
the correlation between radiation dose and plaque extent at 
the margins of the IRS. intravascular ultrasound studies must 
be carried out. 
The location of the segment receiving a low dose may vary 
between systems and sources. Thus. the confidence margin to 
be taken may vary accordingly. 
The position of the source relative to the various balloon 
inflations was assessed by comparing still frames at the same 
part of the cardiac cycle from cineangiograms performed in 
the same projections. However. small inaccuracies in the 
definition of the IRS and the edges. derived from the axial 
movement of the radiation source during the cardiac cycle, 
cannot be completely ruled out. 
This study was not placebo-controUed. Thus. the effect of 
the sham source on the balloon~injured coronary segments 
has not been determined. 
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Clinical Investigation and Reports 
p-Particle-Emitting Radioactive Stent Implantation 
A Safety and Feasibility Study 
AJ. Wardeh, MD; I.P. Kay, MBChB; M. Sabato, MD; V.L.M.A. Coen, MD; 
A.L. Gijzel. MD; J.M.R. Ligthart, BSc; A. den Boer, BSc; P.C. Levendag, MD, PhD; 
WJ. van der Giessen, MD. PhD; P.W. Serruys. MD. PhD 
Background-This study represents the Heart Center Rotterdam' s contribution to the Isostents for Restenosis Intervention 
Study. a nonrandomized multicenter trial evaluating the safety and feasibility of the radioactive Isostent in patients with 
single coronary artery disease. Restenosis after stent implantation is primarily caused by neointimal hyperplasia. In 
animal studies, ,B-particle-emitting radioactive stents decrease neointimal hyperplasia by inhibiting smooth muscle 
cell proliferation. 
Methods and Results-The radioisotope np. a ,B-particle emitter with a half-life of 14.3 days, was directly embedded into 
the Isostent. The calculated range of radioactivity was 0.75 to 1.5 j.l..Ci. Quantitative coronary angiography 
measurements were perfonned before and after the procedure and at 6-month follow-up. A total of 31 radioactive steots 
were used in 26 patients; 30 (97%) were successfully implanted, and 1 was embolized. Treated lesions were in the left 
anterior descending coronary artery (0= 12), the right coronary artery (0=8), or the left circumflex coronary artery 
(n=6). Five patieots received additional, nonradioactive stents. Treated lesion lengths were 13±4 mm, with a reference 
diameter of 2.93±0.47 mm. Minimum lumen diameter increased from 0.87±0.28 mID preprocedure to 2.84±0.35 mID 
postprocedure. No in-hospital adverse cardiac events occurred. All patients received aspirin indefinitely and tidopidine 
for 4 weeks. Twenty-three patients (88%) returned for 6-month angiographic follow-up; 17% of them had in-stent 
restenosis, and 13% had repeat revascularization. No restenosis was observed at the stent edges. Minimum lumen 
diameter at follow-up averaged 1.85±0.69 mm. which resulted in a late loss of 0.99±0.59 mm and a late loss index of 
0.53±0.35. No other major cardiac events occurred during the 6-month follow-up. 
Conclusions-The use of radioactive stents with an activity of 0.75 to 1.5 ,u.Ci is safe and feasible. (Circulation. 
1999;100:1684-1689.) 
Key Words: I3-rays _ angioplasty _ radioactive isotopes. restenosis _ stents 
Percutaneous transluminal coronary angioplasty (PI'CA) is an accepted treatment for coronary artery disease. l However, 
angiographic restenosis is reported in 40% to 60% of patients 
after a successful PTCA 1.2 The main mechanisms of restenosis 
include late constriction of the arterial wall (vascular shrinkage) 
and neointimal hyperpJasia.3-6 which are due to the migration 
and proliferation of smooth muscle cells and myofibroblasts 
after balloon-induced trauma of the arterial wall and the depo-
sition of an extracellular matrix by the smooth muscle cells.6-9 
Stent implantation reduces the restenosis rate10.11 by preventing 
clastic recoil and late constrictive remodeling.1Z However. the 
occurrence of restenosis after stent implantation remains unre-
solved. especially in small vessels and long lesions. in which it 
may occur in >30% of cases.J3 Restenosis is primarily caused 
by neointimal hyperplasia. which occurs due to trauma of the 
arterial wall by the stent struts.5 
Irradiation is used to decrease neointimal proliferation 
because the actively proliferating cells have an increased 
sensitivity to the lethal effects of radiation. which inhibits 
benign hyperplastic reactions such as keloid formation and 
heterotopic ossification.14.15 Several experimental and clinical 
trials showed that brachytherapy with a radioactive source 
after PTCA or stent implantation can reduce restenosis by 
inhibiting neointimal hyperplasia. 16-19 and several animal 
studies demonstrated a dose-related reduction of in-steut 
restenosis with the use of radioactive stents.~o-:::: Further-
more, a dose-dependent delay in the endothelialization of the 
stent occurred. which increased the chance of subacute 
thrombosis. ZOZl 
This study evaluated the safety and feasibility of radioac-
tive stent implantation (activity level. 0.75 to 1.5 J.Lei) in 
single-lesion, native coronary artery disease. 
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TABLE 1. BaUoon Inflation and Stent Deployment Data 
?redllatation Stent Deployment Postdilatation 
Les'lon Type of 
Patient $tent Diam, rnm Aim Length, mm Diam, rnm Aim Diam, mm Aim Length, mm Length, mm 
PS; 3.0 20 3.0 10 3.5 16 30 17 
PS 3.0 8 20 3.5 3.0 16 15 11 
3 PS 3.5 14 30 3.5 10 3.5 16 13 10 
4 PS 3.5 8 30 3.5 12 NO NO NO 15 
5 8X" 2.5 14 20 3.0 12 3.5 16 13 15 
6 BJ( 3.5 20 3.5 10 4.0 12 13 12 
7 PS 3.0 10 20 3.0 12 3.5 10 13 11 
8 BJ( 4.0 6 15 3.5 12 4.5 16 15 10 
9 BX 2.5 6 15 3.5 16 2.5 12 15 14 
10 BX 3.5 10 20 3.5 11 4.0 18 13 19 
11 8X" 3.0 12 13 3.5 11 4.0 18 13 8 
12 BXt~ 3.0 10 20 3.0 12 3.0 18 20 17 
13 BX" 3.0 10 20 3.0 8 3.5 16 13 17 
14 BX 3.0 B 15 3.5 12 NO NO NO 14 
15 BX 3.0 12 13 3.0 10 4.0 14 13 7 
16 BX 3.0 12 13 3.0 10 4.0 16 13 10 
17 BX 3.5 12 20 3.5 4.0 16 13 12 
18 BXt 3.0 8 20 3.0 10 4.0 18 20 23 
19 8X 3.5 7 20 3.5 7 4.0 14 13 10 
20 BXt 3.0 14 29 3.0 18 3.5 16 29 15 
21 BX 3.5 8 20 3.5 8 NO NO NO 12 
22 8X 3.5 15 3.5 8 4.0 12 13 10 
23 BXt 3.0 10 20 3.5 10 4.0 16 20 16 
Mean 3.2 10 19 3.3 11 3.7 15 16 13 
SO 0.4 3 5 0.2 0.5 2 4 
Atm indicates maximum atmospheres; Diam, maximum diameter; NO, not done; PS, Palmaz-$chatz. 
"1 additional nonradioactive stent implanted; t2 BX stents implanted; :j:2 addttionaJ nonradioactive stents implanted. 
Methods 
Patient Population 
The Isostents for Restenosis Intervention Study (IRIS) is :l DOnr.m~ 
domizcd. multicenter trial evaluating the safety and feasibility of 
rndioactivc stents. The data presented here represent the experience 
of the Heart Center Rotterdam. Patients who had single coronmy 
lesions with a maximum lesion length of 28 mm (maximum. 2 
mdioactive stents of 15 mm implanted in bndcm position) and 
objective evidence of ischemia were eligible. Exclusion criteria 
included the following: a recent myocardial infarction (MI; creatine 
kinase [CK] isoenzyme contUningM and B subunits [ME] >3 times 
the upper limit of normal within 5 days of the intervention); left 
ventricular ejection fraction <40%: allergy or contraindication to 
aspirin. ticlopidine. or stainless steel; and lesions located in the left 
main artery or at the ostium of the right coronary artery. The Medical 
Ethic:il Committee of the University Hospit:ll Rotterdam approved 
the study. All patient~ provided written. informed consent before the 
procedure. 
Radioactive Slen!, Dosimetry, and Safety Issues 
Two types of stents were implanted in this study: the P:ilmaz-Schatz 
(Cordis Corp, Johnson and Johnson Interventional Systems Co) and 
BX stent (Isostent Inc). Phosphorus.32 f2p). a pure ,B-enritter with a 
half-life of 143 days. was produced by neutron irradiation of red 
amorphous Jlp for 10 days to aehleve a concentration of 20XlO-~ 
12pf'lp (100 mCi). The irradiated phosphorus was then placed into a 
mass separator. ioni;red. and accelerated. A dipole magnet separated 
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the 32p and )Ip. Subsequently. ~P was directly impluotcd into the 
met:l.l stent surface.21 The calculated radioactivity of the stents at 
implantation was 0.75 to 1.5 .u,Ci. and the dose delivered over 100 
days at 1 mm from the stent surface was c:ileulated for each stent All 
personnel were trained in the appropriate handling of radioactive 
materials. During implantation. the lucite shleld enclosing the stent 
and the sheathed introduction system prevented exposure of the 
operator to the radiation of the stent Background measurements of 
radioactivity were made by means of a Geiger counter (Modcll4c. 
Ludlum Measurements Inc). All disposable materials that were in 
contact with the stent were immediately disposed of in a plexiglas 
container, and radioactivity measurements were made by the radia-
tion technician. 
Quantitative Coronary Angiography 
Quantitative coronary angiography (QCA) was performed preproce-
dure, postprocedure. and at 6-month follow-up. Coronary angiogra-
phy was performed after intracoronary administration of nitrates. 
The off-line analysis of 2:;2 orthogonal projections was perfonned by 
the CMS IT analysis system (Pie Medical BY). Calibration of the 
system was based on dimensions of the catheters not filled with 
contrast medium. This method of analysis has been cxtensively 
validatcd and applied in numerous cliolc:il trialS.24-Z~ The following 
measurements wcrc obtained in each projection: minimum lumen 
diameter (MID). reference diameter. percent diameter stenosis 
(%DS). and lesion length. Lesion length was user-defined.U> Proce. 
dural success was defined as <20% OS as measured by online QCA. 
Short-term gain was defmed as MLO postprocedure minus MLD 
preprocedure, Late loss was defined as MLD postprocedure minus 
111..0 at follow·up. Late loss index was defmed as short·term gain 
divided by late loss.Z7 Rcstcnosis was defined as >50% OS at 
follow-up located within the stent or ::55 rom from the stent edges. 
The latter represents an area where tissue is subjected both to 
balloon-induced trauma and to a lower dose of radiation.~l which 
may stimulate restenosis. This edge-effect phenomenon bas recently 
been described in patients and called the "candy-wrapper cffect."211 
To qU:l.lltify an edge effect. a QCA segmental analysis was per-
formed, At both postprocedure and follow-up, the treated vessels 
were first divided into segments "-'5 rom in length: then. the me:m 
diameter of the 5-mm segments distal and proximal to the stent edges 
were calculated using the CAAS IT analysis system. Careful com-
parison of the proximal and wsW edges was performed postproce-
dure and at follow-up. 
Procedure and Follow·Up 
Patients received 250 mg of aspirin and 10 000 IU of bep3rin at the 
start of the procedure. The activation clotting time was maintained at 
>300 s. After balloon predilatation.. the radioactive stent was 
implanted at a nominal deployment pressure of 8 to 10 atm. If 
needed. stent deployment w:lS optimized using shorter postdilatation 
balloons of longer diameters to higher pressures (Table 1). Extreme 
care was taken to avoid inflating the bolloon outside the edges of the 
stent Because of the poor radiopacity of the Palmaz-Schatz and thc 
BX stents. the best angiographic view was selected. and images were 
filmed in a magnified field (5 inch) with digital zoom enhancement 
to optimize stent visuali7..a.tion. All patients received ticlopidine 250 
mg BID for 4 weeks after stent implantation and aspirin 80 mg daily 
indefinitely. CK and CK-:M:8 measurements were made. and the 
ECG was recorded at 6 and 12 to 18 hours postprocedure in :ill 
patients. 
Patients returned for 1- and 6-month clinical follow-up. An ECG 
was perfonned at each visit The 30-day and 6-month clinical end 
points were death. Q-wave MI (using the Minnesota code criteria~). 
non Q-wave:MI (CK-MB rise >2 times normal upper limit). bypass 
surgery. target segment revascula.ri7..a.tion.. sustained abrupt closure. 
or subacute thrombosis of the target vessel. 
At the 6-month visit, an exercise stress test was performed. Target 
vessel reva..'\Cuhrization was performed on the basis of clinical 
symptoms and/or evidence of ischemia on exercise testing. 
Statistical Analysis 
Data are presented as mean:!:SD. Continuous data were compared by 
2-tailed Student's t test or linear regression when appropriate. 
Results 
Baseline Characteristics 
Baseline demographics. anginal status. and lesion character-
istics are shown in Table 2. 
Procedural Success 
A total of 30 of the 31 stents (97%) were successfully 
implanted (26 were BX Isostent and 4 were Palmaz-Schatz) 
in 26 patients. One stent (EX) was lost in the peripheral 
circulation without clinical sequelae. Eighteen patients were 
successfully treated with a single radioactive stent, and 4 
required a second radioactive stent to cover lesions> 15 mm. 
Five patients received additional nonradioactive stents: 2 due 
to procedural dissection not covered by the radioactive stent. 
2 because a second radioactive stent was not available. and 1 
because a second radioactive stent became dislodged when 
trying to implant it distal to the first radioactive stent All 
procedures were successful. and no complications occurred. 
Radioactive Stent Feasibility Study 
TABLE 2. Patient Demographics 
Sex, male/female 1818 (69/31%) 
Age, y 
Average 60 
Range 43-74 
Risk factors 
Diabetes mellitus 1 (4%) 
Hypercholesterolaemia 16(62%) 
Hypertension 11 (42%) 
Smoking 15 (58%) 
Family history 11 (42%) 
,",ces 
2 302%) 
3 10 (38%) 
4 13(50%) 
Lesion type, AHAiACC 
Bl 8(31%) 
B2 18 (69%) 
Data are n (%) unless otherwise indicated. AHA indicates American Heart 
Association, and ACC, American COllege of cardiology. 
Follow-Up 
The mean hospital stay was 1.8 days. All patients were 
angina-free at hospital discharge. At 30-day follow~up. no 
clinical end points had occurred: 24 patients (92%) were 
asymptomatic. and 2 patients (8%) had recurrent angina 
pectoris (AP) of Canadian Cardiovascular Society Classifica-
tion (CCS) 1 (n=l) and CCS 2 (n=I). All 26 patients 
returned for 6-month clinical follow~up. Twenty-one (81%) 
were asymptomatic. and 5 patients (19%) had AP CCS 1 
(n=I), CCS 2 (n=2), CCS 3 (n=I), or CCS 4 (n=I), 
Six-month angiograpbic follow-up was performed in 23 
patients (88%). The remaining 3 patients (12%) refused: 2 of 
them were asymptomatic. and the third had AP CCS 1. Four 
patients had angiographic restenosis (17%). All restenotic 
lesions were diffuse (located throughout the entire length of 
the stent). One of the 4 restenoses occurred in a patient with 
a single radioactive stent 1 restenosis was in a patient 
receiving 2 radioactive stents in combination with a nonra-
dioactive stent, and 2 restenoses were observed in patients 
receiving a combination of 1 radioactive and 1 nonradioactive 
stent In the restenotic patients who received an additional 
nonradioactive stent, restenosis occurred in both the radioac-
tive and the nonradioactive stent On QCA. no discernible 
differences existed between the patterns of proliferation 
between the Palmaz-Schatz and BX stents. No cases of 
restenosis at the stent edges were noted. Two of the 4 
restenotic patients underwent a re-PTCA. One was referred 
for bypass surgery for in-stent restenosis in the proximal left 
anterior descending coronary artery and progression of a 
previously nonsignificant lesion in the proximal left circum-
flex artery (main stem equivalent). One was treated medi~ 
cally; this patient was asymptomatic. with a negative stress 
test No other clinical end points existed at 6-month 
follow-up. 
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TABLE 3. Dosimetry and QCA Analyses 
Lesion 
Length, 
mm 
Preintervention Postintervention 
Type of Activity, 
Patient stem }.tel 
Dose, 
cGy MLO OS RD MLO OS RO MLD OS RO 
Acute 
Gain 
laO, 
Loss w 
PS:j: 1.07 712 
712 
647 
647 
712 
1000 
500 
824 
748 
1157 
587 
B27 
908 
748 
67B 
712 
953 
678 
677 
500 
953 
700 
500 
743 
165 
RCA 
lAO 
Lex 
RCA 
lAO 
RCA 
lAO 
Rex 
Rex 
lAO 
LAO 
lAO 
lAO 
lAO 
ReX 
LAO 
RCA 
RCA 
ReX 
lAO 
Rex 
RCA 
RCA 
17 
11 
10 
15 
15 
12 
11 
10 
14 
19 
0.65 76 2.64 2.48 19 3.04 1.74 30 2.51 1.83 
1.54 
>47 
m 
1.9D 
1.42 
1.97 
2.52 
1.43 
>19 
2.83 
1.37 
1.8D 
2.13 
>54 
2.17 
2.07 
2.15 
1.94 
1.69 
1.66 
1.75 
1.76 
1.97 
D.39 
0.74 
"2 
D.16 
1,31 
2.33 
D.4D 
1.31 
0.06 
D.61 
1.23 
2 PS 1.07 1.02 52 2.12 2.56 8 2.78 0.54 77 2.39 
3 PS 0.97 D.46 85 3.05 2.93 15 3.41 2.77 18 3.36 
4 PS 0.97 D.75 79 3.50 2.91 22 3.73 1.6D 47 3.01 
BX" t07 0.9D 59 2.22 2.80 3.07 D.47 87 3.61 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
" 23 
Mean 
SO 
8X 
PS 
BX 
BX 
BX 
BX-
BlW 
BX· 
BX 
BX 
BX 
BX 
BXt 
BX 
BXt 
BX 
BX 
BXt 
1.50 
0.75 
1.24 
1.12 
1.73 
0.88 
124 
1.36 
1.12 
1.02 
1.06 
1.43 
1.00 
1.02 
0.75 
1.43 
1.06 
0.75 
1.10 
0,25 
17 
17 
14 
7 
10 
12 
23 
10 
15 
12 
10 
16 
13 
4 
1.64 53 
D.67 75 
0.99 74 
D.50 77 
0.99 71 
0.59 79 
1.0D 58 
D.69 72 
D.62 79 
0.49 83 
1.10 67 
D.85 75 
0.83 73 
D.96 71 
1.13 6D 
1.23 62 
1.16 66 
D.9D 68 
D.87 70 
D.28 9 
3.49 3.06 
2.67 2.64 
3.65 3.51 
2.08 1.92 
3.31 3.18 
2.73 3.42 
2.37 2.36 
2,45 2.48 
2.96 2.75 
2.81 3.03 
3.36 3.27 
3.44 2.92 
3.08 2.99 
3.28 2.90 
2.81 2.81 
3.31 2.89 
3.37 2.91 
2.75 2.66 
2.93 2.84 
0.47 0.35 
15 3.59 2.45 
15 3.12 1.58 
19 4.31 2.76 
12 2.19 1,n 
18 3.87 2.39 
17 4.11 2.65 
16 2.81 0.86 
14 2.87 1.73 
12 3.12 1.61 
16 3.59 2.20 
10 3.63 1.87 
9 3.19 0.83 
3.07 2.51 
17 3.50 2.87 
17 2.81 1.97 
21 3.61 2.03 
9 3.18 1.72 
23 3.45 1.73 
15 3.31 1.85 
5 0.48 0.69 
23 3.18 0.61 0.43 
39 2.58 1.07 0.54 
44 4.2D 0.75 0.3D 
26 2.39 D.16 D.11 
16 2.82 D.79 0.36 
2D 3.32 0.77 0.27 
55 1.90 1.51 1.1D 
11 1.94 D.76 0.42 
44 2.86 1.15 D.54 
25 2.91 D.83 D.33 
34 2.81 1.41 0.65 
70 3.29 2.D9 1.D1 
28 3.47 D.48 0.22 
17 3.46 D.03 D.02 
39 323 D.84 D.50 
39 3.34 D.85 0.51 
45 3.12 1.20 D.68 
42 2.99 D.93 D.53 
38 2.99 0.99 D.53 
20 0.54 D.59 D.35 
Dose ind'icates dose over 10D days at 1 mm from the stent surface; OS, percentage diameter stenoses; lAD, left anterior descending artery; LeX, left circumflex 
artery; W, late loss index; PS, Palmaz-Schatz stem; RCA, right coronary artery; and RO, reference diameter. OGA measurements are in mm. 
"1 addttional nonradioactive stent implanted; t2 ax stents implanted: :12 additional nonradioactive stents implanted. 
QCA Measurements 
QCA and procedural data are presented in Table 3. MLD 
increased from O.87:!:O.28 mm preprocedure to 
2.84:!:0.35 mm postprocedure (P<O.OOOl). MLD at 
follow-up was 1.85:!:0.69 mm (P<O.OOOI relative to post-
procedure), resulting in a late loss index of 0.53:!:0.35. 
Segmental analysis of the mean diameter of the 5-mm 
segments distal and proximal to the stent edges showed 
significant cbanges. The proximal diameter decreased from 
3.19:!:0.42 mmpostprocedure to 2.78:!:0.62 mm at follow-up 
(P=0.006). The distal diameter decreased from 
2.69:!:0.49 mm postprocedure to 2,45:!:0.50 mm at follow-up 
(p~O.0167). 
Radiation Doses 
Stent activity level and the cumulative dose over 100 days 
that was delivered to a 1 mm depth outside the stent are 
presented in Table 3. No correlation existed between stent 
activity or delivered dose and .MLD or late loss index at 
follow-up. No additional environmental radiation was mea-
sured during the procedure. 
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Discussion 
This nonrandomized study illustrates that .B-partic1e-emitting 
radioactive stent implantation is safe and feasible, with no 
subacute or 3D-day clinical events recorded. Subacute throm-
bosis was not seen. despite the concern regarding delay in 
endothelialization, as previously reported in animal stud-
ies.10.23 The embolization of the radioactive stent had no 
clinical sequelae at this level of activity. When stents with 
higher levels of radioactivity are implanted. this may not 
remain true. Detecting an embolized radioactive stent is a 
problem because (1) the .B-radiation of the stent is not 
measurable outside the body and (2) the stents have a 
relatively low radiopacity. Clearly. there is room to increase 
the radiopacity or to add markers to the stents. 
Using a multivariate model constructed from the data of 
the Benestent trials that was based on similar lesions. vessel 
size, and short~term result, a predicted restenosis rate of 12% 
and an .MLD at follow-up of 2.05 mm was calculated.30•31 
Thus. the actual results achieved are somewhat less favorable: 
however, in such a small patient cohort. no definite conclu-
sions can be drawn except that the late results are within the 
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Figure 1. TwCKIimensional dose representation for 1~j.tCi 3:!p 
Palmaz-5chatz stent. Cumulative dose given over 100 days is 
shown (source, l$Ostent Inc). 
acceptable limits for safety and feasibility of this stent. It 
must be noted that 3 of the 4 patients who had in~stent 
restenosis had multiple stents implanted. which increases the 
risk of rest enos is: in the group of 18 patients who bad a single 
radioactive stent implanted. only 1 had restenosis. Overall, 
these 6-month clinical and angiograpbic results are similar to 
the published results of nonradioactive stents.10•11 
The Milan group was the first to report restenosis within 
the stent and at the edges of the stent (the candywwrapper 
phenomenon); this restenosis was possibly caused by inw 
creased balloon injury (barotrauma) and the lower radiation 
dose at the stent edges.21 .2l! In the Rotterdam series. particular 
attention was paid to avoiding balloon injury outside the stent 
to minimize the edge effect No cases of edge restenosis were 
seen in this cohort: however. the proximal and distal mean 
diameter at the stent edges. measured postprocedure and at 
followwup. decreased significantly. Because extreme care was 
taken to avoid inflating the balloon outside the stent edges. 
this edge effect may be caused by the lower radiation dose. 
Dosimetry 
Previous work by Janicki et al32 on the 1.0-~Ci Palmaz-
Schatz stent demonstrated the nonunifonnity of dosing in 
areas adjacent to stent strut wires and those areas between the 
wires. Models showed that for a 32p stent of 1.0 p.Ci that was 
15 mmin length, at a distance of 0.1 mm, dose values of2500 
cGy were delivered at the strut wires (peaks) and 800 cGy 
between the wires (valleys) over 1 half-life (14.3 days). The 
nonunifonnity of dosing. reflective of stent geometry. de-
creased at distances 1 to 2 mm from the stent surface. 
Although these data provide an in-vitro analysis of dosing 
from a radioactive sten!, the actual dose distribution is 
probably affected by variations in atherosclerotic plaque 
morphology and the symmetry of the lesion and stent expan-
sion. The 2D dosimetry representation of the Palmaz-Schatz 
and BX stent were done using the Janicki modeP2 (Figures 1 
and 2). 
Currently. dose-finding studies examining restenosis after 
implantation of 32p BX stents in patients with lesion morphol-
ogy similar to that described in this study are underway. It is 
Radioactive Stent Feasibifity Study 
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Figure 2. Twc-.dimensional dose representation for 1-t-tCi 32p 
BX stent. Cumulative dose given over 100 days is shown 
(source, lsostent Inc). 
possible that increased doses will decrease in-stent restenosis. 
as has been described in animal studies.21-23 Therefore. a 
European Dose Response trial has been started with activities 
ranging from 1.5 to 3. 3 to 6. 6 to 12, and 12 to 20 p.Ci. 
Conclusion 
This study reports that the implantation of .s-partic1e-emit-
ting radioactive stents with an activity of 0.75 to 1.5 p.Ci is 
safe and feasible. 
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· Editorial 
I Like the Candy, I Hate the Wrapper 
The 32p Radioactive Stent 
Patrick W. Serruys, MD, PhD; L Patrick Kay, MBChB 
U nited States patent 5059166. issued October 22. 1991. to Robert and Tnn Fischell. described an "intraarterial stent with the capability to inhibit 
intimal hyperplasia. ") The proponents of this patent went on 
to say in their proposal: "Since radiation from a radioisotope 
source is capable of selectively inhibiting the growth of 
hyperproliferating cells as compared with normal cells. a 
radioisotope material which forms part of the stent can be 
used to decrease the rate of arterial reclosure. The radloiso~ 
tope could be placed inside the stent, alloyed into the metal 
from which the stent is made, or preferably. it can be coated 
onto the stent's exterior surface." So began the story of the 
radioactive stent Eight years and several animal species later. 
we are becoming aware of the bright and dark sides of this 
treatment modality in the human model. 
See p 18 
The safety and efficacy study by Albiero and colleaguesz 
describes the dose·related decrease noted at 6·month 
follow·up of intrastent neointimal hyperplasia after implan-
tation of 3~ radioactive stents at activities of 0.75 to 12 .u.Ci. 
Whereas in·stent restenosis was all but obliterated at higher 
doses of radiation, intralesion restenosis was high because of 
late lumen loss at the stent edges. Aptly, the authors coined 
the term "candy wrapper" to describe this new restenotic 
pattern. It is possible that the animal workers who implanted 
the first radioactive stents observed this phenomenon. Unfor-
tunately, the significance of this finding may not have been 
immediately apparent 
Historical and Dosimetric Considerations 
The study by Albiero and colleagues reflects the courage of 
the investigators who, despite indifferent and at times con· 
tradictory results from animal work. persisted in their en-
deavor to discover whether radioactive stent implantation 
would be effective in humans. 
Previously, Hebrlein et al.3.4 using the rabbit iliac model, 
polyisotopic sSCo (elements $SCo, S6CO, S7Co. ~i. and sSFe) 
with activity levels of 17.5 and 35 J,LCi. and later 3~ stents 
(activity levels of 0.5, 4, 6. and 13 .u.Ci), had demonstrated a 
The opinions expressed in this editorial :tIe not ncccss:ui1y those of the 
editors or of the Americ:m Heart Association. 
From the Thornxeenter. Rotterdam. The Nether1:mds. 
Reprint requcst.~ to Prof Patriek W. Scrruys, Head of the Department 
of Interventionai Cardiology. Thornxcenter Bd 418, University Hospital 
Dijkzigt, Dr Molewaterplcin 40, 3015 GD Rotterdam, The Netherlands. 
(CirculaJion. 2000~101:3--7.) 
© 2000 Americ:m Heart Association. Inc. 
CirculaJion is available at http://www.circulationaha.org 
dose·dependent effect of inhibition of neointimal hyperplasia 
within the stent It had already been noted that lower activity 
levels were able to reduce neointimal hyperplasia. but the 
effect was lost at 12 weeks, particularly at the stent ends. 
Between struts and at stent ends. endothelialization occurred 
more rapidly and was dose.dependent 
In the porcine coronary restenosis model of Carter et al,5 
different activities of 32P.containing stents were used. 
Mitche1l6 makes the following observation on these findings: 
"The doses delivered by the different activities of l.."'p were 
divided into 3 categories: low «2000 cGy), intermediate 
(4000 cGy) and high (> 10 000 cGy). Based on these values. 
the average dose rates to the tissue over the 25~day period of 
the study were: low (3 cGylh). intermediate (6 cGylh). and 
high (15 cGy/h). It is interesting that both the high and low 
doses and dose rates were effective in reducing the extent of 
restenosis, whereas, the intermediate dose/dose rate was 
ineffective if not worse than the control. These findings do 
not conform to the findings that would be expected as dose 
and dose~rate are reduced. One might expect the high dose! 
dose rate to be effective and perhaps the intermediate and low 
dose/dose rate to be ineffective. The fact that the low 
dose/dose rate treatment was effective in this study suggests 
that perhaps an inverse dose-rate effect is operative over a 
narrow range of dose rates in this model." As suggested 
above, it is not only the total dose of irradiation delivered to 
the tissue that is important but also the dose~rate time interval 
in which radiation is delivered.. This reflects the simultaneous 
processes of DNA repair. concurrent with the damage in~ 
duced by radiation exposure, This is particularly important in 
comparisons of the high dose-rates of catheter·based tech-
niques with those of radioactive stents that use low dose~ 
rates. An increase in the dose-rate at which certain cell lines 
are irradiated in vitro demonstrates a killing effect that is most 
marked between 1 and 100 cGy/mln. 4.7 However. at 0.6 
cGy/min. there is more effective cell killing than at 0.2 or 2.6 
cGy/min. This is due to cell cycle blockade. At this dose~rate. 
the cells are selectively blocked at GJmitosis. a more 
radiosensitive phase of the cell cycle. Once this occurs, the 
low-dose-rate treatment becomes much more efficient with 
respect to killing (inverse dose-rate effect).6 
We previously made the following comment on these 
conflicting observations: "so far incremental doses have 
always resulted in more cell death or decreased cell prolifer-
ation. We cannot exclude that there is a U~shaped dose-
response curve for endovascular radiation. but in view of all 
the earlier reports. this is unlikely,"8 Of course. it is possible 
that the European rabbit was more receptive to the effects of 
brachytherapy than the American pig. In general the results 
derived from certain animal testing and the dose-finding 
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effect in human series of Albiero et a1 appear logical and are 
in keeping with the general rule of bracbytherapy: the more 
you irradiate. the more you inhibit proliferation. up to the 
point at which detrimental effects appear. 
Recently, more information has become available on the 
delayed endotheliali7.ation of the radioactive steot.9 with the 
consequent risk of late thrombosis. Albiero and colleagues 
endeavored to avoid the thrombotic sequelae of late endothe-
lialization by using longer courses of antiplatelet agents. We 
are aware of only 1 episode of subacute thrombosis occuning 
in humans after radioactive stent implantation to date, in 
contrast to recent findings using the combination of conven-
tional stents and catbeter~based radiation,IO,ll 
Not All Radioactive Slents Are Equal: 
Techniqnes of Stent Activation 
The clinical effect of a radioactive stent may be modulated by 
use of radioisotopes with different half-lives. energy. activity. 
and penetration. Consequently. in the interpretation of results 
originating from different radioactive stent trials that used 
different isotopes. extrapolation between stents and isotopes 
may be inappropriate. The trials discussed above used 2 
different techniques to make the stents radioactive: (1) direct 
ion implantation (that used by Isostent to create the 31p stent) 
(lsostent Inc. Belmont. Calif. personal communication): 
phosphorus-containing 31p isotope produced by neutron acti~ 
vation was inserted into the ion source of an implanter. 
Ionized 31p and 31p atoms were accelerated and separated by 
a magnet so that only the 3:!p was implanted directly onto the 
stent surface. (2) Bombardment with charged particles (as 
used by Hebrlein et al)3.4: the stents were placed into a 
cyclotron and bombarded with deuterons. Metallic stent 
particles were transformed into several radioisotopes. Later. 
proton bombardment was used to reduce the high~energy 
'Y~radiation emitted by the stents. 
Other methods currently available include electrodeposi~ 
tion (a technique for the manufacture of a 'Y~radiation­
emitting stent) and finally. isotope-emitting gold and phos-
phorylcholine stents. Clear advantages of 1 technique over 
another will be the subject of future consumer reports. 
The 32p Stent: An Antirestenotic Slent Using 
an Electron-Beam Fence 
In our enthusiasm to control vessel recoil and remodeling 
after balloon angioplasty. stent implantation has become 
increasingly popular. With conventional stenting. we have 
elinllnated recoil and remodeling as components of the 
restenotic process. However. this has been at the cost of 
exacerbating neointimal proliferation secondary to chronic 
vessel wall irritation. leading to in-stent restenosis.l:: 
As a means of preventing neointimal proliferation. the idea 
of creating an electron~beam fence has been raised. Simply. 
the idea is to place radioactivity where it should be in the first 
place: at the endoluminal surface. generating a fence that 
should "fry" any smooth muscle cells or myofibroblasts 
trying to reach the endoluminal cavity created by the stent 13 
In this model. the concept of irradiating a target volume. as is 
desirable with cancer or catheter~based technologies. may not 
be relevant Catheter~based brachytherapy involves the use of 
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a single~hit. bigh-dose administration of intracoronary radia~ 
tion. It seeks to target a volume of myofibroblasts and smooth 
muscle cells within the adventitia by irreversibly altering the 
DNA. such that on cell division. death will occur. This clearly 
decreases the reproductive capacity of the adventitia as a unit. 
and consequently. the potential for restenosis. Using the 
radioactive stent approach. we do not have to neutralize the 
huge reservoir of quiescent myofibroblasts lying dormant in 
the adventitia. Prevention of the migration and invasion of 
myofibroblasts occurs because of the continuous and low 
dose-rate. as witnessed by Albiero et al. adding credence to 
the concept of the electron-beam fence. This takes place 
regardless of the bulk of the atherosclerotic plaque and extent 
of penetration of the radiation. Equally. it occurs despite the 
eccentric placement of the radioactive stent within the vessel. 
In a preliminary report. the Milan groUp14 demonstrated that 
a heterogeneous adventitial exposure (maximum dose. 
4378±3078 cGyl14 d; minimum dose. 563±360 cGy/14 d; 
range. maximum dose. 644 to 12210 cGyl14 d; range. 
minimum dose. 153 to 1461 cGyl14 d) still results in a 
homogeneous stent response with respect to the formation of 
neointimal hyperplasia. 
Initially. basic scientists and radiotherapists perceived the 
concept of an electron-beam fence as being a fantasy created 
by cardiologists. objecting that it was not realistic. Ulti-
mately. however. the proponents of the fence may just be 
correct 
Application of the concept of an electron-beam fence to the 
stent edge. however. makes one aware of its potential 
Achilles' heel. The range of the stent radioactivity is limited. 
and whereas those cells behind the stent struts may be well 
fenced at the doses discussed. cells proximal and distal to the 
extremity of the stent, in injured areas treated by the balloon 
(up to 3 mm outside the stent: personal communication. 
Ioostent). may not be effectively covered by the range of the 
stent radiation. The latter phenomenon has been described in 
radiotherapeutic terms as "geographical miss": the mismatch 
between the irradiated and injured area15 (Figure 1). 
The Problem of the Candy Wrapper and Its 
Prevention: Is the Candy Wrapper Another 
Oculostenotic illusion? 
Stent-edge renarrowing occurs after conventional stent im-
plantation.16 This may not be angiograpbically visible. be-
cause the luminal ingrowth at the stent edges is in juxtapo-
sition to the neointimal hyperplasia within the stent. 
producing a smooth contour on the luminogram. In contrast. 
after radioactive stenting. a visual gradient at the extremities 
becomes apparent, because nothing will grow within the 
stent, which makes all edge restenoses obvious. 
In the study by Albiero et al. we note that lesions received 
a further percutaneous intervention on the basis of whether 
there was evidence of >50% intralesion angiographic steno-
sis. It may be that a word of caution is required in the 
assessment of the stent-edge lesion so as not to be seduced 
into believing that all such stenoses require treatment. given 
that the transition from the pristine stent lumen to the stent 
edge may appear great. 
Cumulative dose [Gy, 143 days] for3.0 mm 
P-32 8XJ-15 BetaStentat1.0 mm 
Axial distance from end of stant (mm) 
The propensity for edge restenosis to occur at either the 
proximal. distal, or both edges also remains ill-defined. It is 
conceivable that after conventional stenting. stent-edge reste-
nosis with luminal narro'Ning adjacent to a pristine stent 
lumen could result in a rheological condition with consequent 
alteration of shear stress. promoting what is finally viewed as 
a candy wrapper. 
Identifying the mechanism by which the candy wrapper 
occurs may permit a more focused strategy concerning its 
treatment Using intravascular ultrasound. the authors de-
scribe an increase in plaque/media in the region 1 to 3 mm 
immediately proximal and distal to the stent and a decrease in 
the external elastic membrane from 4 to 10 mm. To combat 
these identified vascular changes that induce stent-edge 
restenosis. various modifications to existing radioactive stent 
morphology could be proposed: (1) the square-shouldered 
balloon, (2) the cold-end sten!, (3) the hot-end sten!, (4) a 
hybrid radioactive stentlradioactive catheter-based system. 
(5) a self-expanding radioactive sten!, and finally (6) the 
')I-stent 
The appropriateness of anyone of these suggestions will 
depend on what underlies the change in plaque volume andlor 
shrinkage in vessel size. As usual in medicine, the problem is 
likely to be multifactorial. with confounding factors. At first 
sight the elements may be portrayed schematically as in 
Figure 2. 
Is the edge effect secondary to low-dose radiation at the 
margins of the stent, or due to balloon injury at the stent 
edges, or a combination of the 2? In this study, the univariate 
Injured 
Lowdosc NIH 
Healthy :"' __ "!II""-_~I Diseased 
High dose 
Uninjured 
Figure 2. Multifaceted interaction that creates candy wrapper. 
Uke the Candy, Hate the Wrapper 
Figure 1. Dose representation for a 3.D-mm-
diameter P-32 BX lsostent with activity level 4.2 
""Ci measured at 1 mm from stent struts. y axis: 
Total dose to tissue in Gy. x axis: Vertical line rep-
resents edge of stent. Area to right of vertical line 
is within stent. Area proximal (or distaO to stent is 
depicted to left of vertical line. Maximal balloon 
overhang is described to a total of 2.7 mm axially. 
Each isodose curve describes dose delivered to 
tissue by stents of different activity levels (24, 36, 
and 48 ""Gi), both within and proximal/distal to 
stent. Model assumes that a dose of 30 Gy is 
required to inhibit neointimal proliferation. Note 
that as stent activity decreases, dose delivered to 
tissue proximal/distal to stent is no longer suffi-
cient to cover area injured by balloon, 
analysis suggests that those vessels with a higher fInal 
balloon-to-artery ratio, smaller reference lumen diameter, and 
smaller final minllnum lumen diameter by angiography are 
most susceptible to adverse stent-edge morphological change. 
If the edge effect is the result of balloon-induced trauma 
and low-dose radiation (Figure 3A), then limiting the trauma 
outside the stent and expanding the irradiated area beyond the 
injured area should be attempted. Conceivably, the most 
practical approach may be to use a square-shouldered balloon 
(to minimize the injured area outside the stent) in combina-
tion with an extension of the area of irradiation beyond the 
injured area ("hot-end stent") (Figure 3B). 
If the candy wrapper were purely the result of negative 
remodeling induced by low-dose radiation in an injured area, 
then the lengthening of the stent by a nonradioactive, cold-
end stent would be a logical solution to prevent remodeling at 
the extremities (Figure 3C). If plaque constitutes a large 
percentage of the healing process manifested by the candy 
wrapper. then cold-end stent implantation is unlikely to work. 
Similarly, neointimal proliferation may occur at the edges of 
the radiation within the stent if this treatment modality is 
used. 
A more elaborate. sophisticated approach would be the 
hybrid combination of a radioactive stent with the use of 
catheter-based radiation. The sources could be incorporated 
on the shaft of the balloon at the balloon extremities (Figure 
3D). This approach would ensure that the injured area 
receives appropriate radiation. 
If the candy wrapper is the result of an aberrant response by 
noninjured healthy or diseased tissue subjected to radiation, 
then this may suggest that low-dose radiation has a stimula-
tory effect on noninjured tissueP This would be the worst 
possible scenario, because clearly. noninjured healthy or 
diseased tissue will always be irradiated at some stage. 
In the event that excessive vascular remodeling is present 
after hot-ended or hybrid therapy, then a self-expanding 
nitinol radioactive stent may playa useful role (Figure 3E). 
The ')I-stent would have better tissue penetration than the 
,B-eroittiag rivals. However. the energy generated by the 
former will be a drawback, with increased radiation exposure 
to patients, relatives. and personneL It is conceivable that a 
low-energy. y-radiation-emittiag stent would minimize this 
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environmental risk. yet provide adequate clinical effect 
Further scientific exploration of this area is clearly justified. 
Conclusions 
Although a decade bas elapsed since the inception of radioactive 
stenting. we are now beginning to understand that this treatment 
modality is indeed a double-edged sword. The path of evolution 
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Figure 3. A, JIIustration of a balloon~ 
expandable BX stent. Radiation is 
deplcted in orange. Note that trauma to 
vessel wall extends beyond that of radi-
ation. B, Square--shouldered balloon lim-
its area of injury, whereas radiation from 
hot-ended stent extends to normal/unin-
jured tissue. C, Cold-end stent w'rth raol-
ation limited to central area D, Hybrid 
radioactive stent with catheter-based 
sources at each end to ensure that 
injured area receives adequate radiation 
coverage. E, Self-expanding radioactive 
nitinol stent. 
is clearly a slow one: meticulous work has been performed to 
clarify the efficacy of the radioactive stent Albiero and col-
leagues have pointed us in a new direction, beyond the stent 
itself, and that is to carefully analyze the effect of injury and 
low-dose radiation on vessel healing at the stent edge. The true 
sweetness of the candy will only be appreciated once the 
pathopbysiology of stent-edge restenosis is understood. 
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Clinical and angiographical follow-up after 
implantation of a 6-12 flCi radioactive stent in 
patients with coronary artery disease 
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P. W. Serruys' 
'Thoraxcenter Rotterdam, University Hospital Rotterdam, Dijk:igt, Rotterdam, The Netherlands; 
2The Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 
Aims This study is the contribution by the Thoraxccntcr, 
Rotterdam, to the European 32p Dose Response Trial. a 
non-randomized multiccntrc trial to evaluate the safety and 
efficacy of the radioactive Isostcnt6> in patients with single 
coronary artery disease. 
Methods and Results The radioactivity of the stent at 
implantation was 6-12 j.LCi. All patients received aspirin 
indefinitely and either ticlopidinc or c1opidogrcl for 
3 months. Quantitative coronary angiography measure-
ments of both the stent area and the target lesion (stent area 
and up to 5 mm proximal and distal to the stent edges) were 
pcrfonncd prc- and post-procedure and at the 5-month 
follow~up. Forty~two radioactive stents were implanted in 
40 patients. Treated vessels were the left anterior dcsccnd~ 
ing coronary artery (n=20). right coronary artery (n= 10) or 
left circumflex artery (n= 10). Eight patients received 
additional non~radioactive stents. Lesion length measured 
10 ± 3 mm with a reference diameter of 3'07 ± 0·69 mm. 
Minimal lumen diameter increased from 0'98 ± 0·53 mm 
pre~proccdure to 2·29 ± 0·52 mm (target lesion) and 
2-57 ± 0'44 rom (stent area) post-procedure. There was 
one procedural non-Q wave myocardial infarction, due to 
transient thrombotic closure. Thirty-six patients returned 
Introduction 
In-stent restenosis is almost exclusively caused by 
neointimal hyperplasia formation. which occurs due to 
trauma of the arterial wall caused primarily by the stent 
struts and balloon dilatations[L,2]. 
Revision submitted 15 May 2000. and accepted 22 May 2000. 
Correspondence: Prof. Patrick W. Serruys, MD, PhD. Head of the 
Department of Interventional Cardiology, Thoraxcenter Bd 406, 
University Hospital Dijkzigt, Dr. Molewaterplein 40, 3015 GD 
Rotterdam, The Netherlands. 
for angiographicaJ follow-up. Two patients had a total 
occlusion proximal to the radioactive stent. Of the patent 
vessels. none had in-stent restenosis. Edge restenosis was 
observed in 44%. occurring predominantly at the pro:cimal 
edge. Target lesion revascularization was performed in 10 
patients and target vessel rcvascu1arization in one patient. 
No additional clinical end-points occurred during follow~ 
up. The minimal lumen diameter at follow-up averaged 
1·66 ± 0·71 rom (target lesion) and 2·12 ± 0·72 (stcnt area): 
therefore late loss was 0·63 ± 0'69 (target lesion) and 
0·46 ± 0-76 (stent area), resulting in a late loss index of 
0·65 ± 1·15 (target lesion) and 0-30 ± 0-53 (stent area). 
Conclusion These results indicate that the usc of radio-
active stents is safe and feasible. however, the high inci-
dence of edge restcnosis makes this technique currently 
clinically non-applicable. 
(Eur Heart J 2001; 22: 669-675. doi:10.1OS3Jeubj.2000.2283) 
© 2001 The European Society of Cardiology 
Key Words: p-particJes, angioplasty, radioisotope, resteno-
sis, stent. 
See page 669 for the Editorial comment on this article 
Vascular brachytherapy with a radioactive source 
after PTeA or stent implantation has been sho'iVll. in 
several experimental and clinical trials. to be a promis-
ing treatment in reducing restenosis rates. by inhibiting 
the process of neointimal hyperplasia[3--6J. Several ani-
mal trials have demonstrated a dose-related reduction 
of in-stent restenosis. following radioactive stent 
implantation(7-91. However. a dose-dependent delay in 
endothelialization of the stent has been shown. which 
increases the risk of subacute and late thrombotic 
occlusions[S.101. Recently. a porcine coronary model in-
dicated that continuous low-dose rate irradiation by 
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high-activity J2p radioactive stents may promote an 
'atheromatous' neointima by the 6-montb follow-up[111, 
Controversially, in normal canine coronary arteries, 
radioactive stents result in a larger fibrin-rich neointima 
at follow-up, as compared to a control groupEl2], 
In patients treated with implantation of 32p radio-
active stents with activities ranging from 0-75 to 12 llei 
angiographic restenosis was reported in 43-62% of the 
cases, with the restenosis primarily located at the edges 
of the stent[13]. The edges represent an area where tissue 
is subjected both to balloon-induced trauma and a lower 
dose of radiation. which may stimulate edge resteno-
SiS[9.14J. Our group reported that the implantation of a 
radioactive stent with an activity of 0·75 to 1·5 J,lCi was 
feasible and safe, with an in-stent restenosis rate of 17% 
and no occurrence of edge restenosis['4J. 
The aim of this study was to evaluate the safety and 
efficacy of implantation of a radioactive stent, with an 
activity level of 6-12 )lCi, in patients with single. native. 
coronary artery disease. 
Methods 
Patient population 
The European 32p Dose Response Trial was a non-
randomized multicentre trial to evaluate the safety and 
efficacy of radioactive stent implantation. with activities 
ranging from 1·5-3·0. 3-6 and 6-12)lCi. The data 
presented here is the experience of the Thoraxcenter 
Rotterdam. 
Patients with single, native. coronary lesions. with a 
maximum lesion length of 28 rom (treatable with a 
maximum of two radioactive stents, implanted in 
tandem position). and objective evidence of ischaemia 
were eligible. Exclusion criteria were: recent myocardial 
infarction (creatine kinase-ME >three times the upper 
limit of normal. within 5 days of the intervention); left 
ventricular ejection fraction <40%: allergy or contrain-
dication to aspirin. ticlopidine. clopidogrel or nicket 
lesions located in the left main. 
The Medical Ethical Committee of the University 
Hospital Rotterdam approved the study. All patients 
provided written informed consent before the procedure. 
Radioactive stent, dosimetry and safety 
issues 
The BX8 Isostent (Isostent8 Inc., San Carlos. CA 
U.s.A.) was implanted in this trial. It was 15mm in 
length and available in diameters of 3·0 and 3'5 mm. The 
BX@) Isostent was made radioactive by Phosphorus-32 
e2p)l9]. The initial activity of the stents was measured 
and thereafter the date at which the radioactivity should 
have decreased to 6-12)lCi (radioactivity level suitable 
for implantation) was calculated. The dose delivered 
over 100 days at 1 mm from the stent surface was 
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calculated for each implanted sten!. All personnel were 
trained in the appropriate handling of radioactive 
materials. During implantation. the lucite shield enclos-
ing the stent and the sheathed introduction system 
prevented exposure of the operator to the radiation of 
the sten!. All disposable materials, which were in con-
tact with the stent. were immediately disposed of in a 
plexiglas container. 
Quantitative coronary angiography 
Quantitative coronary angiography was performed pre-
procedure. post-procedure. and at the 6-month follow-
up. Coronary angiography was performed after 
intracoronary administration of nitrates. The off-line 
analysis of at least two orthogonal projections was 
performed by means of the CAAS II (Cardiovascular 
Angiographical Analysis System. Version II) (Pie Medi-
cal B.V .• Maastricht. The Netherlands). Calibration of 
the system was based on dimensions of the catheters not 
filled -.v:ith contrast medium. which has been extensively 
validated and applied in numerous clinical trials[lS-17J. 
The following measurements were obtained in each 
projection for the target lesion: minimal luminal diam-
eter. reference diameter. diameter stenosis and lesion 
length. Lesion length was measured by means of a 
computer algorithm[17]. Procedural success was defined 
as %diameter stenosis <20%. measured by on~line quan-
titative coronary angiography. Acute gain was defined 
as minimal luminal diameter post-procedure minus 
minimal luminal diameter pre-procedure. Late loss was 
defined as minimal luminal diameter post~procedure 
minus minimal luminal diameter at follow-up. The late 
loss index was defined as late loss divided by acute 
gain[18J• For analytical purposes. three regions of interest 
were defined: (1) stent area. (2) target lesion and (3) 
target vessel. The stent area was defined as the segment 
which included only the radioactive stent(s). The target 
lesion was defined as the stent area and 5 rom proximal 
and 5 mm distal to the edge of the radioactive sten!. The 
target vessel was defined as the target lesion and the 
remaining segments of the treated vessel. Target lesion 
restenosis was defined as >50% diameter stenosis at 
follow~up.located within the target lesion. Edge resteno-
sis was defined as >50% diameter stenosis at follow~up. 
located at the proximal and/or distal edge. In order to 
quantify an edge effect. a quantitative coronary angiog~ 
raphy sub segmental analysis was performed in 30 
patients. excluding patients with ostial lesions or occlu-
sions pre-procedure or at follow-up. Target vessel 
stenosis was defined as >50% diameter stenosis at 
follow~up. located on any segment of the treated vessel. 
Quantitative coronary angiography measurements were 
performed by means of the CAAS II analysis system. 
Careful matching of the segments, encompassing the 
proximal and distal edges and the stent area. was 
performed pre-. post-procedure and at follow-up (see 
also Fig. 1). 
Figure 1 Quantitative coronary angiography methodology. Quantitative coronary angio~phy measurements were 
performed at pre-procedure, post-procedure and follow-up. FU"St, the Ref. diam. was measured from sidc--branch 
to sidc--branch (blue lines). Subsequently, the vessel was subdivided in segments of approximately 5 mm in length. 
Minimal lumen diameter, mean diameter and diameter stenosis were measured for the proximal edge, stent area and 
distal edge. DE=d.istal edge; FU=follow-up; PE=proximal edge; Pre=prc--procedure; Post=post-proccdure; 
Stcnt=stent area. 
Procedure (JJZd follow-up 
Patients received 250 mg aspirin and 10000 inter-
national units heparin at the initiation of the procedure. 
The activation clotting time was maintained at > 300 s. 
After balloon pre-dilatation. the radioactive stent was 
implanted at a nominal deployment pressure of 6-18 
atmospheres. Extreme care was taken to minimize the 
trauma at both edges by taking the following, previously 
published[14], precautions: the best angiographic view to 
optirrtize stent visualization was chosen and the dia-
phragm was used to further enhance stent imaging. If 
needed, stent deployment was optimized using shorter 
post-dilatation balloons of larger diameter, to higher 
pressures. All post-dilatation balloons had a radio-
opaque marker at each end. Images were filmed in a 
magnified field (5 inch), using digital zoom enhancement 
(3 inch) in order to avoid inflating the balloon outside 
the stent edges (see Table 1). All patients received either 
ticlopidine 250 mg twice daily or clopidogrel 75 mg daily 
for 3 months after stent implantation and aspirin 80 mg 
daily indefinitely. Creatinine kinase and creatine 
kinase-MB measurements were made and the electrocar-
diogram was recorded at 6 and 12-18 h post procedure 
in all patients. 
Patients returned for a 1- and 5-month clinical follow-
up. An electrocardiogram was recorded at each visit. 
Clinical end-points were: death, Q wave myocardial 
infarction (using the Minnesota code criteria[191), non-Q 
wave myocardial infarction (creatine kinase-MB rise 
>twice normal upper limit), target lesion revasculariza-
tion (reintervention of the stent area andlor revasculari-
zation of the proximal and distal edge), target vessel 
revascularization (revascularization of any segment of 
the treated vessel), non target vessel revascularization, 
subacute[10] and late[2l] thrombotic occlusion of the 
target vessel. At the 5-month visit an exercise stress test 
was performed. Revascularlzation was performed on the 
basis of clinical symptoms andlor evidence of ischaemia 
on exercise testing. 
Table 1 Balloon inflation and stent deployment data 
Stent 
Pre-dilatation deployment Post-dilatation 
Nom. ~i.ze balloon 3'09::0·43 3·28:::: 0'25 3·51:::: 0·50 
Balloon length 16±3 14±2* 
Stent length 16±3'" 
Pressure 9=4 10::::3 16::::2 
Balloon artery ratio 1,06:1 H7:J 
Stent artery ratio Hl:1 
"'38 patients with one Isostent. two patients with two Isostents. 
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Table 2 Baseline patient de11Wgraphics and anginal Table 4 Five-month clinical follow~up 
status 
Gender 
Mole 
Female 
Age (years) 
Average 
Range 
Risk factors 
Previous MI 
Diabetes mellitus 
Hyperlipidaemia 
Hypertension 
Smoking 
Family history 
Anginal class 
CCS2 
CCS3 
CCS4 
30(75%) 
10(25%) 
58 
38-75 
20(50%) 
4(10%) 
29 (73%) 
18(45%) 
14(35%) 
13(33%) 
11 (27-5%) 
23 (57'5%) 
6 (15%) 
MI=myocardial infarction; CCS=Canadian Cardiovascular 
Society. 
Table 3 Baseline lesion characteristics 
Treated vessel 
LAD 
LCx 
RCA 
Lesion type 
A 
B1 
B2 
C 
Ostial lesions 
Total occlusions 
lostent restenosis 
Lesion length 
20(50%) 
JO(25%) 
10(25%) 
.5 (12-5%) 
13 (32'5%) 
18 (45%) 
4 (lO%) 
5(12-5%) 
3(8%) 
2(5%) 
1O±3mm 
LAD=Left anterior descending coronary artery; LCx=left circum~ 
flex artery; RCA:::right coronary artery. 
Statistical analysis 
Data are presented as mean ± standard deviation. Con~ 
tinuous data was compared by means of the two~tai1ed 
Student's t-test or linear regression when appropriate. 
Results 
Baseline characteristics 
Baseline demographics and anginal state are shown in 
Table 2. lesion characteristics in Table 3. 
Procedural data 
All 42 stents were successfully implanted in 40 patients. 
Thirty-eight patients were successfully treated with a 
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Angina free 
Target lesion revascularization 
PTCA 
CABG 
Target vessel revascularo..ation 
Non~target vessel revascularo..ation 
Late occlusion 
Myocardial infarction 
Death 
26 (65%) 
1OC:~5%) 
9 (22'5%) 
1 (2'5%) 
II (28%) 
I (2'5%) 
2(5%) 
1(3%) 
0(0%) 
single radioactive stent. two required. a second radio~ 
active stent to cover lesions > 15 mm. Eight patients 
received additional non-radioactive stents due to proce-
dural dissections. There were three transient thrombotic 
occlusions during the procedure. two due to dissections 
and one due to a combination of a dissection with a low 
activation clotting time. Treatment was with Reopro in 
one patient and a combination of ReoPro and rtPA in 
the other two patients. Despite the Reopro and rtF A. 
one non-Q wave myocardial infarction occurred. leading 
to a maximum creatinine kinase of 673 IV .1- 1 (normal 
upper lintit 190 IV .1-') and an MB of 78 (normal 
upper limit 24 IV .1- 1). All further procedures were 
uncomplicated. A good final angiographical result was 
achieved in all patients. 
Follow-up 
The mean hospital stay was 1·7 days. All patients were 
angina free at hospital discharge. At the 30-day 
follow-up no clinical end-points had occurred. Thirty-
two (80%) patients were asymptomatic. whereas eight 
(20%) patients had recurrent angina pectoris. All 40 
patients returned for the 5-month clinical follow-up (see 
Table 4). Twenty-six (65%) were asymptomatic and 14 
(35%) patients had angina pectoris: Canadian Cardio-
vascular Society 1 (n=4). 2 (n=7). 3 (n=2) and 4 (n= 1). 
The patient in angina Canadian Cardiovascular Society 
4 had chest pain with ST-elevation. during his protocol-
required 5-month exercise stress test. This was treated by 
primary angioplasty of a non-target vessel Creatinine 
kinase rose to a maximum level of 257 IV .1-: (normal 
upper limit 190 IU .1-') with an MB of 30 IU .1-' 
(normal upper limit 24 IV .1- 1). Since there was neither 
a creatinine kinase rise of more than twice the upper 
limit of normal. nor new Q wave formation on the 
electrocardiogram. this was. by definition according to 
the protocol. not considered as a myocardial infarction. 
A 5~month angiographic follow-up was performed in 
36 (90%) patients. The remaining four (10%) patients 
refused.: three were asymptomatic and the fourth had 
angina pectoris. Canadian Cardiovascular Society 3. 
Two late occlusions were noted. which were both proxi-
mal to the stent at angiographic follow-up. These two 
patients had recurrent angina >3 months after the index 
Table 5 Quantitative coronary angiography analysis of the target lesion and sten/. 
area (n=36*) 
MLD 
%DS 
Ref. diam. 
Acute gain 
Late loss 
ill 
Restenosis. n (%) 
0'98±0'S3 
68±IS 
3'07±0'69 
Po~ 
Lesion Stent 
2·29 ± 0'S2 2'S7 ± 0·44 
28±1l 18±1l 
3·17±0·53 
1·31±0·6S HO±0'S9 
Follow~up 
Lesion Stent 
H6±0'71 2·12±a.72 
46±21 3O±21 
3·03 = 0'46 
0,63 ± 0·69 
0'6S± HS 
16(44%) 
0·46 ± 0·76 
0'30±0'S3 
0(0%) 
*Results of all 36 patients, who returned for angiographic foUow~uP. four patients refused. 
%DS=% diameter stenosis: FU=follow~up; Lesion=target lesion (stent area and up to S mm 
proximal and distal to the stent edge); LLI=late loss index: MLD=m.inim.allumen diameter: 
Pre=pre-procedure: Post=post-procedure: Ref. wam,=reference wameter; Stent=stent area. 
Quantitative coronary angiography measurements are in mm. 
procedure, more specifically: within 1 week of discon-
tinuation of the c1opidogrel. without any signs of a 
myocardial infarction. Sixteen (44%) patients (including 
the two total occlusions) had angiographic edge resteno-
sis. There was no in-stent restenosis in the 34 patent 
vessels. Ten of the 16 restenoses occurred in patients 
treated with a single radioactive sten!. two restenoses 
were in patients receiving two radioactive stents. four 
restenoses were observed in patients receiving a combi-
nation of one radioactive and one non-radioactive stent. 
Examining the four restenotic patients who had an 
additional non-radioactive stent implanted at the base~ 
line procedure. one had a total occlusion proximal to the 
Isostent, therefore it cannot be established whether the 
BX-Isostent and the distally placed non-radioactive 
stent were patent. Of the remaining three patients. the 
restenoses all occurred at the edge. located contralateral 
to the non-radioactive stent (one implanted proximal 
and two implanted distal to the Isostent), whereas the 
non-radioactive stent had no restenosis. One of the two 
patients, treated with a radioactive stent for in-stent 
restenosis. had a restenosis at follow-up. This restenosis 
was located at the proximal edge. In the three patients 
treated initially for a total occlusion, one restenosis and 
one reocclusion occurred. Nme of the 16 restenotic 
patients underwent a target lesion re-PTCA, one patient 
was referred to bypass surgery because it was the third 
in-stent restenosis in this patient, the remaining six 
were treated medically since these patients were both 
asymptomatic and had a negative stress test. 
Quantitative coronary angiography 
measurements 
Quantitative coronary angiography data, as measured 
for the target lesion and stent area. are presented in 
Table 5. Results of the subsegmental analysis of the 
stent area and the edges in a subgroup of 30 patients 
are shown in Table 6. Location of the restenosis is 
summarized in Table 7. Restenosis was observed to 
occur more often at the proximal edge compared to the 
distal edge (P=O·02). 
Table 6 Subsegmental analysis of the stent area and 
edges (subgroup of 30 patients*) 
Prox. edge Stent area Dist. edge 
MLD 
Pre 2'52±0'SI 1·09 ± 0'48 2·33 ± 0·70 
Post 2·81 ±0'S3 2'57=0·46 2·37:::: 0·63 
F1.J 2'OS ± a.71 2'26±0'S2 2'07 ± 0'63 
%DS 
Pre l7±10 SS±16 13±6 
Post 9±4 17±8 13±8 
FU 22±13 22:::: 12 16=12 
Mean. diam. 
Pre 2,99 ± 0,79 2-4S±0'7S 2·68±0·SO 
Post 3·09±0'S5 3'10±0'43 2'70± 0'S8 
FU 2·S7±0·60 2·89 ± 0,58 2'44±0'S7 
Acute gain 0·29 ± a.69 1-47 ±0'S2 0'04±0'61 
Late loss 0·76 = 0-66 0·31 ±0'S6 0'30 ± 0·66 
LLI KA 0'23±0'46 NA 
Restenosis rate.. n (%) 10 (33%) 0(0%) 5 (17%) 
*Exc1uded from subsegmental analysis were two patients with 
ostial lesions, one patient with a total occlusion pre~procedure and 
three patients with total occlusions at follow-up. 
%DS=% diameter stenosis; Dist. edge=d.istal edge: FU=follow-
up: LLI=late loss index; Mean. wam,=mean wameter. 
MLD=minimal lumen diameter; KA=not applicable: Prox. 
edge=proximal edge: Pre=pre-procedure; Post=post-procedure, 
QCA measurements are in m.m. 
Table 7 Location o/the restenosis (n=16) 
Proximal edge 
Distal edge 
Proximal and distal edges 
Stent area 
Unknown (proximal occlusion) 
9 (56%) 
4 (2S%) 
1(6%) 
0(0%) 
2 (13%) 
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Radiation doses 
Stent activity level was 8·6 ± 1-6 ).lei at implantation, 
resulting in a calculated cumulative dose given over 
100 days delivered to a 1 mm depth from the sten! 
surface of 58 ± 10 Gy. There was no correlation between 
stent activity or delivered dose and minimal luminal 
diameter or late loss index at follow-up. 
Discussion 
This non-randonmed study illustrates that the implan-
tation of a 6--12 J.lCi ,B-particle emitting radioactive sten! 
is safe and feasible. with one procedural non-Q wave 
myocardial infarction and no subacute or 30-day clinical 
events recorded. Subacute thrombosis was not seen 
despite the concern of delay in endothelialization, as 
previously reported in animal studies[S.lOl. Two late 
occlusions were seen. which were probably late throm-
botic stent occlusions, since both patients had recurrent 
angina. within 1 week of discontinuation of the clopi-
dogrel. However. since both occlusions were proximal to 
the stent. and stent patency could not be observed at 
angiography, severe edge restenosis cannot be fully 
excluded. Therefore, it may be desirable to give patients 
at least 6 months of clopidogre1 following radioactive 
stent implantation. 
The Milan group has previously reported restenosis 
not only within the stent. but also at the edges of the 
stent[13J, possibly caused by a combination of balloon 
injury (barotrauma) and lower radiation dose at the 
stent edges[9.141. In this series particular attention was 
paid to avoid balloon injury outside the stent. in order 
to minimize barotrauma at the edges. Despite these pre-
cautions, edge restenosis was seen in 44%, occurring 
predominantly at the proximal edge. The commonly 
occurring narrowing observed proximal to the edge of 
the stent may. in combination with a complete inhibition 
of neointimal proliferation inside the stent, create 
unfavourable rheological conditions. such as a diverging 
flow pattern, which in itself will self-perpetuate the 
neointimal proliferation[22]. Careful shear stress analysis 
could.elucidate the cause of restenosis at the proximal 
edge[231. 
Since in all cases the pre-dilatation was performed 
with a balloon longer than the BX-Isostent and the 
balloon used for stent deployment extended outside the 
edges of the stent. geographical 'miss' occurred in 100% 
of the cases. Since geographical miss has been shown to 
be one of the determinants of edge restenosis[241, future 
therapies will concentrate on the prevention of geo-
graphical miss by minimizing trauma and/or increasing 
radiation dose at the edges. Several new therapies are 
currently under investigation. Direct stenting will pre-
vent trauma caused by pre-dilatation with balloons 
longer than the radioactive stent. Square shouldered 
balloons, used for stent deployment. in which the entire 
balloon remains within the stent. will mininlize baro-
72 
trauma at the proximal and distal edges. Cold end 
stents. in which the centre of the sten! is made radio-
active, while the proximal and distal 5 mm of the stent 
edges are non-radioactive may prevent edge restenosis. if 
this restenosis is caused by negative remodelling. The 
final therapeutic option is the implantation of hot end 
stents, in which the stent edges are made more radio-
active compared to the centre of the sten!. This strategy 
increases the dose delivered to the traumatized 
proximal and distal edge, thereby decreasing the chance 
of geographical miss[22J. 
Conclusion 
These results indicate that the use of radioactive stents. 
with an activity of 6-12 J,tCi. is safe and feasible: how-
ever. the high incidence of edge restenosis makes this 
technique currently clinically non-applicable. 
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Radioactive stents delay but do not prevent 
in-stent neointimal hyperplasia. 
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Radioactive Stents Delay but Do Not Prevent In-Stent 
Neointimal Hyperplasia 
I. Patrick Kay, MEChE; Alexander J, Wardeh, MD; Ken Kozuma, MD; David P. Foley, MEBCh, PhD; 
A.H. Marco Knook, MD; Attila Thury, MD; George Sianos, MD; 
Willem J. van der Giessen, MD, PhD; Peter C. I.evendag, MD, PhD; Patrick W. Serruys, MD, PhD 
Background-Restenosis after conventional stenting is almost exclusively caused by neointimal hyperplasia. f3~Particle­
emitting radioactive steots decrease in-stent neointimal hyperplasia at 6-month follow-up. The purpose of this study was 
to evaluate the I-year outcome of 3Zp radioactive steots with an initial activity of 6 to 12 JLCi using serial quantitative 
coronary angiography and volumetric ECG-gated 3D intravascular ultrasound (IVUS). 
Methods and Results-Of 40 patients undergoing initial stent implantation. 26 were event-free after the 6-month follow-up 
period and 22 undctwcnt repeat catheterization and IVUS at 1 year: they comprised half of the study population. 
Significant luminal deterioration was observed within the stents between 6 months and 1 year, as evidenced by a 
decrease in the angiographic minimum lumen diameter (-0.43±0.56 mm; P=O.028) and in the mean lumen diameter 
in the stent (-0.55±O.63 mm; P=O.OOl); a significant increase in in-stent neointimal hyperplasia by NUS 
(18.16±12.59 mm3 at 6 months to 27.75±11.99 mm' at 1 year: P=O.OOl) was also observed. Target vessel 
revascularization was perfonned in 5 patients (23%). No patient experienced late occlusion. myocardial infarction. or 
death. By I year, 21 of the initial 40 patients (65%) remained event-free. 
Conclusions-Neointimal proliferation is delayed rather than prevented by radioactive stent implantation. Clinical 
outcome 1 year after the implantation of stents with an initial activity of 6 to 12 /LCi is not favorable when compared 
with conventional stenting. (Circulation. 2001;103:14-17.) 
Key Words: radioisotopes _ restenosis _ stents _ angiography 
I mplantation of32p radioactive stents with activities ranging from 3.0 to 12 /LCi in coronary artery lesions has been 
reported to inhibit neointimal hyperplasia within the stent at 
6-month follow-up.I.2 The major limitation of this therapy is 
significant renarrowing at the stent edges, which is called the 
"candy wrapper" or "edge effect."1 Catheter-based radiation 
significantly reduces the recurrence of restenosis 6 months 
after percutaneous transluminal coronary angioplasty for 
in-stent restenosis. but 3-year follow-up reveals greater lumi-
nal deterioration in y-radiation-treated patients.3,4 Such find-
ings indicate the need for longer follow-up beyond the 
traditional 6 months in patients treated with intracoronary 
radiation. The purpose of this study was to assess late results 
after the implantation of radioactive stents using repeat 
catheterization with quantitative coronary angiography and 
3D intravascular ultrasound (IVUS) at 1 year. 
Methods 
Patient Population 
The European 'Zp Dose-Response Trial was a nonrandomized mul-
ticenter trial evaluating the safety and efficacy of implanting radio-
active stents with activity levels of 3 to 12 p.el in single. native 
coronary artery lesions. All stents were implanted in de novo lesions. 
except for 1 ca.<:e of in-stent restcnosis. For the purposes of this 
analysis. this case wa.~ excluded. Other inclusion and exclusion 
criteria. as well as immediate and 6-month results. were previously 
reported. I ': Only patients undergoing 6-month angiographic and 
NUS follow-up who did not experience major adverse cardiae 
events during the first 6 months were included. The study was 
pelformed in :1Ccordance with the Dec1aration of Helsinki and the 
European Guidelines for Good Clinical Practice. Ethical approval 
was provided by the Medical Ethical Committee of the University 
Hospital Rotterdam. All patients gave written. informed consent. 
Radioactive Slenl 
The BX Isostcnt eZp) (Isostent Inc). which is IS mm in length and 
3.0 or 3.5 mm in diameter, was used. The initial :1Ctivity of the stents 
was measured and. thereafter. the date at which thc radioactivity 
would have decreased to 6 to 12 p.Ci was calculated. 
Procedure and Clinical Follow-Up 
Procedural details have been published previously.s All patients 
received either 250 mg of ticlopidine BID or 75 mg of c1opidogrcl 
per day for 3 months after stent implantation and 80 mg of aspirin per 
day indefinitely. Rcvaseularization was performed on thc basis of 
clinical symptoms and/or evidence of ischemia on exercise testing. 
Clinical end points were death. Q-wave myocardial infarction. 
non-Q-wave myocardial infarction (creatine kinase-ME rise >2 
Received August 17. 2000: revisioll received October 20. 2000: accepted October 20. 2000. 
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TABLE 1. Baseline Characteristics of the 22 Patients Studied 
Male sex 20 (91) 
Age, '1 " (3&-73) 
Risk factors 
Previous MI 12(5~ 
Diabetes mellitus 3(14) 
Hyperlipidemia 18 (82) 
Hypertension 9(41) 
Smoking 8 (36) 
Family history 7 (32) 
CCS class 3/4 15(68) 
Treated vessel 
lAD 12(5~ 
LCx 5(22.~ 
RCA 5(22.~ 
Lesion type 
A 2 (9) 
B1 10(45.~ 
82 8~6.~ 
C 2 (9) 
lesion length, mm 10=3 
Values are n (%), mean (range), or mean=SD. MI indicates myocardial 
Infarction; CCS, Canadian Cardiovascular Society; lAD, left anterior descending 
coronary artery; Lex. left circumfiex artery; and RCA, right coronary artery. 
times normal upper limit), target vessel revascu1ariMltion. Don-tatget 
vessel revasculaIization, and early and late thrombotic occlusion of 
the target vessel. 
Angiographic and IVUS Procedures 
Angiograpby in multiple projections wa.; performed before the 
procedure. after stenting. and at 6-month and l.year follow-up. The 
stentcd vessel segment" were examined with quantitative coronary 
angiograpby (CAA.S n analysis system.. 6.7 Pie Medical BY) nnd 
meeh:mical NUS (CardioVascular Imaging System). NUS images 
were acquircd to coincide with the peak of the R wave by using an 
ECG·triggered pullback device with a stepping motor at 0.2 mmI 
step. Tlris system eliminates the artifacts caused by the movement of 
the heart during the cardiac cycle. ~ The ECG'j:;ated image acquisition 
and digiti7..ation was performed by a workstation designed for 3D 
rcconstruction (EcboScan. Tomtec). A Microsoft Windows-based 
contour detection program was used for the volumetric 3D analysis.K 
Core Laboratory Analysis Procedures 
Quantitative coronary angiography using at least 2 orthogonal 
projections was performed. For analytical purposes, the followinj:; 3 
regions of interest were defined: (1) stent. (2) target lesion, and 
(3) target vessel. The stent included only the radioactivc stent The 
target lesion was defined as the stent and 5 mm proximal and 5 mm 
distal to the cdge. The target vesscl was defmed as the target lesion 
and the remaining segments of the treated vessel. Target lesion 
rcstenosis was defined as >50% diameter stenosis. located within 
the t:lrJ:;et lesion, at follow-up'? Edge restenosis was defined as 
>50% diameter stenosis.. located at the proximal ::mdlor distal edge, 
at follow-up. 
Quantitative NUS ::malysis of the stent and 5 mm proximal and 
distal to the stent was performed, Lumen and stent boundaries were 
detected using a minimum cost algorithm. Total stent and lumen 
volumes were calculated as previously described.H Neointimal vol-
ume was calculated a ... stent volume minus luminal volume. Fea ... j· 
bility, reproducibility, and intcrobserver and intraobservcrvariability 
of this system have been validated in vitro and in vivo,H 
Statistical Analysis 
Data are presented as mean::!:SD, Continuous data were compared 
using repeated measures ANOVA or a 2-tailed Student's f test as 
appropriate. 
Results 
Baseline demographics and lesion characteristics are shown 
in Table L Between 6 months and 1 year, target lesion 
revascularization and target vessel revascularization were 
performed in 4 patients (18%) and 5 patients (23%), respec-
tively. No late occlusion was seen, No patient died or 
experienced myocardial infarction, In total 21 of 40 patients 
(53%) were event-free through the I-year fOllow-up. 
Quantitative Coronary Angiography and 
IVUS Measurements 
Quantitative coronary angiography data. presented as a sub-
segmental analysis of the stent area and the edges, are shown 
in Table 2. A significant decrease in the minimum and mean 
lumen diameters was noted between 6 months and 1 year 
(P=0.028 and P=O,OOl. respectively) compared with both 
edges. The late loss of mean lumen diameter was significantly 
larger after 6 months than before 6 months. Furthermore, in 
11 patients (50%), the minimum lumen diameter at the edge 
at 6 months was detected within the stent at 1 year ("migra-
tion" from the stent edge to within the stent), Lesion progres-
TABLE 2. Subsegmental Quantitative Coronary Angiography Analysis 
Baseline 6 Months 1 Year 
Minimum lumen diameter, mm 
Proxlmal edge 2.92::0,53 2.23::0.73' 2.0B::0.50 
Stent 2.50::0.47 2.36::0.47· 1.93=:0.52* 
Distal edge 2.29::0,61 2,17::0.58 2.08::0.49 
Mean lumen diameter, mm 
Proximal edge 3.19=:0.56 2.73::0.57'" 2.50::0.40* 
sten! 3.12::0.42 3.09:!:O.58 2.54::0.41* 
Distal edge 2.64:::0.56 2.51::0.56 2.36:=:0.50 
·P<0.05, tP=0.0041, :lP'=O.025, §P=O.028, IIp=O,001 by ANOVA. 
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Baseline to 6 
Months 
0.69::0.80t 
0.14::0.52t 
0.36::0.49t 
0.39=0.62§ 
0.03=0.62§ 
0.12=:0,49§ 
l1lte Loss 
6 Months to 
1 Year 
0.15::0.51* 
0.43::0.56t 
0.09=0.49;0 
0.22=0.5111 
0.55=0.6311 
0.16::!:O.5211 
To,," 
0.84 
0.57 
0.45 
0.61 
0.68 
0.28 
P Between 
Periods 
0.060 
0.16 
0.9 
0.33 
0.041 
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Figure 1. Mean neointimal area in stent at 6 months (_) and 1 
year ( ... ) using IVUS. 
sian to >50% diameter stenosis was observed in 5 patients. 
This was due to a progression of in~stent restenosis in 4 
patients and a progression of a proximal stenHdge lesion in 
the other. 
rvus was completed in 19 patients: omissions were due to 
equipment failure2 or patient clinical instability,l rvus anal~ 
ysis demonstrated a significant increase in neointimal hyper-
plasia between 6 months and 1 year (18.16±12.59 mm3 to 
27.75±11.99 nunl ; increase of 52.8%; P=O.OOl). mainly in 
the mid and distal portions of the stent (Figure I), An increase 
in neointimal hyperplasia >25% (range, 25% to 360%) 
occurred in 12 cases (63%). as shown in Figure 2. No change 
in lumen volume was noted at the stent edges between 6 
months and 1 year. 
Radiation Doses 
The radioactive stents had a mean activity of 8.6±1.6 ,u.Ci at 
implantation and delivered 58±10 Gy to a depth of 1 mm 
from the stent at 100 days. with a dose rate of > 15cGy/b. 
There was no correlation between stent activity or delivered 
dose and changes in minimum or mean lumen diameter at 
6-month or 1 ·year follow-up. 
Discussion 
A worrying late progression of in·stent neointimal hyperpla· 
sia was observed between 6 months and 1 year after the 
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implantation of radioactive stents, leading to target vessel or 
lesion reintervention in 5 of 26 patients (19%) who had been 
event-free at 6 months. The event-free rate at 1 year after the 
implantation of 6 to 12 ,u.Ci radioactive stents was 21 of 40 
patients (53%). which compares poorly to the expected 
outcome after the implantation of a nonradioactive stent. 10 
In contrast to the tissue growth seen in malignancy. the 
DNA synthesis that occurs after nonradioactive stenring in 
experimental models terminates after 6 weeks.! I At this time 
point. the activity of the radioactive stent used in this study 
would have been sufficient to inhibit cellular proliferation. 
Thereafter. the majority of lumen deterioration occurs in the 
first 3 months after conventional stent implantation, with 
minimal change between 6 months and 1 year,l2-14 and actual 
regression of neointimal hyperplasia between 1 and 3 years 
after stenting,lS This latter phenomenon has been attributed to 
a reduction in the proteoglycan content of hyperplastic 
tissue. 16 Accordingly. the findings reported here of "break-
through" or "rebound" hyperplasia causing further lumen 
deterioration between 6 months and 1 year must be inter-
preted as being specific to the effects of radioactivity, 
presumably due to a fall- off in radiation levels. The obser-
vation that the radioactive stent may provide a substrate for 
atherosclerosis may well have been predicted by Carter et al's 
porcine model.!7 
Because no significant stenosis progression was observed 
at the stent edges among our patients. the candy wrapper 
effect may be considered a short-tenn healing response to 
vessel wall injury beyond the stented vessel segment com-
bined with the effects of low-dose radiation,18.19 
Unexpected late luminal deterioration has also been re-
ported between 6 months and 3 years among patients treated 
by catheter-based ,},-radiation after repeat intervention for 
in-stent restenosis (mean loss of 0.37 mm with 4 of 17 
patients [26%] progressing to restenosis [diameter stenosis 
>50% D. compared with no major changes in the placebo 
groUp,4 The difference in the time frame of this virtual 
"rebound hyperplasia" between radioactive stenting and 
catheter-based ,},-radiation therapy may be a function of the 
biological effects of and response to the type and dosage of 
radiation administered. Alternatively, late loss may also have 
Figure 2. Cumulative distribution curve of 
percent changes in late neointimal growth 
after 6 months, as measured by IVUS. 
~ 
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occurred between 6 months and 1 year and remained subclin~ 
ica! in the catheter-based study. 
Conclusions 
Neointimal hyperplasia is delayed rather than prevented by 
radioactive stent implantation. The combination of this phe-
nomenon of rebound hyperplasia with the established phe-
nomenon of edge restenosis calls into question the clinical 
applicability of radioactive stenting using current approaches. 
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MINI ABSTRACT 
The problem after radioactive stent implantation is edge restenosis due to neointimal 
hyperplasia and vessel remodeling. The aim of this trial was to evaluate whether 
extending the radioactive stent with non-radioactive Cold Ends might diminish this edge 
restenosis by preventing remodeling at the injured extremities. The 25 mm in length (15 
mm radioactive center segment & 5 mm non-radioactive ends) "Cold Ends" Isostents 
were preferably implanted by direct stenting. A total of 43 stents were implanted in 43 
pts with de novo native coronary artery disease. There were 2 procedural & 1 subacute 
stent thrombosis. One late (3.5 months) stent thrombosis occurred after discontinuation 
of antiplatelett therapy. QCA results showed that the restenosis occurred at the transition 
zone from radioactive to non-radioactive. The overall in-stent restenosis rate of22% was 
relatively low, compared to other radioactive stents. Edge restenosis is mainly caused 
by a proliferative response, induced by a combination oflow dose radiation and balloon 
injury. 
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ABSTRACT 
Aims. "P ~-emitting stents with an activity of 3-24 !lCi have shown >40% edge 
restenosis due to neointimal hyperplasia and vessel remodeling. The aim of this trial 
was to evaluate whether extending the radioactive stent with non-radioactive Cold Ends 
might diminish this edge restenosis by preventing remodeling at the injured extremities. 
Methods and results. The 25 mm in length (15 mm radioactive center segment & 5 mm 
non-radioactive ends) "Cold Ends" Isostents had an activity of 6-24!lCi at implantation. 
When possible, direct stenting was performed. A total of 43 stents were implanted in 43 
pts with de novo native coronary artery disease. Treated vessels were LAD (n=20), RCA 
(n=15) and LCx (n=8). QCA measurements were done pre-, post-procedure and at 6-mo 
FU. 
There were 2 procedural & 1 subacute stent thrombosis. One late (3.5 months) stent 
thrombosis occurred after discontinuation of antiplatelett therapy. QCA results are 
available for 37 pts. Eight in-stent restenoses were located in the non-radioactive (Cold 
Ends) segments, and 5 restenoses were both at the radioactive segment and at a Cold 
End. 
Conclusion. Restenosis of the radioactive segment occurred in 15%, all occurring at the 
transition zone from radioactive to non-radioactive. The overall in-stent restenosis rate 
was 22%. Cold Ends stents therefore have a relatively low restenosis rate compared to 
other radioactive stents. Edge restenosis is mainly caused by a proliferative response, 
induced by a combination oflow dose radiation and balloon injury. 
Key words ~-particles. angioplasty • radioisotope. restenosis • stent 
Abbreviations 
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ACT: Activation Clotting Time 
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INTRODUCTION 
Vascular brachytherapy with a radioactive source after PTCA or stent implantation has 
been shown, in several clinical trials, to inhibit the process of neointimal hyperplasia 
and thereby in-stent restenosis 1-4. Several animal trials have demonstrated a dose-related 
reduction ofin-stent restenosis, following radioactive stent implantation 5.'. However, a 
dose-dependent delay in endothelialization of the stent was shown, thereby increasing 
the risk of subacute and late thrombotic occlusions 6.8. 
In patients treated with implantation of 32p radioactive stents with activities ranging 
from 0.75 to 12 J.!Ci, angiographic restenosis was reported in 43-62% of the cases with 
the restenosis being primarily located at the edges of the stent and caused by neointimal 
hyperplasia and/or vessel remodeling.'. These edges represent an area where tissue is 
subjected both to balloon-induced trauma and a lower dose of radiation, which may 
stimulate edge restenosis 7.10. The aim of this trial was to evaluate whether extending the 
radioactive stent with non-radioactive Cold Ends might diminish this edge restenosis by 
preventing remodeling at the injured extremities. 
METHODS 
Patient Population. 
The 32p radioactive "Cold Ends" stent trial was a non-randomized multi-center trial to 
evaluate the safety and efficacy of radioactive "Cold Ends" stent implantation, with 
activities ranging from 6-24 J.!Ci. The data presented here represents all patients treated 
with "Cold Ends" stents, and were treated at the centers in Aalst, Milan, and Rotterdam. 
Patients with single, de novo, native, coronary lesions, with a maximum lesion length 
of 15 mm (treated with a 25 mm Cold Ends stent), and objective evidence of ischemia 
were eligible. Exclusion criteria were: recent MI (CK-MB > 3 times the upper limit 
of normal, within 5 days of the intervention); left ventricular ejection fraction <40%; 
allergy or contraindication to aspirin, ticlopidine, clopidogrel or nickel; lesions located 
in the left main coronary artery. 
The Medical Ethical Committees of the enrolling centers approved the study. 
All patients provided written informed consent before the procedure. The trial was 
conducted according to the GCP guidelines. 
Radioactive stent, dosimetry and safety issues. 
The BXJTM Betastent (Isostent™ Inc., San Carlos, CA, USA) was investigated in this 
trial. It was 25 mm in length and available in diameters of 3.0 & 3.5 mm. The 15 mm 
center segment was made radioactive by Phosphorus-32, whereas both 5 mm edges 
(the Cold Ends) were kept non-radioactive '. The initial activity of the stents was 
measured and thereafter the date at which the radioactivity had decreased to 6-24 J.!Ci 
(radioactivity level suitable for implantation) was calculated. All personnel were trained 
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in the appropriate handling of radioactive materials. During implantation the lucite 
shield enclosing the stent and the sheathed introduction system prevented exposure of 
the operator to the radiation of the stent. All disposable materials, which were in contact 
with the stent, were immediately disposed of in a plexiglas container. 
Quantitative coronary angiography. 
Quantitative coronary angiography (QCA) was performed pre-procedure, post-procedure, 
and at 6-month follow-up. Coronary angiography was performed after intracoronary 
administration of nitrates. The off-line analysis of at least two orthogonal projections 
was performed by means of the CAAS II analysis system (pie Medical B.V., Maastricht, 
The Netherlands) by the Thoraxcenter Rotterdam angiographic corelab. Calibration of 
the system was based on dimensions of the catheters not filled with contrast medium 11.13. 
Lesion length was measured by means of a computer algorithm 13. Procedural success 
was defined as %DS <30%, measured by on-line QCA. Acute gain was defined as 
MLD post-procedure minus MLD pre-procedure. Late loss was defined as MLD post-
procedure minus MLD at follow-up. Late loss index was defined as late loss divided by 
acute gain 14. For analytical purposes, 3 regions of interest were defined: 1) target vessel, 
2) target lesion (total stent) and 3) radioactive area. The radioactive area was defined as 
the segment, which included only the radioactive segment of the stent, IS mm in length. 
The target lesion was defined as the total stent area, consisting of the radioactive segment 
and both Cold Ends, being 25 mm in length. The target vessel was defined as the target 
lesion and the remaining segments of the treated vessel. 
QCA Methodology 
First, the minimum lumen diameter (MLD), reference diameter (RD) and diameter 
stenosis (DS) were measured from side-branch to side-branch for the target vessel. 
Subsequently, the MLD, mean diameter (MD) and DS were measured for the total 
stent (approximately 25 mm in length). Finally, the MLD, MD and DS were measured 
for the radioactive segment (approximately IS mm in length), First the total stent 
(approximately 25 mm in length) was delineated as the region of interest, by means of a 
proximal and distal cursor. Thereafter, by moving the cursors 1/5 of the total stent length 
(approximately 5 mm) away from the proximal and distal stent edges towards the center 
of the stent, the radioactive segment (approximately IS mm) was identified. Target 
lesion restenosis was defined as >50% DS at follow up, located within the target lesion. 
Cold Ends restenosis was defined as >50% DS at follow up, located at the proximal 
and! or distal Cold Ends segment of the stent. 
Procedure and follow-up. 
Patients received 250 mg aspirin and 10000 international units heparin at the initiation 
of the procedure. The ACT was maintained at >300 seconds. Preferably direct stenting 
was performed. The radioactive stent was implanted at a nominal deployment pressure 
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of 8-18 atmospheres. Also, post-dilatation was avoided to minintize balloon trauma. 
The radioactive segment of the stent had to completely cover the original lesion length. 
Extreme care was taken to minimize the trauma at both edges by taking the following, 
previously published 10, precautions: The best angiographic view to optimize stent 
visualization was chosen and the diaphragm was used to further enhance stent imaging. 
If needed, stent deployment was optimized using shorter post-dilatation balloons of 
larger diameter, to higher pressures. All post-dilatation balloons had 1 radio-opaque 
marker at both extremities. (see Table 1 for balloon inflation and stent deployment 
data). All patients received either ticlopidine 250 mg BID or clopidogrel 75 mg daily 
for 6-7 months after stent implantation and aspirin ~80 mg daily indefinitely. CK and 
CK-ME measurements were made and the ECG was recorded at 6 and 12-18 hours post 
procedure in all patients. 
Patients returned for 1 and 6-month clinical follow-up. An ECG was recorded at each 
visit. Clinical endpoints were: death, Q-wave MI (using the Minnesota code criteria 15), 
non Q-wave MI (CK -ME rise> 2 times normal upperlimit), target lesionrevascularization 
(reintervention inside the stent area), target vessel revascularization (revascularization of 
any segment of the treated vessel), non-target vessel revascularization, subacute!6 and 
late17 thrombotic occlusion of the target vessel. 
At the 6-month visit an exercise stress test was performed. Revascularization was 
performed on the basis of clinical symptoms and/or objective evidence of ischemia. 
Statistical analysis 
Data is presented as mean ± standard deviation. Continuous data was compared by 
means of the two-tailed Student's t-test or linear regression when appropriate. 
Table 1. Balloon inflation & stent deployment dat~ measured by quantitative coronary 
angiograpby_ 
Predilatation Stent Deployment Postdilatation 
Nom. Size Balloon, mm 2.68±O.51 3.2I±O.37 3.48±0.56 
Balloon Length, rom 18±4 20±5 
Stent Length, mm 25±3 
Balloon Artery ratio 0.90:1 1.16:1 
Stent Artery ratio 1.07:1 
Direct stenting 16 (37%) 
No post-dilatation 10 (23%) 
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RESULTS 
Baseline characteristics 
Baseline demographics and anginal state are shown in Table 2, lesion characteristics in Table 3. 
Procedural data. 
All 43 stents were successfully implanted in 43 patients. All patients were successfully 
treated with a single Cold Ends radioactive sten!. Five patients received additional 
non-radioactive stents due to procedural dissections. There were 3 transient stent 
occlusions: 2 procedural & I subacute stent thrombosis. The last occurring during an 
NUS evaluation of the stent performed 1 day post procedure for logistic reasons. None 
of these stent thrombosis lead to a myocardial infarction. All other procedures were 
uncomplicated. Procedural success was achieved in all, but 2, patients. These 2 patients 
had a DS of33 and 30%. 
Follow-up. 
All patients were angina free at hospital discharge. At 30-day follow-up no other subacute 
stent thrombosis occurred. Thirty-nine (91 %) patients remained angina free, whereas 4 (9%) 
patients had recurrent AP. One late (3.5 months) stent thrombosis, without total occlusion, 
occurred after discontinuation of all antiplatelet therapy by the patient himself, leading to 
a non-Q-wave MI, for which a primary target lesion revascularization was performed. All 
43 patients returned for 6-month clinical follow-up (see Table 4). Thirty-three (77%) were 
asymptomatic and 10 (23%) patients had Angina Pectoris Class: CCS I (n=I), CCS 2 (n=6), 
CCS 3 (n= I) and CCS 4 (n=2, including the above mentioned MI). Six-month angiographic 
follOW-Up was performed in 37 (86%) patients. The remaining 6 (14%) patients refused; 
5 were asymptomatic and 1 had AP CCS 2. No additional late occlusions were observed 
during the 6-month follow-up. Eight (22%) patients had angiographic restenosis (see Table 
5). Nine (21%) patients underwent a target lesion re-PTCA: 7 due to binary restenosis (DS 
>50%),2 patients were treated for recurrent angina with a DS <50%: 1 patient had recurrent 
angina and an MLD of I. 71, while the other was the one with the late stent thrombosis, 
leading to an acute MI (see above), with an MLD of 1.69 mm. One restenotic patient was 
treated medically since this patient was both asymptomatic and had a negative stress test. 
There were 2 additional repeat PTCAs: I because of progression of atherosclerosis in the 
target vessel and I because of progression of atherosclerosis in a non-target vessel. 
QCA measurements. 
QCA data are presented in Table 5. Location of the restenosis is summarized in Table 6. 
Stents implanted by direct stenting followed by post-dilatation or direct stenting without 
post-dilatation have a significantly worse late loss index at follow-up compared to stents 
implanted after balloon predilatation (see Figure I). Cold Ends stents showed only in 1 
patient (3%) a diffuse restenosis (both diffuse throughout the radioactive segment and 
proximal Cold End) restenosis, while other non-radioactive stents have the tendency to 
be more diffuse restenotic. For a patient example see Figure 2. 
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Table 2. Baseline patient demographics and anginal status. 
Gender Male 34 (79%) 
Female 9 21%) 
Age Average 58 
Range 41-80 
Risk Factors Previous MI 20 (47%) 
Diabetes Mellitus 3 (7%) 
Hyperlipidemia 32 (74%) 
Hypertension 16 (37%) 
Smoking 16 (37%) 
Family History 19 (44%) 
Anginal Pectoris Stable 32 (74%) 
Unstable 11 (26%) 
Table 3. Baseline lesion characteristics. Table 4. Six-month clinical follow-up. 
Treated vessel LAD 20 (46.5%) Angina Free 33 (77%) 
LCx 8 (19%) Target Lesion Revascularization(TLR) 9 (21%) 
RCA IS (34.5%) PTCA 9 (21%) 
Lesion type A IS (35%) CABG 0(0%) 
B 26 (60%) Target Vessel Revascularization (incl. TLR) 10 (23%) 
C 2 (5%) Non Target Vessel Revascularization 1(2%) 
Total occlusions 2(5%) Late Occlusion 1(2%) 
Lesion length 10±4mm Myocardial Infarction 1 (1%) 
Death 0(0%) 
Total MACE 11 (26%) 
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Table 5. QCA Analysis (n~37). 
"" I 
Pre Post Follow-up 
Radioactive Total Stellt Vessel Radioactil'e Total Stelll Vessel 
MLD 1.03±OA4 2.68±O.46 2.57±O.43 2.i4±OA4 2.04±O.53 1.79±O.56 1.66±O.49 
%DS 66±B 1O±12 B±B 28±H 28±17 37±19 42±16 
RDorMD 2.99±O.60 3.00:tO.45 3.03:tO.45 3.00±O.52 2. 66:tO.5J 2.56:tO.49 2.87±O.5i 
Acute Gain 1.66±O.57 l.55±O.55 l.i l±O.54 
Latc Loss O.65±O.57 O.79±O.58 O.49±O.49 
LLI O.42±OAI O.60±O.64 O.55±O.83 
Restcllosis, n (%) 5 (14%) 8 (22%)8 (22%) 
*results of all 37 patients, who rctumed for angiographic follow-up, 6 patients refused. 
%DS = % diameter stenosis, FU = follow-up, LLI = late loss index, MLD = minimum lumen diameter, :MD = mean diameter, Pre = pre-procedure, Post = 
post-procedure, Radioactive = radioactive segment (15mlll ill length), RD = reference diameter, Total Stellt = radioactive segment and both Cold Ends (251l11ll 
ill length), Vessel = Total vessel (sidebrauch to sidebranch). MLD, MD, RD., Acute Gain and Late Loss measurements are in mill. 
Table 6. Location of the Restenosis (n=8). 
Proximal Sterrt Segment 5 (14%) 
Distal Stent Segment 1 (3%) 
Prox. & Distal Stent Segment 2 (5%) 
r =0.4386 
p=O.0066 
Figure 1-
" 
Angiographic follow-up 
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" 
.. " 
Late loss index at follow-up versus direct stenting of the radioactive stent with and without postdilatation. 
Stents implanted by direct stenting followed by post-dilatation or direct stenting without post-dilatation have a 
significantly worse late loss index at follow-up compared to stents implanted after balloon predilatation (p=O.0066). 
O=predilatation followed by stenting, 1 =direct stenting & post-dilatation, 2=direct stenting without post-dilatation. 
Figure 2. 
Example of a patient at 6-month angiographicJollow-up. 
The Wallstent (4.5 long), implanted in the ramus circumfiexus, had a diffuse in-stent restenosis (see yellow 
arrows in Figure A), while the Cold Ends sterr!., implanted in the right coronary artery, showed a good result 
in the radioactive segment, with Cold Ends restenosis (see yellow arrows in Figure B). 
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Radiation doses 
Stent activity level was 7 .58±2. 78 !lCi at implantation. There was no significant 
correlation between stent activity and late loss or late loss index at follow-up. 
DISCUSSION 
The results of this non-randomized study show that the implantation of a 6-24 !lCi 
J3-radioactive "Cold Ends" stent is safe and feasible, with a total MACE rate of 26% at 
6-month follow-up. 
This trial was conducted to investigate whether edge restenosis 9, occurring in more 
than 40% of the cases, treated with an isodose radioactive stent 18 and possibly caused 
by a combination of balloon injury (barotrauma) and lower radiation dose at the stent-
edges 7.10, can be diminished by using Cold Ends radioactive stents. Using IVUS analysis, 
edge restenosis seemed to be caused both by negative remodeling and neointimal 
hyperplasia 19.21. Therefore, it was hypothesized that edge restenosis could be reduced if 
the remodeling component of the edge restenosis phenomenon could be attenuated by 
the scaffolding properties of Cold Ends stents. The Cold Ends stents were manufactured 
as 15 mm isodose radioactive stents, extended with 5 mm non-radioactive Cold Ends 
segments. Furthermore, in order to control the extent of the barotrauma caused by 
predilatation outside the stent area, direct stenting was performed whenever possible. 
Also, post-dilatation of the stent was only performed, when necessary, and strictly inside 
the stent. 
What was observed in this trial was a shift of the restenosis, usually occurring at the 
edges of the isodose radioactive stent, into the Cold Ends segment. More specifically, 
the most severe restenosis occurred at the transition zone from radioactive to non-
radioactive segments, a region located in dose falloff. This phenomenon has also been 
recently demonstrated, by the group of the Thoraxcenter, in an experimental setup in 
which a half radioactivelhalf non-radioactive stent was implanted in coronary arteries 
of pigs. It was clearly demonstrated that the peak level of neointimal hyperplasia was 
observed specifically in front of the last radioactive strut, thus in the region of dose fall-
off. This strongly suggested that the combination of low dose radiation in association 
with chronic injury by the stent, implanted in non-atherosclerotic tissue, is the main 
determinant ofneointimal hyperplasia 22. Other trials also noted that low dose radiation 
has a stimulatory effect, compared to higher dose radiation 23.25 • All these trials give 
support to the hypothesis that a combination of low-radiation dose and balloon injury, 
actually stimulates neointimal hyperplasia. Edge restenosis was relatively low with 
overall 22% restenosis compared to the other radioactive stent trials, despite the fact 
that the Cold Ends stents were 25 mm in length, while the other radioactive stents were 
15 mm in length. The deleterious effects of the negative remodeling, seen at the stent 
edges in previous radioactive stent trials, were prevented at the Cold Ends segments. 
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Interestingly, patients after direct stenting have a higher late loss compared to patient 
with predilatation followed by stenting. Even more surprisingly, the patients with a 
combination of direct stenting and no post-dilatation have the highest late loss during 
follow-up. This may support the hypothesis that edge restenosis is mainly caused by 
low dose radiation, rather than the degree of injury. One of the other options to reduce 
edge injury, currently under investigation, is the use of square shouldered balloons: They 
are used for radioactive stent implantation, in which the entire balloon remains within 
the stent during stent deployment, thereby minimizing barotrauma at the proximal and 
distal edges. If edge restenosis is not diminished in that trial, it will give support to the 
hypothesis that the low dose radiation, or dose fall-off in itself, is the main contributor 
of edge restenosis. 
CONCLUSION 
The implantation of Cold Ends radioactive stents is feasible and safe. In 14% instent 
restenosis of the transition zone of the radioactive to non-radioactive Cold Ends 
segment was observed. A pure proximal and/or distal Cold Ends restenosis was noted in 
8%. Cold Ends stents therefore have a relatively low restenosis rate compared to other 
radioactive stents, despite the use of a longer stent. This favorable effect was obtained 
by preventing negative remodeling at the edges. Edge restenosis is mainly caused by 
the proliferative response, induced by a combination oflow dose radiation and balloon 
Injury. 
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Background Edge rcstcnosis is a major problem after 
raclioactivc stcnting. The cold-cnd stcnt has a radioactive 
mid-segment (15'9 rom) and non-radioactive proximal and 
distal 5'7 mID segments. Conceptually this may negate the 
impact of negative vascular remodelling at the edge of the 
radiation. 
Method and Results BeG-gated intravascular ultrasound 
with three-dimensional reconstruction was performed post-
stent implantation and at the 6-month follow-up to assess 
rcstcnosis within the margins of the stent and at the stent 
edges in 16 patients. Angiographic rcstcnosis was witnessed 
in four patients, all in the proximal in-stent position. By 
intravascular ultrasound in-stent ncointiroal hyperplasia, 
with a > 50% stented cross-sectional area, was seen in eight 
patients. This was witnessed proximally (n:::2), distally 
(n:::2) and in both segments (n:::4). Echoluccnt tissue, 
dubbed the 'black hole' was seen as a significant component 
of neointimal hyperplasia in six out of the eight cases of 
Introduction 
Conventional stenting has eliminated recoil and negative 
remodelling as components of the restenotic process. 
However, this has been at the cost of exacerbating 
neointimal proliferation secondary to chronic vessel wall 
irritation, leading to in-stent restenosis[1.21. 
Intracoronary radiation has been developed in an 
attempt to decrease restenosis after balloon angioplasty 
and stent implantation. Studies recently performed 
in humans demonstrated a dose-dependent inhibition 
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Correspondence: P. W. Serruys. MD. PhD, FACe. FESC. 
Professor ofInterventional Cardiology. Thoraxcenter, Acadernisch 
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3000 DR Rotterdam, The Netherlands. 
restenosis. Neointimal hyperplasia was inhibited in the area 
of radiation: li neointimal hypcrplasia:::3'72rom3 (8'6%): 
in-stent at the edges of radiation proximally and distally ~ 
ncointimal hyperplasia was 7·9 rom3 (19'0%) and l1'4rom3 
(25'6%), respectively (P:::O·017). At the stent edges there 
was no significant change in lumen volume. 
Conclusions CoJd-cnd stcnting results in increased. 
neointimaJ hyperplasia in in-stent non-radioactive 
segments. 
(Eur Heart J 2001; 22: 1311-1317, do;;10.10531 
eubj.2000.2542) 
© 2001 The European Socicty of Cardiology 
Key Words: Stcnts, remodelling, radioisotopes, angio-
plasty, ultrasonics. 
See page 1245 for the Editorial commcot on this article 
of neointimal hyperplasia at the 6-month follow-up 
in stents with activity levels >3 J,lCiP,41. However. a 
significant increase in neointimal hyperplasia was noted 
at the extremes of the stent and at the edges. Edge 
restenosis was mainly due to an increase in plaque and 
to a lesser extent. remodelling of the native vessel 
wall[4.51. A fall-off in radiation in areas receiving vascular 
injury was proposed as a possible stimulatory mech-
anism. In order to minimize the effect of vascular 
remodelling on stent-edge restenosis, the stent design 
was modified. The 'cold-end' stent (Isostent@ Inc" San 
Carlos, CA. U.S.A.) was rendered radioactive in its 
mid·portion (15·9mm in length): the edges (5·7mm 
each) were non-radioactive (Fig. 1). 
We aimed to analyse tissue growth within the stent 
and at its edges and to define the segments that had the 
greatest propensity to restenosis after the implantation 
of a cold-end stent. 
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r~_~r~_n,-------,~=-t>;t __ n~_n~_r 
5·0mm 5·7:rnm 15·9mm 5·7:rnm 5·0mm 
Figure 1 A cold-end stent with a central radioactive 8e2-DIcnt and proximal and distal non~radioactivc 
segments. Analysis of each segment was performed individually to assess neointimal hyperplasia. This 
included ncointimal hyperplasia over the length of the stent and edges. 
Methods 
Patient selection 
We analysed neointimal hyperplasia and vascular 
remodelling in 16 patients who had completed a 
6-month angiographic follow-up with intravascular 
ultrasound analysis. All patients had single native vessel 
coronary artery disease, normal left ventricular function 
and objective evidence of ischaemia. 
Implantation technique 
Pre-dilation of the lesion was performed where necessary 
followed by stent implantation High-pressure balloon 
inflation to ensure good strut apposition to the vessel 
wall was then performed at the operator's discretion. At 
this time we used a shorter balloon to ensure that the 
edges of the balloon did not extend beyond the limits of 
the stent3.Intravascular ultrasound was used to ensure 
optimal stent deployment. 
Medication 
Patients received 250 mg aspirin and 10 000 inter~ 
national units of heparin at the initiation of the pro-
cedure and the activated clotting time was maintained 
at >300 s. All patients received aspirin 80 mg daily 
indefinitely and clopidogrel 75 mg daily for 6 months. 
Radioactive stent 
The stent was 27·3 mm in length and available in diam~ 
eters of 3'0 and 3'5 mm. It was made radioactive in its 
central portion by phosphorus~32 e2p)l31. The 5·7 mm 
edges were shielded from radiation. The initial activity 
of the stents was measured and thereafter it was 
calculated at what date the activity had decreased to 
3·0-12·0 ]lCi. suitable for implantation. 
Intravascular ultrasound image acquisition 
analysis 
After the final balloon inflation and administration 
of intracoronary nitrates. ECG~gated intravascular 
100 
ultrasound pullback was performed. This was repeated 
at the 6 month follow~up. The segment was subjected to 
three~dimensional reconstruction and examined with a 
mechanical intravascular ultrasound system (Clearview, 
CardioVascular Imaging System, Sunnyvale. CA 
U.S.A.) with a sheath~based intravascular ultrasound 
catheter incorporating a 30 MHz single-element trans~ 
ducer rotating at 1800 rpm. The intravascular ultra~ 
sound transducer was withdrawn through the stationary 
imaging sheath by an ECG~triggered pullback device 
with a stepping motor[6]. Intravascular ultrasound 
images were acquired, coinciding with the peak of the R 
wave, which eliminates the artefacts caused by the 
movement of the heart during the cardiac cycle. After 
each image acquisition. the transducer was withdrawn 
0·2 mm to acquire the next image coincident with the 
R-wave. By definition. this permits acquisition of five 
slices per mm. enabling the operator to easily define the 
sten! margins. By increasing the frequency of sampling 
this approach may also decrease error due to regression 
to the mean created by the use of greater step sizes and 
non_ECG_gating[7,SJ. 
BCG-gated image acquisition and digitation was 
performed using a workstation designed for three-
dimensional reconstruction of echocardiographic 
images[6] (EchoScan. Tomtec. Munich. Germany). A 
Microsoft Wmdows®-based contour detection program. 
developed at the Thoraxcenter. was used for automated 
three-dimensional analysis of up to 200 intravascular 
ultrasound imagest91• This program constructs two 
longitudinal sections and identifies the contours corre-
sponding to the lumen-intima and media-adventitia 
boundaries. using a minimum-cost based software 
algorithm. The feasibility. reproducibility and the inter-
and intra-observer variability of this system have been 
previously described in clinical protocols[5,9]. 
Quantitative intravascular ultrasound 
analysis 
At the stent edges. the area encompassed by the lumen-
intima and media-adventitia boundaries defined the 
luminal and the total vessel volumes. respectively. The 
difference between luminal and total vessel volumes 
defined the plaque volume, Within the boundaries of 
the sten! total vessel volume. stent volume. neointimal 
hyperplasia. and lumen volumes were obtained. The 
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neointimal hyperplasia presented was a value measured 
at follow-up (stent volume-lumen volume). 
The assessment of total vessel volume in stented 
patients has previously been reported[5.IOJ• In our study 
the delineation of the total vessel volume boundary was 
possible in all stented patients. When the total vessel 
volume boundary was not visible in a single cross-
sectional view. the computer extrapolated it from the 
contours of the immediately previous and following 
cross--sections. In addition. the use of three-dimensional 
reconstruction with multiple longitudinal views. facili-
tates the visualization of vessel structures outside the 
stent. 
Definitions and segments of analysis 
Stent edges were defined as those volumes axially 5 mm 
proximal and distal to the final sten! strut. In addition. 
segments in-stent proximally and distally were analysed 
separately to assess neointimal hyperplasia in areas 
which were subject to injury and received stent implan-
tation. Effectively. these were segments which received a 
fall-off in radiation. Finally the in-stent radioactive 
segment was analysed (see Fig. 1). To facilitate com-
parison between the non·radioactive in·stent segments 
(5'7 mm) and the central radioactive segment (1S'9 mm). 
lengths were normalized to a standard length (S mm) 
and appropriate comparisons made. Restenosis was 
defined as an angiographic restenosis >SO% at 
6-month follow-up. by off-line quantitative coronary 
angiography. 
Statistical analysis 
Quantitative data are presented as mean ± standard 
deviation. Volumetric data derived from the three· 
dimensional reconstruction of the intravascular ultra-
sound image were compared immediately after 
treatment and at follow·up using the two-tailed paired 
Student's t-test. ANOVA was used to compare multiple 
variables. A value of P<O·OS was considered statistically 
significant. 
The Medical Ethical Committee of the University 
Hospital Rotterdam approved the study and all patients 
provided written informed consent before the procedure. 
Results 
Baseline clinical and procedural characteristics are 
described in Tables 1 and 2. Table 3 describes 
quantitative coronary angiography data pre- and 
post-intervention and at the 6-month follow-up. 
In-stent radioactive segment 
Neointimal hyperplasia measured within the margins of 
the stent is presented in Fig. 2. Intra~stent neointimal 
Table 1 Clinical characteristics 
Age (mean) 
Male (%) 
Prior MI (%) 
Unstable angina (%) 
Smoking (%) 
Hypercholesterolaemia (%) 
Family history (%) 
Hypertension (%) 
Diabetes (%) 
Tabk 2 Procedural characteristics 
Vessel 
LAD 
LCx 
RCA 
Lesion length (rom) 
Balloon length~post (mm) 
Final balloon sb.e (mm) 
Max inflation pressure! (atms) 
Max inflation pressure2 (atms) 
Balloon-to--artery ratio 
52(41-78) 
69 
75 
40 
56 
69 
56 
40 
o 
6 
7 
3 
11·2±4·5 
1$-6±5·7 
3·9±0·5 
10=4·0 
16±2·2 
1·12 
Max inflation pressure! =balloon at time of stent implantation. 
Max inflation pressure2=balloon inflation within stent. 
LAD=left anterior descending coronary artery; LCx=left 
circumflex artery; RCA=right coronary artery. 
Table 3 Angiographic data 
MLD 
OS 
RO 
Acute gain 
Late loss 
Late loss index 
0'9S ± 0·40 
67±14 
2·97=0·46 
FU=6-month follow-up. 
Po~ 
2·26±0·40 
26::::8 
3·06 ± 0-41 
1·2S±0'46 
FU 
1,67±0'48 
42±13 
2·82 ± 0-43 
0·59 ± 0-49 
0-57 ± 0·56 
MLD=minimum lumen diameter; DS=diameter stenosis; 
RD=reference diameter. 
hyperplasia was significantly decreased in the radio~ 
active mid-segment of the stent: 3·72 ± 3·3 mm3 (8'6%). 
compared with the proximal: 7,90 ± 7·2 mm3 (19-0%) 
and distal: 11·42 ± 10'S mm3 (2S'6%) in-stent segments. 
Over the entire stent length there was a 30·48 mm3 (14%) 
increase in neointimal hyperplasia. No evidence of 
remodelling was seen behind the stent with the total 
vessel volume remaining unchanged. 
In-stent non-radioactive segment 
Significant neointimal in-growth was noted distally and 
proximally from 2-3 mm within the radioactive segment 
and extended on average to the extremities (non-
radioactive) of the stent (see Fig. 3). Four individuals 
experienced angiographic restenosis in the proximal 
101 
Chapter 9 
ANOVA,p=0·017 
<I O __ ~~~~~L--L~~~~ 
Distal Radioactive Proximal 
stent stent stent 
Figure 2 Ncointimal hyperplasia (mm3) in the three 
in-stent segments. Each segment is standardized to a 5 rom 
length for comparison. 
portion of the stent. However. the greatest mean volume 
of tissue growth as quantified by intravascular ultra-
sound was seen in the distal stent. Neointimal hyper-
plasia. with a >50% stented cross-sectional area. was 
seen in eight patients. This was witnessed proximally 
(n=2). distally (n=2) and in both segments (n=4). 
Tissue growth in-stent was due to a combination of 
conventional neointimal hyperplasia and echolucent. 
bypodense material. described by this group as the 
'black hole' (p. W. Serruys, personal communication. 
Rotterdam. 1999). This was witnessed (Fig. 4) in the 
non-radioactive proximal and distal in-stent segments in 
six out of the eight patients. 
rOlal vessel volumes 
No significant change in total vessel volumes or plaque 
behind the stent was seen between post-procedure and 
follow-up. No echolucent tissue was seen behind the 
stent. 
Stent edge 
Late lumen loss was seen at the stent edge without 
evidence of restenosis. On average. there was evidence of 
a decrease in total vessel volume) with little change in 
plaque as a cause of late lumen loss. 
Stent activity 
Mean stent activity at implantation was 6·9 ± 1·9 J..l.Ci. 
Discussion 
Dose-finding studies in humans have sho'Nn that in-stent 
neointimal hyperplasia is decreased in a dose-dependent 
manner after the implantation of stents with activity 
levels >3·0 J..l.Ci[3.4J. Unfortunately. stent edge restenosis 
was a side effect of this treatment modality at these 
activity levels. Because the sten! edge is systematically 
30,------,------,---------------------,------,------, 
+ 
20t 
~~ 15, 
O~=::;--
_---Radiation length---_ 
_ --------Stentlength--------_ 
Figure 3 Graph showing neointimaI hyperplasia (% increase) over the length of the stent and edges. 
Note significant hyperplasia proximally and distally in-stcnt and the relative sparing of the radioactive 
mid-segment of the stent. Note also that significant in-growth begins within the radioactive segment of 
the stent and extends to the non-radioactive proximal and distal extremities of the stent. 
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Figure 4 Representative example of ccholuccnt tissue ('black holc'). (a) A transverse section. A black hole 
is seen from 9 o'clock to 3 o'clock. (b) A longitudinal reconstruction. Arrowhead points to scmi-circular 
echoluccnt tissue seen adjacent to the stcnt struts. 
damaged by barotrauma at the time of balloon expan-
sion, a situation of geographical misS[lll. in which the 
damaged edges receive low dose radiation, is gennane to 
radioactive stenting in the absence of appropriately 
shaped balloons. Previously we have argued: 'If the 
candy wrapper (bilateral edge restenosis) were purely the 
result of negative remodeling induced by low..Jose radia-
tion in an injured area.. then the lengthening of the sten! 
by a non-radioactive. cold-end would be a logical solu-
tion to prevent remodeling at the extremities. If plaque 
constitutes a large percentage of the healing process 
manifested by the candy wrapper then cold-end stent 
implantation is unlikely to work. Similarly neointimal 
proliferation may occur at the edges of the radiation 
within stent using this treatment modality'[121. This 
prediction appears to have materialized in the current 
study, with migration of the restenotic edge from outside 
the stent to within the stent at the edges of radiation. 
Neointimal hyperplasia 
Neointimal hyperplasia in the true radioactive segment 
was suppressed at the 6-month follow-up to a degree 
similar to that noted in the 32p radioactive stent dose-
finding trial previously reported by this group (mean 
neointimal hyperplasia=lH7mm' (13-94%». using a 
15 rom stentl5l. Regrowth of tissue starting 1-2 rom 
within the radioactive extremes and extending out of the 
stent was noted in the 32p radioactive stent dose finding 
trial, translating to significant stent-edge hyperplasia 
proximally. In the cold-end sten!, neointimal hyper-
plasia was noted in the final millimetres of radiation and 
extended bilaterally. In the latter study, this left the true 
stent edges relatively, although not completely, spared 
as there remained evidence of tissue growth in three 
individuals, which started within the radioactive portion 
and continued to the true vessel lumen. No angiograpmc 
restenosis occurred in these three however. Again. we 
must assume that the position of such restenosis is 
caused by geographical miss. Why some individuals are 
affected and others not is unclear, but may be explained 
by an idiosyncratic individual response to healing. 
dose heterogeneity along the length of the sten!, tissue 
type behind the sten!, plaque burden and even strut 
apposition to the vessel walL 
Echolucent tissue 
In nearly 50% of subjects, echolucent tissue was present 
within the stent at the distal or proximal (in-stent) edge 
of radiation and consituted on average 50% of neo-
intimal ingrowth in areas of restenosis. These echolucent 
lesions had the following characteristics: a homogeneous 
black appearance without backscatter. Images with 
ring-down or other artefacts were excluded and no 
attenuation behind intraluminal echodense structures 
was seen. Exclusion of other causes of relative echo-
lucency such as contrast[131, thrombusC14] or a lipid 
lake[151 was performed. Lesions were discrete and readily 
distinguishable from conventional neointimal hyper-
plasia. After radioactive stenting. all appeared to be 
juxtaposed to stent struts. 
We have performed atherectomy on four such lesions 
detected at the 6-month follow-up after radioactive 
stenting and found that they contain a hypocellular 
matrix with areas of proteoglycan, similar to that seen 
in the animal model[16.171. The mixture of neointimal 
hyperplasia and proteoglycan, which has a high water 
content. may explain the echolucent tissue adjacent to 
the stent struts noted in Fig. 5. Further pathological 
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Figure 5 Photomicrographs (a) and (b) show neointima consisting of 
arboryzing smooth muscle cclls in a protcoglycan matrix:. H&E stain; 
bars=50_ 
assessment is required before definitive comment can be 
made on this interesting observation. Equally. the long-
term incidence of restenosis from such lesions is yet to be 
determined. 
Edge remodelling 
This was similar to that seen after non-radioactive 
stenting. whereby non-restenotic late lumen loss was due 
to negative remodelling!5,18J• 
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Implications for the future: dealing with the 
edge effect 
If the edge effect is the result of balloon-induced trauma 
and low dose radiation then limiting the trauma to 
outside the stent and expanding the irradiated area 
beyond the injured area should be attempted. For radio-
active stents. conceivably the most practical approach 
may be to extend the area of irradiation beyond the 
injured area using a 'hot..end stent'. Tills involves liter-
ally concentrating the greatest activity of the stent at 
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the stent edges; such stents are already undergoing 
multicentre trials. A further therapeutic option is that of 
hybrid treatment with radioactive stent implantation 
followed by catheter-based therapy localized to the sten! 
edges only. 
Conclusion 
Cold-end stent implantation, a strategy devised to pre-
vent edge restenosis after radioactive stenting results in 
migration of the restenotic edge from outside the sten! to 
within the stent at the edges of radiation. This adds 
credence to the hypothesis that injury and low..Jose 
radiation stimulate neointimal hyperplasia[191. 
The Wenckebach award was made to P. W. Serruys by the 
Dutch Heart Foundation and is utilized for brachytherapy research 
in the catheterization laboratory. I. P. Kay is supported by the 
National Heart Foundation of New Zealand. Auckland and 
the Ian Gordon Mackenzie Scholarship, Gniversity of Otago, 
Dunedin. Kew Zealand. 
References 
(1] Farb A. Sangiorgi G, Carter AJ et a1. Pathology of acute and 
chronic coronary stenting in humans. Circulation 1999; 99: 
44--52. 
[2] Murphy JG. Schwartz RS, Edwards WD et al. Percutaneous 
polymeric stents in porcine coronary arteries. Initial experi-
ence with polyethylene terephthalate stents. Circulation 1992; 
86: 1596-1604. 
[3] Wardeh A..T, Kay IP, Sabat6 M et aI. ft-particie-emitting 
radioactive stent implantation: a safety and feasibility study. 
Circulation 1999: 100: 1684--9. 
[41 Albiero R. Adamian M. Kobayashi N et aI. Short- and 
intermediate-term results of np radioactive ,lkmitting stent 
implantation in patients with coronary artery disease: the 
Milan Dose-Response Study. Circulation 2000; 101: 18-26. 
[5] Kay IP, Sabate M. Costa MA et aI. Positive geometric 
vascular remodeling is seen after catheter-based radiation 
followed by conventional stent implantation, but not after 
radioactive stent implantation. Circulation 2000; 102: 1434-9. 
[6] von Birgelen C, Mintz GS, Nicosia A et aI. 
Electrocardiogram-gated intravascular ultrasound image 
acqUlSltlon alter coronary stent deployment tac!lttates on-lIne 
three-dimensional reconstruction and automated lumen 
quantification. J Am Coll Cardio11997: 30: 436-43. 
[7] Bland JM, Altman DG. Some examples of regression towards 
the mean. BMJ 1994; 309 (6957): 780. 
[8] von Birgelen C, de Feyter PJ, de Vrey EA et aI. Simpson's rule 
for the volumetric ultrasound assessment of atherosclerotic 
coronary arteries: a study with ECG-gated three-.dimensional 
intravascular ultrasound. Coron Artery Dis 1997; 6: 363-9. 
[9] von Birge1en C, Di Mario C, Li W et aI. Morphometric 
analysis in three-dimensional intracoronary ultrasound: an in 
vitro and in vivo study performed with a novel system for the 
contour detection oflumen and plaque, Am Heart J 1996; 132: 
516-27. 
PO] Prati F. Di Mario C, Moussa I. In-stent neointimai 
proliferation correlates with the amount of residual plaque 
burden outside the stent. An intravascular ultrasound study. 
Circulation 1999; 99: 1011-14. 
[11] Paterson R. The treatment of malignant disease by radio-
therapy, 2nd edn. London: Edward Arnold Publishers Ltd, 
1963. 
[12] Serruys PW, Kay IP. I like the candy, I hate the wrapper. 
Circulation 2000; 101: 3-7. 
[13J Kay IP, Sabate M, Ligthart JMR. van cler Giessen WJ, de 
Feyter PJ, Serruys PW. Intracoronary ultrasound longi-
tudinal reconstruction of a postangioplasty coronary artery 
dissection. Circulation 1999; 99: e17. 
[14J Serrano P, Kross lM, Ligthart B1R, Costa MA. Sabate M, de 
Feyter PJ. Diagnosis of an intracoronary thrombus with 
intravascular ultrasound. Circulation 2000; 101: e84-e85. 
[I5] Gronholdt M-L M, Nordestgaard BG. Wiebe BM, Wilhjelm 
re. Sillesen H. Echolucency of computerized ultrasound 
images of carotid atherosclerotic plaques are associated with 
increased levels of triglyceride-rich lipoproteins as well as 
increased plaque lipid content. Circulation 1998; 97: 34-40. 
[16] Carter AJ. Scon D. Bailey L, Hoopes T, Jones R, Virmani R. 
Dose-response effects in an atherosclerotic porcine coronary 
model. Circulation 1999; 100: 1548-54. 
[17] Hehrlein C, Kaiser S. Riessen R. Metz J, Fritz P, Kubler W. 
External beam radiation after stent implantation increases 
neointimal hyperplasia by augmenting smooth muscle cell 
proliferation and extracellular matrix. accumulation. J Am 
Coll Cardioll999; 34: 561-6. 
[18] Hoffmann R. Mintz GS, Dussaillant GR et al. Patterns and 
m.echanism of in-stent restenosis. A serial intravascular ultra-
sound study. Circulation 1996; 94: 1247-54. 
[19J Weinberger J, Amols H. Ennis RD, Schwartz A, Wiedermann 
JG, Marboe C. Intracoronary irradiation: Dose response 
for the prevention of restenosis in swine. Int J Radiation 
Oncology BioI Phys 1996; 36: 767-75. 
105 

Chapter 10 
Edge Restenosis After Implantation of "Hot Ends" 
32P Radioactive S-Emitting Stents. The Milan and 
Rotterdam Experience. 
Submitted 

Edge Restenosis After Implantation of "Hot Ends" 
Edge Restenosis After Implantation of "Hot Ends" 
32p Radioactive B-Emitting Stents 
The Milan and Rotterdam Experience 
Remo Albiero', MD; Takahiro Nishida', MD; Alexander J. Wardefl2, MD; 
Patrick Kay2, MBChB; Neil J. Weissman, MOS; Garon Stankovic', MD; 
Takuro Takagi', MD; Nicola Corvaja', MD; Carlo Di Mario', MD, PhD; 
Patrick W Serruys2, MD, PhD; Antonio Colombo', MD 
I From EMO Centro Cuore Columbus, Milan, Italy 2 From Thoraxcenter Rotterdam, 
University Hospital Rotterdam, Rotterdam, The Netherlands. 3 From Intravascular 
Ultrasound Imaging and Cardiac Catheterization Laboratories, Washington Hospital 
Center, Washington, DC, US 
ABSTRACT 
Background-A high restenosis rate has been reported atthe edges ("edge restenosis") 
of32P radioactive stents with an initial activity level up to 21 ~Ci. This edge effect might 
be due the systematic balloon injury in the first 2 mm outside the stent margins in 
combination with a sub-therapeutic level of radiation at the stent edges. The aim of this 
study was to evaluate whether an increased activity at the proximal and distal end of the 
stent ("hot ends") might diminish the problem of "edge restenosis", by extending the 
area of irradiation beyond this injured area. 
Methods and Results- The "hot ends" 32p radioactive B-partic1e-emitting stent has a 
length of 18 mm. The initial radioactivity level is 2.6 ~CjJmm in the proximal and distal 
2 mm of the stent, and 0.57 ~CjJmm in the central 14 mm of the stent. The initial total 
radioactivity of the stent is - 18.5 ~Ci. From July until Nov 1999, 53 patients (pts) with 
56 lesions were treated in Milan (36 patients with 39 lesions ) and Rotterdam (17 patients 
with 17 lesions) by implantstion of 56 "hot ends" 32p radioactive stents. There were 
no procedural events. At the 6-month angiographic follow-up, performed in 51 patients 
with 54 lesions (96%), intralesion binary restenosis was 33% (19% at the proximal edge, 
7% at the distal edge, and 7% at both edges). 
Conclusions-Radioactive 32p "hot ends" stents did not solve the problem of edge 
restenosis. 
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CONDENSED ABSTRACT 
Restenosis at the edges of 32p radioactive stents of 3-12 !lCi activity was possibly 
explained by the lower dose of radiation delivered in the balloon injured arterial segment 
at the stent ends. We evaluated whether an increased radioactivity at both stent edges 
("hot ends") might diminish "edge restenosis", by extending the area of irradiation 
beyond the balloon injured area. Six months after stenting, there were no deaths, or stent 
occlusions. Only one patient had an AMI. However, intralesion binary restenosis was 
33%. Radioactive '2p "hot ends" stents did not solve the problem of edge restenosis. 
Key words: radioisotopes, restenosis, stents, ultrasonics 
In patients with coronary artery disease treated with '2p radioactive B-emitting stents 
with an initial activity of 3 to 21!lCi, intrastent restenosis at the 6-month angiographic 
follow-up was ~% 1-'. However, the intralesion restenosis rate was >30% due to 
restenosis at the stent edges ("edge restenosis") 1-'. This edge effect might be due to 
the systematic balloon injury in the first 2 mm outside the stent margins in combination 
with a sub-therapeutic level of radiation at the stent edges 4. The purpose of this study 
was to evaluate whether 32p radioactive stents with an increased activity at the proximal 
and distal end of the stent ("hot ends") could solve the problem of "edge restenosis", by 
extending the area of irradiation beyond this injured area. 
METHODS 
Patient Population 
Inclusion criteria for enrollment in this study were previously reported 1. From July until 
Nov 1999,53 patients with 56 lesions were treated in Milan (36 patients with 39 lesions) 
and Rotterdam (17 patients with 17 lesions) by implantation of 56 radioactive '2p BX 
"hot ends"stents. 
Radioactive Stent 
The radioactive 32p BX "hot ends" stent had a length of 18 mm. The initial radioactivity 
level (at a pre-specified date) was 2.6 !lCi/mm in the proximal and distal 2 mm of the 
stent, and 0.57 !lCi/mm in the central 14 mm of the stent. The initial total radioactivity of 
the stent was -18.5 !lCi. The activity reported in this study was that calculated at the date 
of implantation. The stent was mounted on a 20-mm-long balloon. The characteristic of 
the isotope ("P) used in this study was previously described 1. 
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Procedure and Clinical Follow-Up 
The technique used to implant a radioactive stent was previously reported ,. The 
"hot ends"stents were implanted predilating the lesions with a nonoversized balloon, 
deploying the stent at 8 to 10 atm, and postdilating using a shorter balloon inflated at high 
pressure (> 12 atm) inside the stent.After stenting, patients received long-term treatment 
with aspirin (325 mg daily) plus ticlopidine (250 mg twice daily) or clopidogrel (75 mg 
daily) for 23 months. Death, myocardial infarction, stentthrombosis, and target lesion 
revascularization (TLR) were defined as previously reported. l.s-,. TLR was performed 
on the basis of clinical symptoms and/or evidence of ischemia on exercise testing. 
Angiographic and intravascular ultrasound (IVUS) analyses 
The methods used for angiographic analysis and IVUS imaging, and the definitions of 
intrastentand intralesion restenosis were previously reported 1.s-7 
Quantitative IVUS analysis was performed by a Core Laboratory (Intravascular Ultrasound 
Imaging and Cardiac Catheterization Laboratories, Washington Hospital Center, Washington, 
DC). Validation ofIVUS measurements and reproducibility of sequential IVUS mesurements 
in the Washington Hospital Laboratory have been previously reported 8. The image cross 
sections (I mm apart) of the stent and of 5 mm proximal and distal to the stent were analyzed 
measuring postintervention (PI) and follow-up (FU) external elastic membrane (EEM), 
lumen, stent, and plaque (EEM minus lumen) cross sectional areas (CSA). Calculation and 
analysis of late lumen loss (PI-FU lumen CSA), tissue growth at the stent edges (FU-PI 
plaque CSA) and inside the stent (stent-lumen CSA), and remodeling (PI-FU EEM CSA) 
were performed in the 18 lesions with a complete serial IVUS evaluation treated by a single 
"hot end" stent without additional nonradioactive stents. 
Statistical Analysis 
Continuous variables were presented as mean±SD and categorical variables as number 
and percentage. 
RESULTS 
Patient characteristics are shown in Table I.Angiographic and procedural characteristics 
are shown in Table 2. Most of the treated lesions (90%) were de novo lesions. A 
single stent ("hot ends") was implanted in 82% of the lesions, while an additional non-
radioactive stent was required to treat a dissection in 10 lesions (18%). 
Clinical Events 
At 30-day follow-up no subacute stent thrombosis occurred. At 6 months, no late 
occlusion was seen. No patient died and only one patient experienced myocardial 
infarction. TLR was performed in 13/54 (24%) lesions. 
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Table 1. Clinical Characteristics of the 53 Patients Studied 
Male sex 
Age,y 
Risk factors 
Diabetes mellitus 
Hyperlipidemia 
Hypertension 
Smoking 
Family history 
40 (75) 
60.1± 9.6 (36-85) 
6 (11) 
30 (57) 
30 (57) 
7 (13) 
21 (40) 
Values are n (%) or mean±SD (range) 
Table 2. Angiographic and Procedural Characteristics 
No. oflesions 
Radioactivity, ~Ci 
De novo lesions, n (%) 
Vessel: - LAD 
-LCx 
-RCA 
Final balloon size, mm 
Final balloon length, rom 
Final inflation pressure, attn 
Final BalIoon~to-artery ratio 
No. stents/lesion 
Lesions treated by a single stent 
56 
14.0 ± 2.6 (9.5-18.5) 
37 (90) 
30 (54) 
12 (21) 
14 (25) 
3.42±0.47 
14.8±4.0 
14.3±3.0 
1.16±0.17 
1.07±0.26 
46 (82) 
LAD, left anterior descending coronary artery; Lex, left circumflex coronary artery; 
RCA, right coronary artery; Values are mean±SD (range) or number (%) of lesions. 
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Table 3. Quantitative Angiographic Results 
Preintervention n=56 
Reference diameter, rom 3.00 ± 0.61 
MLD,mm 0.95 ± 0.51 
Lesion length, rom 13.9±4.S 
Postintervention n=56 
Reference diameter, mm 3.25 ± 0.51 
MLD,mm 2.95 ±0.57 
Follow-up n=54 
Reference diameter, mm 3.01 ± 0.49 
J\.1LD,mm 2.12 ± 0.94 
Intralesion Restenosis, n (%) IS (33) 
- proximal edge 10 (19) 
- proximal + distal edge 4 (7) 
- distal edge 4 (7) 
Values are mean±SD or number (%) of lesions 
Quantitative Angiographic and IVUS Analysis 
Table 3 summarizes the quantitative angiographic results. Intralesion restenosis rate 
was 33%, mainly located at the proximal edge, Moreover, it occurred in 50% (5/10) 
of the lesions treated by an additional non-radioactive stent. There was only one case 
(2%) of diffuse intrastent restenosis. An example of a patient with edge restenosis 
("candy wrapper") 6 months after "hot ends" stent implantation is shown in Figure 1. 
Quantitative IVUS analysis in the 18 lesions with complete serial IVUS evaluation is 
shown in Figure 2: late lumen loss in the first 2 rom outside the proximal stent margin 
was mainly due to tissue growth, while late lumen loss ouside the distal stent margin was 
not higher than inside the stent 
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Figure 1. 
Representative patient vvith "candy wrapper" edge effect 6 months after radioactive 32p '"hot ends" stent 
implantation. Baseline angiography (A) demonstrates a moderate 60% stenosis in the distal circwnfiex 
coronary artery. After implantation (B) of a IS-mm BX "hot ends" stent. At 6 month follow-up (C), there 
is absence of late loss inside stent but a tight stenosis at both stent edges. In this case, NUS imaging 
demonstrated that edge restenosis was due to neointimal hyperplasia without negative remodeling. 
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Plot of mean of late lumen loss, tissue growth, and remodeling (in m.m2) in 18 lesions with complete serial 
NUS evaluation treated by a single 18-mm BX "hot ends" stent. Point represents differences in CSA 
measured in slices 1 mm apart inside stent and in proximal and distal reference segments. 
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DISCUSSION 
The results of this study confum our prior observations 1-3 on the effectiveness of 32p 
radioactive stents in inhibiting intrastent neointirnal hyperplasia. However, the "hot-
ends" stents, designed to prevent edge restenosis, by extending the area of irradiation 
beyond the balloon-injured area outside the stent margins, did not reach this goal. 
Mechanism of edge restenosis 
The edge effect may be considered a short-term healing response to vessel wall injury 
beyond the stented vessel segment combined with the effects of low-dose radiation 1-4. 
In this study, restenosis occurred predominantly at the proximal edge. A reason for 
this result may be the tendency of the operator, in order to avoid distal dissection and 
guarantee a good proximal stent expansion, to postdilate the stent at high pressure 
positioning the balloon close to the proximal margin of the stent, with an increased 
risk of barotrauma at this site. Another possibile explanation for the proximal edge 
restenosis may be the edge shear stress created by the presence of a complete inhibition 
ofneointimal proliferation inside the stent'. 
Conclusion 
Single 32p radioactive B-emitting "hot ends" stents did not solve the problem of "edge 
restenosis. 
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Positive Geometric Vascular Remodeling Is Seen After 
Catheter-Based Radiation Followed by Conventional Stent 
Implantation but Not After Radioactive Stent Implantation 
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Mariano Albertal, MD; Willem J, van der Giessen, MD, PhD; Alexander l Wardeb, MD; 
Jurgen MK Ligthart, BSc; Veronique MA Coen, MD; 
Peter C, Levendag, MD, PhD; Patrick W, Serruys, MD, PhD 
Background-Recent reports demonstrate that intracoronary radiation affects not only neointimal formation but also 
vascular remodeling. Radioactive stents and catheter-based techniques deliver radiation in different ways, suggesting 
that different patterns of remodeling after each technique may be expected. 
Methods and Results-We analyzed remodeling in 18 patients after conventional stent implantation, 16 patients after 
low-activity radioactive stent implantation, 16 patients after higher activity radioactive stent implantation, and, finally, 
17 patients who underwent catheter-based radiation followed by conventional stent implantation. Intravascular 
ultrasound with 3D reconstruction was used after stent implantation and at the 6-month follow-up to assess remodeling 
within the stent margins and at its edges. Preprocedural characteristics were similar between groups. In-stent neointimal 
hyperplasia (NIH) was inhibited by high-activity radioactive stent implantation (NIH 9.0 rom3) and by catheter-based 
radiation followed by conventional stent implantation (NIH 6.9 rom3) compared with low-activity radioactive stent 
implantation (NIH 21.2 rom3) and conventional stent implantation (NIH 20.8 rom3) (P=0.008). No difference in plaque 
or total vessel volume was seen bebind the stent in the conventional, low-activity, or high-activity stent implantation 
groups. However, significant increases in plaque behind the stent (15%) and in total vessel volume (8%) were seen in 
the group that underwent catheter-based radiation followed by conventional stent implantation. All 4 groups 
demonstrated significant late lumen loss at the stent edges: however, edge restenosis was seen only in the group 
subjected to high-activity stent implantation and appeared to be due to an increase in plaque and, to a lesser degree, to 
negative remodeling. 
Conclusions-Distinct differences in the patterns of remodeling exist between conventional, radioactive, and catheter-
based radiotherapy with stenting. (Circulation. 2000;102:1434-1439.) 
Key Words: stents _ remodeling _ radioisotopes _ angioplasty _ ultrasonics 
I n our enthusiasm to control vessel recoil and remodeling after balloon angioplasty (BA). stent implantation has 
become increasingly popular. With conventional stenting, we 
have eliminated recoil and remodeling as components of the 
restenotic process. However, this has been at the cost of 
exacerbating neointimal proliferation secondary to chronic 
vessel wall irritation, leading to in-stent restenosis.l,z 
Intracoronary radiation has been developed in an attempt to 
decrease restenosis after BA and stent implantation. Two 
parallel technologies. one using radioactive stents3-7 and the 
other using catheter-based radiation. ~-1O have been the subject 
of both animal and human studies. Given the different dose 
rates and total doses delivered by each method. one may 
intuitively expect different patterns of remodeling subsequent 
to each approach. 
Whereas the effect of catheter-based radiation after BA on 
vascular remodeling has been described. 11 the response of the 
arterial wall to catheter-based radiation and subsequent stent 
implantation has not been described. Preliminary studies have 
reported the effect at the stent edge after radioactive stent 
implantation.4 However, these reports did not encompass the 
response behind the stent in the arterial wall. 
The aim of the present study was to describe the response 
of the coronary artery to radiation and stenting by examining 
the stent and its edges after radioactive stent implantation and 
also after catheter~based radiation with stent implantation. 
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TABLE 1. Clinical Characteristics 
Groups 
C lA HA CBS 
Patients, n 18 16 15 17 
Age, Y 58 (42-7~ 60 (43-74) 59 (42-75) " (45-74) 
Male, % 70 66 70 60 
PriorMI, % 40 40 4S 40 
Unstable angina, % 60 50 55 55 
Smoking, % 40 55 40 40 
Hypercholesterolemia, % 60 62 55 55 
Family history, % 33 42 30 40 
Hypertension, % 40 42 30 33 
Diabetes, % 5 5 10 
Age values are mean (range). MI indicates myocardial infarction. 
Methods 
Patient Selection 
We an:iJyzed gc()IDCtriC v:lScular remodeling in 4 groups of patients: 
(1) LA group, those who bad undergone impiant:ltion oelp~em.itting 
radioactive stentS at activity levels of 0.75 to 1.5 p.Ci (Isostent Inc): 
(2) HA group, those who bad undergone implantation of ~lp 
radioactive stent~ at activity levels of 6.0 to 12 p.Ci (Isostent Inc); (3) 
CBS group, those who had undergone conventional stent implanta-
tion after suboptimal BA (cJinjcally significant dissection or re..~idual 
stenosis >30%) and cathcter-b3SCd radiation; and (4) C group. those 
who had undergone conventional stent implantation:Uter suboptimal 
BA. 
Stents analyzed were from patients with single-native-vessel 
coronary artery disease. normal left ventricular function, and objec-
tive evidence of ischemia. All groups were matched for patient 
baseline charncteristics. vessel size. lesion. and stent length. Stents 
placed in the ostia1 position or adjacent to major side br:mches. such 
that the sten! edges were unable to be analyzed. were excluded from 
analysis. Only patients who had completed 6-month angiographic 
:md intrnvascular ult:ra...:;ound (NUS) follow-up were included. 
Implantation Technique 
The same group of cardiologists. using a similar technique. im-
planted all stents. Predilation of the lesion wa.~ performed. followed 
TABLE 2.. Procedural Characteristics 
C 
Vessels, n 
lAD 10 
LOx 4 
RCA 4 
Lesion length, mm 9.6:::3.3 
Stent length, mm 14.6:::3.8 
Balloon length after implantation, mm 14.8::!:3.4 
Rnal balloon size, mm 32::!::0.4 
Max inflation pressure 1 11.5±2.4 
Max inflation pressure 2 14.6::!::3.2 
BaJloon-to-artery ratio 1.04::!:0.05 
by stent implantation with use of either a premounted stent or the 
Johnson & Johnson delivery system (Johnson & Johnson Interven-
tiona1 Systems Co). A balloon shorter than the stent was then 
selected. and high-pressure balloon inflation was performed within 
the stent to ensure good sten! apposition. Intr:l.vascular ultrasound 
was used to ensure optimal stent deployment. 
Medication 
Patients received 250 mg aspirin and 10 000 IV heparin at the 
initiation of the procedure. and the activated clotting time was 
maintained at >300 seconds. All patients received aspirin (80 mg 
daily) indefinitely and ticJopidine (250 mg BID) for 2 weeks (C 
group) or clopidogrel (75 mg daily) for 12 week.~ (LA. HA, and CBS 
groups) after stent implantation. 
Radioactive Stents 
The BX stent (Isostent Inc) was the only radioactive stent implanted 
in this trial. It was 15 mm in length and available in diameters of 3.0 
and 3.5 mm. The BX stent wa.~ made radioactive by o~P. The initial 
activity of the stents was measured; thereafter. it was calculated at 
the date on which the activity had decreased to 0.75 to 1.5 J.l.Ci or 6 
to 12 J.l.Ci. levels suitable for implantation. 
Catheter-Based Radiation Delivery System 
The Beta-Cath System (Novostc Corp) was used to deliver localized 
,B-radiation ~Srr'Y) to a depth of 2 mm from the center of the 
Groups 
lA HA CBS 
9 9 
3 4 
4 4 
12.1:::3.8 10.1:::3.3 11.9:::4 
15.0 15.0 15.2::!::4.1 
14.4±2.8 14.1::!:2.6 15,1±3.6 
3.1±0.6 3.4::!::0.5 3.2::!:0.5 
11.6::!:2.6 10.2±2.8 12.2::!:2.6 
15.2±2.4 15.8::!::1.7 15.4±3.3 
1.12::!::0.06 1.10::!:0.06 1.12::!::0.05 
Values are mean::!:SD. lAD indicates left anterior descending coronary artery; LCx, left circumflex coronary artery; 
RCA, right coronary artery; Max inflation pressure 1, balloon attime of stent implantation; and Max Inflation pressure 
2, balloon inflation within stent 
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TABLE 3. Volumes for Edge ProXimal and Distal to Stent (10M mm Length) 
Edge, mml 
LV TW Plaque 
Group ?o~ FlU? ?o~ FlU? Post FlU? 
C 67.7=18.9 58.3::!::19.3~ 124.4=::32.6 116.5:!:34.1~ 56.7±22.6 58.2:±:23.1 
LA 752:!:39.0 67.3:!:34.4~ 126.6:!:58.0 116.4::!::49.0· Sl.4:!:24.S 49.1:!:21.0 
HA 74.9:!:23.0 63.0±23.7'" 126.2::':44.9 117.6:±:46.2* 51.3±16.4 54,6:!:16,1 
CBS 72,6:!:27.7 61,1::1:26.3" 133.2±48.5 138.9:!:46.5t 60.6:::26,1 n.S:::28.6*t 
Values are mean::!:SD. Post indicates baseline; FIUP, follow-up. 
·P<O.05 vs Post (within-9roup comparison); tP<O.OS for between-group comparison (ANOVA). 
source at the site of coronary intervention. The device consisted of 3 
component.~: (1) the tr:l.I1sfer device that stored the radiation source 
train and allowed the positioning of these sources within the catheter; 
(2) the delivery catheter, which was :l 5F multilumen over-tbe-wire 
noncentered catheter that used saline solution to send and return the 
radiation sourcc tr:l.in; and (3) the rndiation source train. which 
consisted of a series of 12 independent cylindrical seeds that 
contained the rndioisotope 90Sr sources and was bordered by 2 gold 
radiopaque m:J.I'kers sep:lI':l.ted by 30 mrn. Other device and proce-
duraJ details have been previously published by this group. 1 1 
Defmitions 
Stent Edges 
Stent edges were defined as those volum($ axi:J..lly 5 mrn proximal 
and dist:J.I to the final stent strut. An edge restenosis was defined as 
an angiographic restenosis >50% at 6-month follow-up located at 
either stent edge. An edge effect was defined as any stent-edge 
ren:l1Towing. 
Patients with b:illoon-injured edges that failed to receive radiation 
in the catheter-based radiation group were excluded. In other words. 
no stents implanted in areas of geographical miss were included in 
the present study. 
IVUS Image Acquisition Analysis 
After the fmal balloon inflation and administration of intracoronary 
nitrates, ECG-gated IVUS pullback was performed. TIlls was re-
peated at the 6-month follow-up. 
The segment subjected to 3D reconstruction was examined with a 
mechanical IVUS system (ClearView. CVIS) with a sheath-based 
IVUS cathcter incorporating a 30-MHz single-element transducer 
rotating at 1800 rpm. The IVUS transducer was withdrawn through 
the stationary imaging sheath by an ECG-triggered pullback device 
with a stepping motor. 1Z IVUS images coinciding with the peak of 
the R wave, which eliminates the artifacts caused by the movement 
of the heart during the cardiac cycle, were acquired. After each 
image acquisition, the transducer was withdrawn 0.2 mrn to acquire 
the next image coincident with the R wave. The ECG-gated image 
TABLE 4. Volumes for Stent 
LV TW 
Group Post FlU? Post 
C 113.9:=29.7 92.8:=28,7* 256.1:=73.2 
LA 127.3:=42.6 105.5:t40.1~ 266.6:t96,5 
HA 122.4:=20.0 111.7:=24.3* 267.8:=66.9 
CBS 128.6:t41.3 121.8:t41.1Y 258.9:t73.6 
acquisition and digitization was performed by a workstation de-
signed for the 3D reconstruction of echocard.iographic imagesl~ 
(EchoScan. Tomtec), A Microsoft Windows-based contour detec-
tion program. developed at the Thoraxcenter. Rotterdam, was used 
for the automated 3D analysis of up to 200 IVUS images. 13 The 
feasibility. reproducibility. and interobserver and intraobscrver vari-
ability of this system have been previously validated in clinical 
protocols. 11 
Quantitative IVUS Analysis 
At the stent edges. the area encompasscd by the lumen-intima and 
media-adventitia boundaries defined the 1umina1 volume (LV) and 
the tom! vessel volume (TVV). respectively. The difference between 
LV and TVV defined the plaque volume, TW, stent volume, 
neointimal hyperplasia (NIH). plaque behind the stcnt (fVV -stent 
volume). and LV were obtained within the axial boundaries of the 
stent 
The assessment of TVV in stented patients has previously been 
reported.14 Although in the previous report the delineation of TW 
was not possible in some patients because of stent shadowing, in the 
present study the delineation of the TW boundary was possible in 
all stented patients, When the TW boundary was not visible in a 
single cross-sectional view. the computer extrapolated it from the 
contours of the previous and subsequent cross sections. In addition. 
the use of 3D reconstruction with multiple longitudinal views 
facilitates the visualization of vessel structures out~de the stent. 
Statistical Analysis 
Quantitative data are presented as mean:=SD. Volumetric data 
derived from the 3D reconstruction of the IVUS imaging were 
compared immedia.tely after treatment and at follow-up by the 
2·tailed paired Student t test Comparison between groups was 
performed by l-way ANOVA. A value of P<O.05 was considered 
statistically significant 
The Medical Ethical Committee of the University Hospital Rot-
terdam approved the study, and all patients provided written in-
formed consent before the procedure. 
Stent. mml 
?BS 
FlU? Post FIUP NIH 
257.3:t67.4 142.2:::54.1 143.7:t49,4 20.8:t11.5 
264.5:t98.3 139.3:t59.1 137.8:t63.7 21.2:=12.1 
265.3:t65.1 145.4.:!:49.1 144.6:=45.3 9.0:!:8.6t 
278.0:t89.8· 130.3:t34.2 149.3:t49.8· 6.9+6.6t 
Values are mean:tSD. Post indicates baseline; FIUP, follow-up; and PBS, plaque behInd the stent. No significant differenCll between 
groups was seen at baseline (Post). 
·P<O.OS vs Post (withln-llfOUp comparison); tP<0,05 for between·group comparison (ANOVA). 
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,-rvv <>PBS NIH 
Figure 1. Remodeling within margins of stent PBS indicates 
plaque behind the stem:. *P<O.05 for values immediately after 
treatment vs fol1ow~up; tP<O.05 for values between groups. 
Results 
Baseline Characteristics 
Eighteen patients were enrolled in the conventional group (C 
group), 16 patients were enrolled in both the O.75~ to 1.5~JLCi 
and the 6.0~ to 12~J.1.Ci radioactive steat groups (LA and HA 
groups. respectively), and 17 patients were enrolled in the 
group subjected to catheter-based radiation plus a steat (CBS 
group). In the C group. 10 ACS Multi-Link (Guidant Corp) 
and 8 NIR (new intravascular rigid-flex stent; Boston Scien-
tificJScimed) stents were implanted. and in the CBS group, 8 
NIR and 9 ACS Multi-Link stents were implanted. Baseline 
characteristics are similar between all groups and are de-
scribed in Table 1. Lesion and procedural characteristics are 
described in Table 2. No statistically significant differences 
were seen between groups in the parameters described in 
Table 2. Comparisons of volumetric data measured at the 
stent edges and within the margins of the stent are presented 
in Tables 3 and 4. 
In-Steot Inhibitioo of NIH 
Intrastent Nlli was decreased after high-activity radioactive 
stent implantation and catheter-based radiation followed by 
conventional stent implantation (P=O.008). Lower activity 
radioactive stents had an effect similar to that of conventional 
stent implantation (see Table 4 and Figure O. 
Behind Steot 
The C. LA. and HA groups demonstrated an absence of 
remodeling behind the stent, with no significant changes in 
TVV or plaque volumes. This is in contrast to the CBS group. 
which demonstrated a significant increase in plaque (imme-
diately after treatment versus follow-up. 15%~ P=O.002) and 
an increase in TVV (after treatment versus follow-up. 8%; 
P=O.003). Intergroup comparison showed that this change 
was significant (Table 4. P=O.Ol). Further comparisons of 
changes within and between groups are demonstrated in 
Figure 1. No cbronicrecoil of the stent was seen in any group. 
Steot Edge 
No significant difference between groups was seen at base-
line (after stent implantation). All groups demonstrated late 
lumen loss at the stent edges. At the stent edges. remodeling 
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Figure 2. Changes in volumes at stent edge. PV indicates 
plaque volume. ~P<O.OS for values immediately after treatment 
vs follow-up; tP<O.OS for values between groups; and tp""NS 
for !i.LV (all groups) and !i.PV (C, LA. and HA groups). 
is similar in the C and LA groups. In these groups. there is 
evidence of a decrease in TVV. with little change in plaque as 
a cause of late lumen loss (Figure 2). In the HA group. a 
target segment restenosis (angiographically >50%) was ob-
served in 7 patients at the stent edges. This was more 
common at the proximal edge (in 6 of 7 patients). The major 
mechanism of such a restenosis appears to be due to an 
increase in plaque at the stent edge. In nonrestenotic patients. 
the edge effect appears to be due to a decrease in TVV and. 
to a lesser degree. an increase in plaque (Figure 3). 
In the CBS group. the edge effect is largely due to an 
increase in plaque. with no negative remodeling seen 
(P=0.045 for plaque increase in CBS versus LA. HA. and C 
groups). No patient with edge restenosis after catheter-based 
radiation was seen in our series of patients. 
Steot Activity and Dose Prescribed 
Mean stent activity at implantation (LA group) was 1.1:±:0.3 
p,Ci. Mean stent activity at implantation (HA group) was 
8.6:±: 1.6 p,Ci. For the CBS group, the mean dose prescribed 
was 16.7:±:2.0 Gy. 
Discussion 
The development of Nlli within the stent witnessed at the 
6-month follow-up is well appreciated15; however. the 
mm' 0 
-, 
'Cr .. tcnntie 
______ --I .0011 r .. tonorie 
-IS L _______________ -----.J 
" LV "TW "PV 
Figure 3. High-activity {B.O- to 12.0-j.tC~ stents. Restenotic 
edges are compared with nonrestenotlc edges. /::,. 'Indicates 
change In volume (immediately after treatment vs follOW-Up). 
·P<O.05 for values immediately after treatment vs follow-up, 
Note greater lumen loss seen in restenotic group. This loss was 
caused by increase in plaque (P<O,05) and a less profound 
decrease in nrv (P<O.OS). !i. nrv is similar in both groups. 
Vascular Remodeling After Radiation and Stenting 
changes that occur at the stent edges or indeed behind the 
stent struts have not been the focus of attention until recent~ 
ly.4 The present study is the first to describe the difference in 
vascular remodeling seen after radioactive stent implantation 
and catheter-based radiation plus stenting with the use of 
modem conventional stents as a benchmark. The key findings 
are as follows: (1) The degree of inhibition of Nlll was 
similar in the HA and CBS groups. (2) There was no 
significant remodeling behind the stent after conventional or 
radioactive stent implantation; however. the CBS group 
demonstrated an increase in plaque behind the stent and in 
TVV. (3) At the steat edge. 3 patterns of remodeling are seen 
at the &.month follow-up: first. a shrinkage in TVV and LV 
was noted in the C and LA groups. These 2 subgroups were 
not associated with stent edge restenosis in this series. After 
high-activity stent implantation. a pattern similar to conven-
tional and low~activity stent implantation is seen in those 
edges that remain nonrestenotic; however, in the restenotic 
edges, plaque increase is the major contributor to lumen loss. 
In the CBS group. a lumen loss similar to that found in the 
other groups is seen; however. this occurs secondary to a 
relatively greater increase in plaque. without loss in TVV. 
Neointimal Hyperplasia 
In the present study. neointimal formation was inhibited after 
higher dose radioactive stent implantation and after catheter~ 
based radiation plus stenting. The present study is in contrasts 
to the recent study by Carter et al,16 who used 32p stents in the 
porcine model, but is in keeping with earlier studies of 
Hehrlein et al,6 who used the rabbit modeL and recent reports 
by Albiero et aL 4 who noted a dose-dependent inhibition of 
NIH. 
Mechanism of Remodeling Behind the Stent 
Catheter-Based Radiation 
After conventional and radioactive stent implantation. little 
positive or negative remodeling is witnessed behind the stent. 
In stark contrast to this is the increase in plaque behind the 
stent and TVV seen after catheter-based radiation and stent-
ing. Part of the key to understanding this process may be 
acquired from understanding the healing process after BA. 
Wilcox and colleagues17•1l:l describe the presence of early 
proliferation of myofibroblasts expressing contractile pro-
teins in the adventitia surrounding the porcine coronary artery 
after BA. Tracing studies have indicated that the same cells 
migrate and fonn part of the neointima. Wilcox and col-
leagues hypothesize that the adventitial myofibroblasts con-
strict the artery at the angioplasty site in much the same way 
as myofibroblasts participate in scar retraction in dermal 
healing. The source of these myofibroblasts may be distant to 
the immediate site of injury. including pericardial. adipose. 
and intramyocardiallayers. 19 
Radiation treatment of porcine coronary arteries after BA 
upregulates p21 synthesis in adventitial cells. especially 
myofibroblasts. Such induction is dose dependent and is 
sustained for at least 7 days after radiation. Additionally. 
radiation inhibits the expression of growth factors. reduces 
the proliferation of adventitial myofibroblasts, and decreases 
the production of a-actin by the adventitial myofibroblasts. 
preventing the formation of the myofibroblast scar around the 
angioplasty site and negative vascular remodeling. 17.20 Data 
from Fareh and et al 21 suggest that inhibition of migration but 
not of cellular proliferation may occur at lower doses of 
radiation. Therefore. cells may remain in situ, unable to 
migrate but able to grow in the presence of a weakened 
external elastic membrane. After 1 week. the effect of the 
radiation diminishes, and cellular proliferation, possibly as a 
reaction to the presence of the stent, continues behind the 
stent in the context of positive vascular remodeling. In our 
cohort of patients. no cases of stent malapposition were seen 
at follow-up. although our group has described this as a risk 
of ongoing positive vascular remodeling.22.23 A further con-
cept to be explored is that relating to the sharp drop-off in 
radiation seen with the /3-radiation source. which may cause 
underdosing deep in the adventitia and geographical miss24 in 
a radial sense rather than the more commonly described 
longitudinal sense. 
Radioactive Stem 
The objective of using the radioactive stent is not to neutral-
ize myofibroblasts in the adventitia: it is the prevention of the 
migration and invasion of myofibroblasts from the adventitia 
through the stent struts and into the lumen. As is seen in the 
HA group, this is accomplished by the continuous and low 
dose rate provided by the radioactive stent. Because of the 
range of the "radioactive fence" created. adventitial cells 
remain intact without upregulation of growth factors and 
inhibition of contractile proteins. Consequently, no remodel-
ing is seen behind the radioactive stent at either activity leveL 
Edge Remodeling 
Hoffmann et al lS have previously described negative remod-
eling at the stent edge after conventional stent implantation. 
In the present study, we have been able to precisely describe 
the decrease in TW as the dominant contributor to nonresteH 
notic lumen loss at the stent edge. Recent reports on radio-
active stents suggest that the edge effect and edge restenosis 
may be due to an increase in plaque at the edge and to a 
component of negative remodeling as one moves axially from 
the stent. 4 The contributing factors to radioactive stent edge 
restenosis have been discussed in detail recently by Serruys 
and Kay.2S 
It may be argued that stent-edge restenosis was not seen in 
the CBS group because no individuals with geographical miss 
were evaluated. However. our objective in the present study 
was to analyze the vascular response to appropriately applied 
catheter-based radiation. which necessitates the exclusion of 
all those in whom injury was not covered by radiation. Recent 
reports have suggested that the combination of suboptimal 
low-dose radiation and injury may make individuals with 
geographical miss vulnerable to edge restenosis.~6 
Study Limitations 
This was a retrospective nonrandomized study of individuals 
who had completed 6 months of follow-up and in whom 
IVUS examination was possible. Individuals who had a total 
occlusion or in whom the IVUS catheter could not be passed 
under acceptable clinical circumstances were not included. 
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No edge restenosis was seen in the CBS group. unlike the 
HA group; however, both the CBS and the HA groups 
reflected the larger parent populations from which they were 
selected in all other features. 
The dosimetry (catheter~based) described in the present 
study relates to prescribed doses only and does not necessarH 
ily reflect the dose delivered 2 mrn from the source in the 
adventitia. Description of dosimetry is beyond the scope of 
the present study; however, previous work by the authors 
(Sabat6 et al27 ). who used a similar radiation source and 
study population. suggests that delivered dose. residual 
plaque burden., and tissue composition playa fundamental 
role on the volumetric outcome at 6 months offollow-up after 
catheter-based ,l3-radiation therapy and BA. 
Conclusions 
Distinct differences in the patterns of remodeling exist 
between conventional. radioactive. and catheter-based radio-
therapy with stenting. Users of radiation need to be alerted to 
edge restenosis seen after higher activity radioactive stent 
implantation and positive remodeling behind the stent seen 
after catheter-based radiation and stenting. Radiation, 
whether it be catheter or stent-based. has forced the interven-
tional community to look closely not only at effective 
inhibition of intimal proliferation but also at the adverse 
response of the artery to the combination of injury and 
radiation. 
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Irradiation for Treatment of Recurrent In-Stent 
Restenosis. 
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Compassionate Use of Intracoronary Beta-Irradiation 
Compassionate Use of Intracoronary 
Beta-Irradiation for Treatment of Recurrent 
In-Stent Restenosis 
Manel Sabate, MD, 1. Patrick Kay, MBChB, Anthonie L. Gijzel, MD, 
Alexander J. Wardeh, MD, Willem J. Van der Giessen, MD, PhD, 
'Veronique L.M.A. Coen, MD, Jurgen M.R. Ligthart, BSc, Marco A. Costa, MD, 
Ken Kozuma, MD, P. Serrano, MD, ·Petcr. C. Levendag, MD, PhD, 
Patrick W. Serruys, MD, PhD 
ABSTRACT: Recurrent in-stent restenosis after balloon angioplasty poses a serious manage-
ment problem. Previously y-radiation has been shown to be effective in patients with in-steDt 
restenosis. The aim of the study was to determine the feasibility and safety of [3-radiation in patients 
with recurrent in-steDt restenosis. From May 1997 to December 1998, 18 patients were treated with 
baUoon angioplasty (0 = 8) or laser (0 = 10), followed by intracoronary !}--radiation at a prescribed 
dose of 16 Gray at 2 mm from the source., for reference diameters by quantitative coronary angiog-
raphy < 3.25 mm or 20 Gray for reference diameters :::3.25 mm. Vessels treated were as foUows: left 
anterior descending: (n = 5); circumflex: (n := 4); right coronary artery: (n := 6); saphenous vein 
graft: (n := 3). Average recurrence rate was 2.4 ::I: 0.7 and the restenotic length was 16::1: 7 mm. 13-
radiation was successfuUy delivered in all patients. Two patients presented complications related to 
laser debulking: a non~Q wave myocardial infarction in one and a rc--angioplasty due to uncovered 
distal dissection in another. Geographical miss, defined as an area which has been injured but not 
covered by the radiation source. was dcmonstrated in 8 paticnts. Seventeen patients (94%) complet-
ed the 6-month angiographic foUow-up. Rcstcnosis (> 50% Diameter Stenosis) was observed in 9 
patients (53%), leading to targct lesion revascularization in 8 patients (47%). Six of the 9 restcnoses 
were located in areas with geographical miss. lntracoronary j3-radiation for recurrent in-stent 
restenosis appears to be a safe and feasible management strategy. However, the mismatch between 
injured and irradiated area may lead to failure of this therapy. 
J INVAS CARDIOL 1999;11;582-588 
Key words: balloon angioplasty, geographical miss, in-stcnt restenosis, laser debulking, 
radiation therapy 
The long-term results ofbaIIoon angioplasty are lim-
ited by the occurrence of restenosis in 30-60% of all 
cases. I':: Mechanisms involved in the restenotic process 
include acute recoil, neointimal proliferation and late 
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vessel constriction,.' ~ Scent implantation demonstrated a 
beneficial effect by prevcnting both the acute recoil and 
the late negative remodeling of the vesseFIl However, 
the restenosis after stent implantation, which is caused 
by neointimal hyperplasia, occurs in 15-20% of the 
casesY Treatment of in-stent restenosis is rather disap-
pointing, with recurrence rates of 38-50%,Q-11 which 
increase with the number of re-interventions.I' Radia-
tion therapy appears to be a novel therapy to inhibit the 
proliferative response after balloon-injury.IJ-I~ Three 
randomized trials have demonstrated the efficacy of 
gamma-radiation in the treatment of in-stent resteno-
sis.11 I? A non-randomized trial reported favorable 
results with the use of bcta-radiation for the treatment 
129 
Chapter 72 
Table 1. Baseline characteristics (n "" 18) 
Gender (male): 
Age (years): 
Coronary risk factors 
Smoking 
Dyslipidemia 
Systemic hypertension 
Diabetes mellitus 
Family history of coronary disease 
Treated vessel 
Left anterior descending 
Left circumflex 
Right coronary artery 
Saphenous vein graft 
Recurrence number 
Stable angina: 
12 (67%) 
62 ± 10 
5 (28%) 
11 (61%) 
8 (44%) 
J (17%) 
8 (44%) 
5 (28%) 
4 (22%) 
6 (33%) 
3 (17%) 
2.4 ± 0.7 
15 (83%) 
ofin-stent restenosis,1" To date, no data exist regarding 
the efficacy of brachytherapy in the subgroup of 
patients with recurrent in-stent restenosis. Thus, we 
designed this pilot study to evaluate the feasibility and 
safety of beta-radiation therapy in patients with recur-
rent in-stent restenosis. 
METHODS 
Patient selection. Patients eligible for the study 
were those with recurrent in-stent restenosis with 
objective evidence of ischemia. The following inclu-
sion criteria were required: the lesion treated involved 
the second episode of restenosis in the same stented 
segment; the lesion length had to measure < 25 mm 
and, the vessel size between 2.5 and 4.0 mm in diame-
ter. Patients were excluded if they had received previ-
ous radiation therapy on the chest; had a left ventricle 
ejection fraction < 40%; suffered from a recent 
myocardial infarction « 3 days), the target lesion 
would not withstand the source dwell time of> 3 min-
utes; the result· after BA was unsuccessful as defined 
by diameter stenosis> 35% or minimal luminal diame-
ter < 1.5 mm; and finally, an allergy or contraindica-
tion to aspirin. Female patients of child-bearing age 
required a negative pregnancy test and undertook not 
to get pregnant during the study. 
Radiation delivery system. The Beta-Cath 
System'· (Novoste Corp., Norcross, Georgia) was used 
to deliver localized beta-radiation at the site of coro-
nary intervention, The device consists of 3 compo-
nents: 1) the transfer device which stores the radiation 
source train and allows the positioning of these sources 
within the catheter; 2) the delivery catheter, which is a 
5 French (Fr) multilumen over-the-wire non-centered 
catheter which uses saline solution to send and return 
the radiation source train; and 3) the radiation source 
train consisting of a series of twelve independent cylin-
drical seeds which contain the radioisotope 90Sr/90Y 
sources and is bordered by 2 gold radiopaque markers 
separated by 30 mm.~1 
Procedure. The Medical Ethics Committee of the 
Erasmus Medical Center, Rotterdam, approved the 
Figure 1. (A) C'...oronm)' angiography of a severe in-stent rest<:'nosis in a Wallstent'" in a saphenous venous bypass graft, (B) treated with 
concentric laser debu/king, (C) followed by intracoronary radiation. (D) Angiographic result of the procedure, (E) No significant angio-
graphic restenosis is observed at 6-month follow-up. 
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study and all patients signed a written informed con-
sent form. Patients received 250 mg aspirin and 10,000 
IU heparin at the initiation of the procedure, and addi-
tional doses of heparin were administered to maintain 
the activated clotting time> 300 seconds. In diffuse 
rcstenosis, plaque debulking was performed by the use 
ofVitesse II~ excimcr laser catheters of 1.7 or 2.0 mm 
(Spectranetics International BV., Colorado Springs, 
Colorado) followed by balloon angioplasty according 
to standard clinical practice. In focal restcnosis, treat-
mcnt was performed only with balloon angioplasty. 
After successful treatment, the radiation delivery 
catheter was placed at the target site. The radioactive 
seeds remained in place during a dwell-time of 2.5 to 
4.0 minutes to deliver a dose of 16 Gy or 20 Gy for 
lesions with a reference diameter by quantitative coro-
nary angiography < 3.25 mm or ::: 3.25 mm, respec-
tively. The dose was prescribed at 2 mm from the 
source. Because of the low penetration force of beta-
energy in tissue, no additional measures were taken to 
protect the patient or staff The delivery of the radioac-
tive seeds was carried out by a radiation oncologist. 
Figure 2. (A) 
Corunary angiog-
ra/lhy of a severe 
in-Sk'nt rCSCl"nosis 
ill the ri,.;ht cora-
lWry artery, (B) 
creaced with bal-
loon all[jopiasl)" 
(e) followed by 
intracoronary 
radiation. (D) 
Despite a good 
angiographic 
result, (E) a 
severe rcstenosis 
was observed at 
fvl1ow-u~. 
FoUow-up. Patients returned for 6-month clinical and 
angiographic follow-up. A control ECG was pcrfonncd at 
the time of the visit. The following clinical endpoints 
were defined at 6 months: death. Q-wave myocardial 
infarction (using the Minnesota code criteria),!" bypass 
surgery, and target lesion revascularization. 
Definitions. III-s!ell! res!enosis was dclincd as focal 
when the restenotic segment measured < 10 mm and dif-
fuse when it measured 2: 10 mm. Procedural success was 
defined as < 35% diameter stenosis post-procedure with-
out acute complications (coronary dissection, acute 
myocardial infarction or death). Geographical miss is the 
tenn used in radio-oncology to define a cause offailurc of 
the treatment due to low-dosage. [n such cases, a small 
part of the treatment zone has either escaped radiation or 
been inadequately irradiated because the total volume of 
the tumor was not appreciated and hence an insufficient 
margin was takcn.~) This concept is translated in interven-
tional cardiology for those cases where the radiation 
source cannot fully cover the injured area. Basically, two 
reasons may account for this phenomenon: coronary 
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Figure 3. Serial coronary angiograms showin,l! a coronary dissection following balloon angioplasry which involved the distal segment of the 
left anterior descending and the second diag01Ull. Additional kissing balloon and stent implantation were performed. The radiation source 
could cover only the original merno!ic area (geographical miss). At jollooH,/p, a diffuse restenosis at the site of the geographical miss was 
demonstrated. 
dissection extended to the edges of the radiation source 
which leads to an additional treatment or source shorter 
than the targeted and injured area. Overall, there exist 
traumatized areas receiving low dose which is potentially 
not able to prevent either neointimal proliferation or ves-
sel shrinkage. To identify those areas with geographical 
miss these steps were followed: during the procedure all 
balloon inflation and laser passes werc filmed in the same 
projcction as was the radiation source. This approach 
allowed us the correct matching of the cinefilms in the 
off-line analysis. By the use of the Rubo DICOM Viewer 
(Rubo Medical Imaging, Uithoorn, The Netherlands), 
cither of the cine!oops showing baHoon inflation, laser 
passcs and radiation source may be displayed simultane-
ously on the screen. By selecting those frames in the same 
part of the cardiac cycle, we were able to define whether 
the radiation source completely covered the injured area. 
Quantitative coronary angiography. Quantitative 
coronary angiography was performed prior and after 
intervention, and at 6-month follow-up, All angiograms 
were analyzed after intracoronary administration of 
nitrates, The off-line analysis of at least two orthogonal 
projections was performed by means of the CAAS II 
analysis system (Pie Medical BV, Maastricht, The 
Netherlands). Calibration of the system was based on 
dimensions of the catheters not filled with contrast 
medillm, This method of analysis has bccn prcviously 
validated.!4 !" The following measures were obtained in 
each projection: minimal luminal diameter, reference 
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diameter, percent diameter stenosis and lesion length, 
Lesion length was user defined and not done by an 
algorithm using curvature analysis of the diameter func-
tion.~) Reference diameter was obtained by an interpo-
lated method." l~ Diameter stenosis post stent 
implantation and at follow-up was defined as the mini-
mal luminal diameter within the injured segment relat-
ed to the interpolated diameter measured over the 
length of the stent. Acute gain was defined as minimal 
luminal diameter measured after treatment minus mini-
mal luminal diameter pre-intervention. Late loss was 
defined as minimal luminal diameter post-intervention 
minus minimal luminal diameter at follow-up. Late loss 
indcx was defined as latc loss divided by acute gain!" 
Rcstenosis was dcfined as > SOOIo diameter stenosis at 
follow up and located in the mediated area on either of 
the edges. 
Statistical analysis. Data are presented as mean ± 
standard deviation or proportions, To compare continuous 
data in patients treated with and without laser the 
unpaired two-tailed Student's t-test was performed. A 
value of p < O.OS was considered statistically significant. 
RESULTS 
Baseline characteristics. From May 1997 to Febru-
ary 1999, 18 patients were treated according to the 
above protocoL Baseline characteristics of the study 
population are presented in Table 1. Number of 
Compassionate Use of Intracoronary Beta-Irradiation 
Table 2. Lesion and quantitative coronary angiography data 
Pat. Laser Stent Stent Lesion Pre [lrQ.£~ur£ Post Dr0S:~Qur~ Follow up Acute Late loss 
no. Type Length Length MLD DS% RD MLD DS% RD MLD DS% RD Gain Index 
1 yes Wallstent 39 26 0045 80 2.28 1.80 30 2.58 1.89 29 2.66 1.35 -0.07 
2 yes BARD 19 19 0.82 68 2.51 1.62 36 2.54 1.63 26 2.21 0.80 -0.01 
3 no Wal!stent 24 24 0.93 52 1.92 104 25 1.92 0.00 100 0.51 2.82 
4 yes Wallstent 34 6 0.70 70 2.37 1.77 28 2046 1.38 43 2041 1.07 0.36 
5 yes WaUstent 34 26 0.07 97 1.87 1.35 23 1.76 0.70 69 2.24 1.29 0.51 
6 no AVE 39 16 0.95 66 2.76 2.02 30 2.90 1.58 41 2.67 1.07 0.41 
7 no NIR 9 9 0.00 100 2.51 1.95 21 2.47 0.35 85 2.35 1.95 0.82 
8 no WaUstent 24 14 0.82 70 2.77 1.98 26 2.67 1.79 29 2.54 1.16 0.16 
9 yes MultHink 35 21 1.49 48 2.86 2048 25 3.31 2.29 41 3.85 0.99 0.19 
10 yes NIR 16 5 0.91 63 2049 2.01 19 2048 1.05 57 2047 1.10 0.87 
11 no WaUstcnt 34 7 0.55 74 2.14 2.25 38 3.61 0.80 80 4.00 1.70 0.85 
12 no Multilink 25 23 1.18 51 2.39 1.77 33 2,66 2.30 16 2.74 0.59 -0.89 
13 yes BARD 19 23 0.92 56 2.10 1.81 31 2.62 0.88 59 2.13 0.89 1.04 
14 yes Crown 22 19 1.04 46 1.93 1.59 19 1.97 NA NA NA 0.55 NA 
15 yes Naevius 15 10 0.53 85 3.48 2.64 25 3.51 1.67 45 3.03 2.11 0046 
16 no NIR 16 16 1.28 56 2.88 2.76 10 3.06 1.34 52 2.80 1.48 0.96 
17 no Beseem 25 9 1.08 47 2.03 1.49 19 1.85 0.81 54 1.76 0.11 1.65 
18 yes Biodyvisio 15 15 0.70 75 2.79 2.16 17 2.60 0.61 78 2.77 1.46 1.06 
Mean 19 16 0.80 67 2045 1.94 25 2.61 1.25 53 2.68 1.14 0.64 
SD 4 7 0.38 16 0042 0040 7 0.53 0.68 24 0.60 0.18 0.82 
MLD", minimallurnen diameter; DS '" diameter stenosis; RD = reference diameter; NA " not available 
recurrences ofrestenoses were 2 in 10 patients (55%), 
3 in 7 patients (39%) and 4 in I patient (6%). 
Procedural data. Lesion characteristics and QCA 
data are presented in Table 2. Laser dcbulking was per-
fonned in 10 patients. Lesion length showed a trend to 
be longer in patients pre~treated with laser as compared 
to patients treated only with balloon angioplasty (17 ± 7 
nun vs. 12 ±3 nun, respectively;p = 0.06). Examples of 
patients treated either with laser debulking or balloon 
angioplasty alone prior to radiation are depicted in Fig~ 
ures 1 and 2. Procedural success was achieved in 16 
patients (89%). In two cases the procedure was compli~ 
cated by a dissection secondary to laser debulking lcad~ 
ing to a transient occlusion of thc vessel: a non~Q wave 
infarction occurred in one case and a re~angioplasty in a 
distal segment was performed in the other patient. Radi~ 
ation was successfully delivered in all cases. The pre~ 
scribed dose at 2 nun from the source was 16 Gy in 16 
patients and 20 Gy in 2 patients. Retrospective analysis 
of the angiograms revealed that geographical miss 
occurred in 8 cases: distal dissection in which additional 
stents were implanted distal to the irradiated area (n = 3) 
and area injured by the balloon but not covered by the 
radiation source (n = 5). An example of the outcome of 
a patient with geographical miss is depicted in Figure 3. 
All patients were discharged asymptomatic. 
Follow~up. Seventeen patients (94%) returned for 
angiographic foIIow~up. One patient refused. Fonow~up 
QCA data are presented in Table 2. Restenosis was 
observed in 9 paticnts (53%). In 7 patients. the location 
of the rcstenosis was at the edge of the irradiated area, 
whereas in 2 patients it was within the irradi~ted area. 
The number of recurrences of restenoses were compara-
ble between restenotic and non~restenotic patients. Six 
of the 7 edge restenoses were in areas with geographical 
miss. There were neither deaths nor Q-wave myocardial 
infarctions observed at 6-month follow-up. Total lesion 
revascularization was perfonned in 8 patients (47%): 3 
patients were referred for bypass surgery and 5 under~ 
went re-PTCA. Progression of atherosclerosis was also 
observed in the non-irradiated vessels in the 3 patients 
referred for surgery. Acute gain. late loss and late loss 
index were similar between patients pre~treated with and 
without laser debulking (p = NS). 
DISCUSSION 
This study describes the use of beta-radiation thera-
py for the treatment of recurrcnt in-stent restenosis. 
Although this treatment modality is feasible and safe, 
the observed restenosis rate in this small cohort of 
patients remains rather high (53%), and is comparable 
to conventional treatment either with balloon angio~ 
plasty or debulking techniques. lo•11 The main finding 
was that the vast majority ofthc rcstenosis were located 
in areas with geographical miss. To date, three ran~ 
domizcd placebo-controlled trials have been carried 
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out to evaluate the efficacy of gamma-radiation in 
patients with restenosis." I" Teirstcin et <11,17 random-
ized 55 patients to receive a 0.030" ribbon containing 
192 lr sealed sources or a ribbon containing placebo 
seeds (Best Industries, Springfield, Virginia), Thirty-
five patients were treated due to in-stent rcstenosis. 
The dosimetry was calculated based on intravascular 
ultrasound measurement in a range of 8-30 Gray to 
the internal elastic membrane. The placebo group 
showed a restenosis rate of 70%, as compared to 14% 
in the irradiated group (p '= 0.0006). This beneficial 
effect was sustained at 2-year follow-up.27 Waksman 
et ai, I~ evaluated 130 patients who had developed in-
stent restenosis up to 47 mm in the Washington Radia-
tion for In-Stent rcstenosis Trial (WRIST). These 
patients were randomized to radiation using a 192 Ir 
ribbon versus a non-radioactive ribbon delivered into 
a non-centered closed-end lumen catheter (Medtronic, 
Minneapolis. Minnesota). The prescribed dose was 15 
Gray to a distance of 2 mm from the center of the 
source for a vessel size of 3.0-4.0 mm, and to a dis-
tance of 2.4 mm from the center of the source for ves-
sel diameter of 4.0-5.0 mm. At 6-month follow-up, 
the irradiated group showed a reduction of 67% in the 
restenosis rate, 79% in total lesion revascularization 
and 63% in major adverse cardiac events. Similarly, 
the multicenter randomized GAMMA-} trial demon-
strated a reduction of 58% in the restenosis rate within 
the stent. When considering the edges of the source, 
the reduction in the restenosis rate was 43%.'~ Using 
beta-radiation therapy. the non-randomized Beta-
WRIST trial demonstrated a reduction in target vessel 
revascularization of 47% when compared to a 
matched group from the placebo ann of the WRIST 
trial.2u Although easier to implement in the catheteri-
zation laboratory, the use of beta-radiation presents 
the potential drawback of the steep dose fall-off, 
which might lead to inhomogeneity of the prescribed 
dose to the vessel walV" This phenomenon may be 
more pronounced when non-centered devices arc 
used, where the dose reaching the predefined adventi-
tial volume might be as less as 30% of the prescribed 
dose.2~ Considering these beta-radiation characteris-
tics, we hypothesize that areas with geographical miss 
may have received a very low dose which has not 
been able to inhibit either proliferation or vessel 
shrinkage. The importance of low-dose radiation in 
injured areas will be addressed in further ongoing rao-
domized studies (START trial! INHIBIT trial). 
Limitations. This was a non-randomized, non-
placebo-contrOlled study with a relatively small num-
ber of patients included. Thus, no conclusions 
regarding effectiveness of the beta-radiation for treat-
ment of this challenging popUlation with restenosis can 
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be drawn. In this regard, the main cause associated to 
the restenosis in this cohort was the presence of injured 
areas not covered by the radiation source. This limita-
tion may be solved with the use of the recently devel-
oped longer radiation sources (up to 10 nun). 
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Late coronary occlusion after intracoronary 
brachytherapy. 
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Brief Rapid Communication 
Late Coronary Occlusion After 
Intracoronary Brachytherapy 
Marco A. Costa, MD; Manel Sabate. MD; Wim J. van der Giessen, MD. PhD; I. Patrick Kay. MEChB; 
Pavel Cervinka, MD; Jurgen M.R. Ligthart. BSc; Pedro Serrano. MD; Veronique L.M.A. Coen. MD; 
Peter C. Levendag, MD. PhD; Patrick W. Serruys, MD. PhD 
Background-Intracoronary bracbytherapy appears to be a promising technology to prevent restenosis. Presently, limited 
data are available regarding the late safety of this therapeutic modality. The aim of the study was to determine the 
incidence of late (> 1 month) thrombosis after PTCA and radiotherapy. 
Methods and Results-From April 1997 to March 1999, we successfully treated 108 patients with PTCA followed 
by iotraeeronary f3-radiation. Ninety-one patients have completed at least 2 months of clinical fOllow-up. Of these 
patients, 6.6% (6 patients) presented with sudden thrombotic events conflrmed by angiography 2 to 15 months after 
intervention (2 balloon angioplasty and 4 stent). Some factors (overlapping stents, unhealed dissection) may have 
triggered the thrombosis process, but the timing of the event is extremely unusual. Therefore. the effect of radiation 
on delaying the healing process and maintaining a thrombogenic coronary surface is proposed as the most plausible 
mechanism to explain such late events. 
Conclusions-Late and sudden thrombosis after PTCA followed by intracoronary radiotherapy is a new phenomenon 
in interventional cardiology. (Circulation. 1999;100:789~792.) 
Key Words: thrombosis _ angioplasty _ radioisotopes 
Thrombotic occlusion after PTCA is associated with increased morbidity and mortality rates. 1 Current tech~ 
niques of stenting followed by antiplatelet therapy have 
dramatically reduced the incidence of this event to <1.5%.~.3 
See p 780 
Intracoronary radiation is a promising new therapy to 
prevent restenosis. Recent randomized trials demonstrated 
a reduction in the restenosis rate and maintenance of 
benefits up to 2-year follow-up.4-6 Presently, limited data 
are available regarding long-term safety after intracoro-
nary brachytherapy. 5.7 Although subacute thrombosis has 
been reported after radiotherapy,4.1:\-9 the incidence of late 
thrombotic events has not been determined. 
The aim of this study was to document the incidence of 
late (> 1 month) thrombotic events after elective PTCA 
followed by intravascular radiotherapy. 
Methods and Results 
From April 1997 to March 1999, 108 consecutive patients 
were successfully treated with catheter-based intracoronary 
,B-radiation at the Thoraxcenter (Rotterdam, The Nether-
lands). The Medical Ethical Committee approved the use of 
radiation therapy and informed consent was obtained from 
every patient All patients presented with stable angina 
pectoris and single vessel disease. Brachytherapy was per-
formed using the Beta-Cath system (Novoste Corporation)IO 
(n=76 patients. 32 stents and 44 balloon angioplasty [BAl). 
or the Guidant intravascular brachytherapy system (Guidant 
Corporation Vascular Intervention)11 (n=32 patients. 13 
Stents and 19 BA). BA and stenting were performed accord-
ing to standard techniques. Intravascular ultrasound (IVUS) 
was performed after radiation with a mechanical ultrasound 
catheter (CVIS. Boston Scientific). Off-line quantitative cor-
onary angiography was performed using CAAS system (Pie 
Medical Imaging BY). Six~month angiographic and NUS 
follow-up was scheduled in all patients. 
All patients were discharged without complications. Nmety-
one patients completed at least 2~month clinical follow-up. We 
observed 1 case of subacute thrombosis occurring 15 days after 
stenting. This patient received an 18-mm long stent (postdilated 
at 10 atm) with optimal NUS result Ticlopidine withdrawal (12 
days after stenting) was the plausible explanation of thrombosis 
in this case. 
Six patients (6.6%) presented with sudden late throm-
botic coronary occlusion. Two of them were treated with 
BA and the remaining 4 received an additional stent after 
radiation. Their clinical characteristics are summarized in 
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Clinical and Angiographic Variables 
Variables 4 5 
Age, Y 57 58 49 73 52 62 
So< Male Female Male Female Female Female 
Pre-procedure 
Target vessel LeX RCA Lex lAO RCA RCA 
Type of lesion 8 8 A A 8 
RD, mm 2.5 >8 2.67 >66 2.84 2.6 
MLD, mm 0.9 1.12 0.64 1.09 0.65 0.55 
OS, % 66 60 76 60 77 78 
Lesion length, mm 13 15 18 112 9.6 9.7 
Procedure 
Brachytherapy system Beta-cath Guidant Beta-Cath Beta-Cath Beta-Cath Beta-Cath 
Source length, mm 30 27 30 30 30 30 
Prescribed dose, Gy 12' 35t 12' 14' W W 
Stent'angiopJasty Stent Balloon Balloon Stem Stent Stem 
Total stent length, mm 41 25 25 16 
Postprocedure 
Dissectionftype No YesIB YesI' No No No 
MLD, mm 2.47 2.07 2.15 2.4 2.34 2.4 
OS, % -1 26 21 9.5 17 7 
Clinical success Yes Yes Yes Yes Yes Yes 
Follow-up 
Event VF Inferior MI Postlateral MI Anterior MI Inferior MI Inferior MI 
Time, mo 2 3 15 10 3 2.5 
Antiplatelet medication Yes Yes Yes No Yes Yes 
Associated factors Long stent Dissection Dissection at f5..mo Aspirin withdrawal No No 
LCX indicates left circumflex artery; RCA, right coronary artery; lAD, left anterior descending artery, RD, reference diameter; MLD, 
minimal lumen diameter; OS, diameter stenosis; VF, ventricular fibrillation; and MI, myocardial infarction. 
*At 2 mm from the source; tat 0.5 mm into the vessel wall. 
the Table. No clinical or anatomic characteristic appeared 
to be related to these events. 
In patient 1, overlapping 9~ and 32~mm NIR stents 
(Medinol Ltd) were optimally implanted as assessed by 
IVUS. Patients 2 and 3 (BA) showed type B dissections 
without compromising flow postprocedure. Patients 4 
and 5 both received a Multilink 25~mm stent (Advanced 
Cardiovascular Systems/Guidant), and patient 6 received a 
NIR 16~mm stent with optimal angiographic results. Stent 
patients were discharged on aspirin (250 mg/d) and ticlo~ 
pidine (250 mg BID for 15 days in patients 3 and 4. and for 
30 days in cases 5 and 6). BA patients received aspirin 
alone. 
Patient 1 was readmitted with ventricular fibrillation 2 
months after the procedure. whereas. patients 2. 5. and 6 
sustained inferior myocardial infarctions (MI) between 2.5 
and 3 months after the treatment. The irradiated segment 
was occluded at 6~month angiogram in patients 1 and 2 
(Figure 1). Thrombotic occlusion was successfully treated 
by primary angioplasty in patients 5 and 6. 
In patient 3. the 6~month IVUS control revealed a 
persistent (unhealed) submedial dissection (Figure 2) with 
no signs of restenosis. Nine months later, this patient 
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sustained a posterolatcral MI which was treated with 
tbrombolytics. Two weeks after this treatment. an angio~ 
gram penormed because of recurrent angina showed the 
occlusion in the irradiated area. Similarly. the 6~month 
IVUS control of patient 4 showed no neointimal hyperpla~ 
sia. Four months after control. she had a stroke and aspirin 
was replaced by acenocoumarol. Ten days later, she 
sustained an anterior MI. The thrombotic occlusion in the 
treated site was confirmed by angiography. 
Discussion 
Progression to total occlusion after BA is a stable process in 
the general nonirradiated population which occurs in approx~ 
irnately 4% of patients. leading to a MI in <0.5%.1"2 In 
contrast. our study shows a high incidence (6.6%) of throm~ 
botic clinical event.~ 2 to 15 months after PTCA and 
brachytherapy. 
Coronary dissection after BA is associated with abrupt 
closure: however. type B dissections (~'1!LBI classifica~ 
tion), as observed after BA in our patients. have not been 
related to thrombotic events.13 The normal healing process. 
present after dissections. may be impaired after intracoro-
nary radiation. 14 Whether unhealed dissections, as demon-
strated in patient 3, is related to late thrombosis remains to 
be elucidated in a larger population. Further. the necessity 
of stenting mild dissections without compromising flow 
after radiotherapy should be investigated. 
The mean time of subacute thrombosis after stenting is 
approximately 5 to 6 days. ~,3 In a recent study, subacute 
thrombosis occurred within the first 24 hours in 86% of 
patients treated with aspirin and ticlodipine for 14 days, 
with no case of thrombotic events occurring after 15 
daYS.IS Colombo et a1 reported only 2 cases (0.6%) of 
thrombosis occurring 2 to 6 months after stenting.:: In 
contrast, in our study. 4 patients receiving a stent (8.8%) 
experienced thrombosis late after radiation. 
Experimentally, reendothelialization after injury takes 
>4 weeks to be completed.16 However. the clinical pre-
sentation of subacute thrombosis infrequently occurs later 
than 15 days after stenting. 15 when the reendothelialization 
process may still be incomplete. Delayed reendotheli-
alization as a trigger mechanism of late stent thrombosis 
after antineoplastic therapy has been hypothesized previ-
ously,17 Farb et al reported incomplete endothelialization 3 
months after placement of ,B-radioactive stent.l~ Neverthe-
less. the same group showed no differences regarding 
endothelial cell growth between radioactive and control 
stents in another experimental model. 19 Further studies 
should address the timing of stent reendothelialization 
after bracbytherapy to determine its role on the pathogen-
esis of late thrombosis. 
Late Thrombosis After Branchytherapy 
Figure 1. Patient 1. A, Preprocedure 
angiography shows a significant lesion in 
the mid-third of left circumflex artery. S, 
Radioactive source placed in treated site. 
C, Postprocedure angiography and IVUS 
images show an optimal result (arrow-
heads). D. At 2 months, the proximal part 
of stent appeared occluded. 
Although multiple stents have been related to subacute 
thrombosis.20 the significance of multiple stent implanta-
tion (patient I) on late thrombotic phenomena has not been 
demonstrated, 
The use of intracoronary ,B-radiation is a coromon 
feature in our patients. However. the judgment of whether 
radiation is the key factor in the pathogenesis of late 
thrombosis should await the analysis of ongoing trials. 
Concomitantly. the benefit of prolonged antiplatelet ther-
apy with the combination of aspirin. clopidogrel, or 
ticlopidine should be considered, 
Limitations 
Our patients were included in well-controlled j3-radiation 
studies with similar baseline characteristics and inclusion 
criteria (lesion length <15 rom, treatment of single vessel). 
However. 2 different systems to deliver .a-radiation were 
used. 
In addition, it is not possible to rule out the natural 
history of coronary disease as a cause of late thrombosis. 
However, the incidence of total occlusion in the general 
nonirradiated population is much lower than that observed 
in our study. In fact. the incidence of late thrombotic 
events would be even higher if. in the interest of complete-
ness, we waited for I-year follow-up in the total patient 
population. 
Finally. whether late thrombosis is a generic complica-
tion of intracoronary radiotherapy or is restricted to the use 
of .a-sources cannot be extrapolated from our findings. 
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Figure 2. Patient 3. A, Postprocedure coronary dissection, demonstrated both on angiography and IVUS, did not compromise flow in 
treated area (arrowhead). S, This dissection persisted unhealed at 6-month control (arrowhead). C, At 15 months, irradiated segment 
appeared occluded. 
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Coronary artery dissection after B radiation 
Outcome from balloon induced coronary artery 
dissection after intracoronary ~ radiation 
I P Kay, M Sabatc, G Van Langenhove, M A Costa, A J Wardeb., A L Gijzel, N V Deshpande, 
S G Carlier, V L M A Coen, P C Levendag, W Van der Giessen, P J de Feyter, P W Serruys 
Abstract 
Objective-To evaluate the healing of balloon induced coronary artery dissection in individuals 
who have received ~ radiation treatment and to propose a new intravascul::tr ultrasound (IVUS) 
dissection score to facilitate the comparison of dissection through time. 
Design-Retrospective study. 
Setting-Tertiary referral centre. 
Patients-31 patients with stable angina pectoris, enrolled in the beta energy restenosis trial 
(BERT-I.5), were included. After excluding those who underwent stent implant3tion, the evalu-
able population was 22 patients. 
Interventions-Balloon angioplasty and intracoronary radiation followed by quantit3tive coronary 
angiography (QCA) and IVUS. Repeat QCA and NUS were performed at six month follow up. 
MaID outcome measurcs-QCA and IVUS evidence of healing of dissection. Dissection 
classification for angiography was by the National Heart Lung Blood Institute scale. IVUS proven 
dissection was defined as p:lrtial or complete. The following IVUS defined characteristics of dis-
section were described in the affected coronary segments: length, depth, arc circumference, pres-
ence offiap, and dissection score. Dissection was defined as healed when all features of dissection 
had resolved. The calculated dose of radiation received by the dissected area in those with healed 
versus non-healed dissection was also compared. 
Results-Angiography (type A = 5, B = 7, C = 4) and NUS proven (partial = 12, com-
plete = 4) dissections were seen in 16 patients following intervention. At six month follow up, six 
:md eight unhealed dissections were seen by angiography (A = 2, B = 4) and IVUS (partial. = 7, 
complete = I). respectively. The mean IVUS dissection score was 5.2 (range 3-8) following the 
procedure, and 4.6 (range 3-7) at follow up. No correlation was found betWeen the dose 
prescnoed in the treated area and the presence of unhealed dissection. No change in :mginal sta-
tus was seen despite the presence of unhealed dissection. 
Conc1usion-~ radiation appears to alter the normal healing process, resulting in unhealed dis-
section in certain individuals. In view of the delayed :md abnonnal. healing observed, long term 
follow up is indicated given the possible late adverse effects of radiation. Although in this cohort 
no increase in cardiac events following coronary dissections was seen, larger populations are 
needed to confirm. this phenomenon. Stenting of all coronary dissections m.ay be warranted in 
patients scheduled for brachytherapy after balloon angioplasty. 
(Heart 2000;83:332-337) 
Keywords: dissection; mtt:lvuscu1::u- ultrasound; angiogrnphy; coronary urtery; bmchythernpy; angiopbsty 
Despite excellent acute results. restenosis at six 
month follow up after coronary artery balloon 
angioplasty remains a serious problem. 1 Exces-
sive neointimal formation. extracellular m.atl'ix 
synthesis. and negative vessel remodelling in 
response to balloon injury have been docu-
mented as the main mechanisms of 
restenosis. ,_7 Intracoronary radiation treatment 
has recently emerged as a means of preventing 
and treating restenosis in coronary arteries 
treated by balloon angiophsty. The theoretic:ll 
benefit of radiation in preventing neointimal 
proliferation resides in the destruction of more 
rapidly dividing smooth muscle cells. "-14 It may 
not be surprising that by inhibiting the above 
deleterious features of healing after balloon 
angioplasty, intracoronary radiation m.ay also 
alter normal healing processes. 
Coronary artery dissection is Common after 
balloon angioplasty. 'Ibis is angiograpbically 
visible in 20-45% of cases following balloon 
angioplasty'~ and present in up to 85% of cases 
when intravascular ultrasound (IVUS) assess-
ment is used. 16 If further angioplasty of the 
lesion is not undertaken, then it is recognised 
that nearly all angiograpbic dissection will heal 
over a six month time frame.1~ \7 Whether 
intracoronary radiation will prevent the process 
of natural healing after balloon induced dissec-
tion has not been documented thus far in 
humans. To examine this, we retrospectively 
analysed coronary artery dissections using 
angiography and IVUS, at the time of treat-
ment and at six month follow up, in patients 
treated with intracoronary radiation following 
balloon angioplasty. We also aimed to compare 
the prescribed dose received by the treated area 
in individuals with non-healing dissection with 
the dose received by those individuals with 
healed dissection. 
Methods 
PATlEJ'.."T SELECTION 
Patients eligible for the study were those 
treated successfully '.Vith balloon angioplascy 
followed by intracoronary irradiation according 
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TabEr; 1 IVUS disscctkm SWTl! 
A" ,""em Deprh FWp 
< 90°::: 1 <5=-1 P:rrtinl:::l y.", - 1 
90--1800 :: 2 5-10 mm " 2 Complete::: 2 No=O 
>180"",3 >10=:::3 
Table 2 Baseline characu:risric.,l' (n ::: 22) 
MclUl (SO) ogc (ye=) 
Coroo:.ry ri'll< fnctOI1l 
Smoking CD (%)) 
HypcrcholCl<tcrolnemiu Cn (%)) 
Fnmily history (0 (%)) 
Hyp<:rten~ioD (n (%)) 
Diabctc' (0 (%)) 
Trco.tcdwsscl 
lAD (n (%)) 
LCX Cn ("10)) 
RCA(n (%)) 
Pre~cribed do~c 
16GyCn (%)) 
14Gy (n (%)) 
12Gy (n (%)) 
55.7 (9.3) 
15 (68) 
12 (55) 
12 (55) 
II (50) 
6 (26) 
12 (55) 
6 (26) 
4 (18) 
9 (41) 
5 (23) 
8 {36} 
LAD, lcit !Ulterior de!lccndin.,; coronary nne:ry; LCX, left 
cir=flex coronary artery. RCA, right coronary artery. 
to the beta energy restcnosis trial (BERT-l.S). 
The purpose of this trial was to evaluate the 
safety md efficacy aflow dose ~ source irradia-
tion following balloon angiopl:lSty with and 
'Without sterrt implantation in patients with sin-
gle "de novo" lesions of native coronary arter-
ies. The design of this trial was a prospective 
multicentre non-randomlsed fe:lsibility study. 
We used a strontium 90 ('oSr) source with 
yttrium as a pure ~ emitter, and patients were 
randomised to receive 12, 14,or 16 Gray (Gy). 
The inclusion and exclusion criteria oftbis trial 
have been previously reported." 
RADlATIO::-< DELIVERY SYSTE.'>1 
The Beta-Cath system (Novoste Corp, Nor-
cross, Georgia, USA) was used to deliver local-
ised ~ radiation to a coronary artery at the site 
of coronary intervention. The device consists 
of three components: (1) the transfer device 
which stores the radiation source train and 
allows the positioning of these sources within 
the catheter; (2) the delivery catheter, which is 
a 5 F multilumen over the wire non-centred 
catheter which uses saline solution to send and 
return the radiation source train; and (3), the 
radiation source train consisting of a series of 
12 independent cylindrical secds which con-
tai.n the radioisotope ~Sr sources and is 
bordered by two gold radiopaque markers 
separated by 30 mm. l " 
IVUS IMAGE ACQl,.'!SITION A."I'ALYSIS SYSTEM. 
The segment subject to analysis was e.xamined 
with a mechanical NUS system (ClearView, 
CardioVascular Imaging System (CVIS), Sun-
nyvale, California, USA) with a sheath based 
J:'VlJS catheter incorporating a 30 MHz single 
dement transducer rotating at 1800 rpm. The 
transducer is placed inside a 2.9 F 15 em long 
sonolucent distal sheath which alternatively 
houses the guidewire (during the catheter 
introduction) or the transducer (during inw.g-
ing, after the guidcwire has been pulled back). 
To assure the correct identification and analy-
sis of the irradiated segment, certain steps were 
followed. First, an angiogram was performed 
after positioning the delivery catheter, and the 
relation between anatomical landmarks and the 
two gold markers was noted. Typically, the 
aorto-ostial junction and the side branches 
were used as landmarks. The landmark closest 
to either of the gold markers was used as a 
guide. During the motorised NUS pullback, 
all side branches were counted and the guiding 
landmark was identified. The correct selection 
of the marker was confumed by visuilising the 
position of the NUS probe during a contrast 
injection. Once the acquisition was completed, 
we selected the segment of interest by taking 
the digitised cross-sectional images pro::cimal or 
distal to the guiding landmark up to 30 mm, 
which is the area encompassed by the twO gold 
markers of the rndiation source. At follow up, 
we selected the same region of interest and 
compared it with that after treatment. 
PROCEDURE 
The medical ethics committee of the Erasmus 
Medical Center, Rotterdam approved the 
study and all patients signed a written in-
formed consent form. In the BERT-l.5 trial 
balloon angioplasty was performed according 
to standard clinical practice. Following suc-
cessful angioplasty, patients were randomised 
to receive 12, 14, or 16 Gy, as calculated at 
2 mm from the centre of the radiation source. 
The 5 F delivery catheter of the Beta-Cath 
Table 3 AngWgraphic pa1'amctcrs prC'" and postintcrocntum and at six month fow,/) up for patients with dissection 
Prc- procedure ]'0,_ Followup 
p- Dose prcscribcd MLD Di<scctWn grade RD DS ("/0) MLD Dis'IXtWn ;:ratk RD DS("/.,J MLD LU 
12 0.77 C 2.58 
" 
1.56 2.41 32 1.63 -0.09 
H 1.23 A 2.72 
" 
2.25 2.84 8 2.60 -0.34 
12 0.78 B 2.44 26 1.80 2.77 
" 
1.77 O.oz 
, 12 0.78 B 3.17 31 2.18 3.11 M 1.75 0.31 
5 H 1.21 B 3.21 
'" 
2.12 B 3.32 35 2.15 -0.03 
6 16 0.82 A 2.73 30 1.92 A 3.01 52 1M 0.'04 
, 16 0.96 B 2M 23 1.85 B 2.04 23 1.58 0.31 
8 16 1.42 C 2.82 
" 
2.12 2.96 51 1.44 0.97 
9 16 0.88 C 2.18 29 1.54 2.16 
" 
1.10 0.67 
10 16 1.31 C 3.98 38 2.45 A 3'5 
" 
1.50 0.S3 
12 12 1.06 A 2.62 3 2.54 3.21 
" 
0.81 1.17 
13 12 1.17 A 2.82 29 2.00 3.27 
" 
1.14 1.04 
16 16 1.33 B 3.21 
" 
2.49 B 3.39 31 2.35 0.12 
" 
14 1.36 B 2.49 25 1.87 2.79 13 2.44 -1.14 
19 12 0.61 B 2.68 21 2.12 B 2.80 31 1.94 0.12 
20 12 1.70 A 4.69 M 2.63 3.86 29 2.75 -0.13 
M= 13.9 1.09 2.92 27.31 2.Q9 2.95 39.25 1.77 0.27 
MLD, .m.i.nimnlluminal dimnetc:r: RD, refcrenc<; dinmercr; DS, di:uneter stenosis; LU, 1= loss ind= 
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Figure] Intravasadar ultrasound images (Lift: and cl!7uTc) shrr,IJing a double lumen bct"Jlccn 12 and 3 o'clock 
postintcT"Vcntion. The right image sJurJlS the same fcsiqn at six momh follow up wUh tlu: unhealed false lumen seen bct::J)lxn 
11 and 2 0 'dod;. 
system was inserted over the guidewire and 
advanced such that the twO marker bands 
encompassed the angioplasty site. The 
guidcwire was removed and the radiation 
source tr:J.i.n containing 12 90$r seeds was posi-
tioned between the gold markers using fluoro-
scopic visualisation. The seeds remained in 
place for 2.5~3.5 minutes to deliver the 
assigned dose of radiation. Following irradia-
tion, repeat ongiography and IVUS pullback 
were performed. Intracoronary nitrates were 
administered before the treated artery was 
examined with IVUS. The 2.9 F NUS cath-
eter (CVIS, Sunnyvale) was advanced distal to 
the treated site. A continuous motoriscd 
pullback at a speed of 0.5 rru:n/s was carried 
out, followed by an angiographic control. At six 
month angiographic follow up, identical quan-
titative coronary angiography (QCA) and 
IVUS examination of the treated area was per-
formed. 
FijJW'c 2 Coronary angiogram showinJ:: (A) lesion pretreatment; (B) radicactive s= 
in ritu.; (C) posrintervcntifm;rmd (D) rhe same lesion at six monrhfollow up. NOliO the 
presence of an edge effeet and absence of angiographic dissection at six month folLrr,),) up. 
DEFINITIONS 
Dissection was defined both angiographically 
and by IVUS. Angiographic dissection was 
defined using the National Heart Lung and 
Blood Institute criteria for the classification of 
dissection. 'o QCA analysis was performed 
before the intervention, after treatment, md at 
si.x month follow up using identical gantry 
positions. Coronary angiography was per-
formed after intracoronary administration of 
nitrates. The offline analysis of at least two 
orthogonal projections was performed by 
means of the cardiovascular angiography 
analysis sytem (CAA.S IT, Pie Medical BV, 
Maastricht, The Netherlands). Calibration of 
the system was based on dimensions of the 
catheters not filled with contrast medium. This 
method of analysis has been previously 
validated. ~~~~ The following measurements 
were obtained in each projection: minimal 
luminal diameter (l'vU..D), reference diameter, 
% diameter stenosis, and lesion length. Lesion 
length was user defined and not done by an 
algorithm using curvamre analysis of the diam-
eter function. The reference diameter was 
obtained by an interpolated method. Acute 
gain was defined as MLD measured after 
treatment minus Ml.D preintervention. Late 
loss was defined as l'vU..D after treatment minus 
MLD at follow up. Late loss index was defined 
as late loss divided by acute gain. Restenosis 
was defined as > 50% diameter stenosis at fol-
low up and located within the treated area. 
IVUS dissection was defined as a longitudi-
nal tear p:JIallel to the vessel wall. '6 In all 
patients with IVUS detected dissection, length, 
arc, and depth were recorded. For inclusion in 
the study all dissections were located within the 
area treated by radiation. A.xial length was 
measured in mil.limetres. Circumferential ex-
tension was measured as an arc in degrees. The 
maximal depth of wall disruption was defined 
as follows: partial-plaque between tear and 
adventitia; complete-full thickness tear ex-
tending through the plaque to the adventitia. l > 
An IVUS dissection score was created to 
rank the severity of dissection (table 1). This 
score facilitates comparison of dissection after 
the procedure and at follow up. A.ssuming that 
a dissection is present, the potential range of 
the dissection score was 3-9. The dissection 
was considered to be healed when all feamres 
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Figure 3 This rvus image IXl1'I'Clatcs with the angiogram in iii: 2. The arrowlreads show 
the presence of an intact lumen (AJ and an unhcakdflap (B), rorrcspundirzg to rJu: same 
area, 
ii!J Acute gain 0 Late loss. Late Joss index I 
"4~ 1.2 
1 
, 
0.8 !-
0.6-
0.4 
0.2 
Hoalod 
(n = 8) 
Non-honlcd 
(n = 8) 
Figun: 4 QCA analysis of hcakd versus non-hcakd 
dissection (p = NS). 
of dissection had disappeared. Partial healing 
was considered to have occurred when at least 
one feature of dissection persisted at follow up. 
Absence ofhea1ing was defined as no change to 
the dissection on follow up. 
The prescribed radiation dose delivered to 
2 mm from the source was recorded and com-
pared between individuals with and without 
healed dissection. 
STATISTICAL ANALYSIS 
Quantitative data are presented as mean (SD). 
The non-paired twO tailed Student's t test was 
Table 4 Poslb/.tl:r1)C/'ltion and W: mcmh follow up of dissection cvaJuaud by lVUS 
used to compare dose levels and healedlnon-
healed clissection. 
Results 
BASEI.Dm CHARACTERISTICS 
From April to December 1997, 31 patients 
were treated at our institution according to the 
BERT 1.5 trial. Eight patients, who received 
stent implantation because of imponant recoil 
or :mgiogra.phic and rvus proven dissection 
after balloon angiopmsty, were excluded from 
the assessment. One patient refused rvus at 
follow up; the same patient had no evidence of 
dissection following treatment. Therefore the 
study population was 22 patients. The baseline 
characteristics of the patients are shown in 
table 2. 
CL:C'!ICAL, ANGIOGRAPHlC, AND NUS FOu.oW'V"P 
At follow up 14 patients (63%) remained 
asymptomatic. Si."< patients presented with 
stable angina pectoris: one with Canadian 
Cardiovascular Society (CCS) class 1 angina, 
one with CCS class 2, and four with CCS class 
3. The follow up angiography demonstrated 
restenosis (> 50% diameter stenosis on quanti-
tative coronary angiography) in five patients 
(24%). These included the four patients with 
CCS class 3 angina. One restenotic patient 
showed aneurysmatic formation within the 
irradiated area. The prescribed dose in resten-
otic patients was 12 Gy in one patient, 14 Gy 
in one patient, and 16 Gy in three patients. 
Dissection was seen in 16/22 patients (73%) 
after intervention using both angiographic and 
rvus criteria. At si." month follow up dissec-
tion was seen in si." patients on angiography 
(38%) and eight patients on NUS (50%) 
(table 3). Disagreement bernreen NUS and 
angiography was caused by the presence of a 
double lumen in one individual (fig 1) and a 
flap in another (:figs 2 and 3). neither of which 
was detected by angiography. P:..ngiographic 
analysis of healed versus non-healed dissection 
is presented in :fig 4. No difference was seen in 
the reference diameter. % di:lm.eter stenosis. 
and MLD before or after the procedure or at 
follow up for either the healed or the 
non-healed dissection groups (uble 3). As 
F\;mintm'WntUm FdWw,p 
IVUS lVUS 
Pmicnt A, LenKth (mm) D'Pm &p ,= A, l.cnGtl, (mm) rxpm Fiop ,~" 
60' 5 P N 4 60' P N , 
2 W 2 P N , 
3 90' 5 C N 6 
4 60' 5 P N 4 30' 2 P :N , 
5 90' 5 P N 5 30' 2 P N 3 
6 ISO" 2 C Y 7 IS0° 2 C Y 7 
7 90' 6 P Y 6 
8 1200 S P N 5 
9 IS0° 3 P N 5 1800 P N 5 
" 
2700 25 C N 8 
" 
90' 4 P N 4 
13 90' 6 P N 5 
16 90' 7 P N , 90' P N 
" 
120" 6 C N 6 
19 90' 7 P N 5 90' 5 P N 5 
zo 1200 3 P Y 5 1200 3 P Y 5 
M,~ 112° 6.2 P", 12/16 :N '" 13/16 5.2 98' 3.4 P:=7IS N"'6IS 4.6 
P, pnrti:tl~ C, complete; N, no; y, yes 
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expected late loss and late loss index were 
greater in the healed dissection group, but the 
difference was not significant. Eight patients 
had persisting dissection after IVUS 
examination-si.x bad no evidence of healing 
and two had partial healing (table 4). Three of 
the healed dissections resulted in restenosis. 
The mem IVUS dissection score was 5.2 
(range 3-8) after the procedure and 4.6 (range 
3-7) at follow up. IVUS healed dissection 
received a mean prescribed dose of 14 Gy and 
non-healed dissection received 13.8 Gy (p 
value not significant). 
Discussion 
We describe coronary artery dissection follow-
ing intracoronary radiation treatment in a 
group of individuals who had dissection noted 
angiograprucally and with IVUS, but who did 
not undergo stent implantation as the lesion 
appeared stable under standard clinical condi-
tions. These dissections were not associated 
with any significant acute or subacute clinical 
sequelae. What is remarkable is that after six 
month follow up, six of the angiographic 
dissections and eight of the NUS proven dis-
sections persisted. In a similar patient popula-
tion who had undergone conventional balloon 
angiopbsty (n = 183),87 patients (47%) suf-
fered a type A-C dissection after coronary 
angiopbsty. Only one dissection persisted at 
sL"( month follow up coronary angiography 
(DEBATE 1 subanalysis, unpublished data, 
1999). 
Why should these dissections fail to heal in a 
predictable manner as previously described in 
conventional angioplasty? In an e..'qlerimental 
model, a reduction of cell proliferation in the 
media and adventitia has been observed in the 
early phase after balloon injury and radiation 
treatment. Furthermore, the e..'qlression of a. 
smooth muscle actin in the adventitia is 
reduced after radiation treatment, suggesting a 
positive effect on vascular remodelling.~) Con-
sequently it appears that radiation treatment is 
directly implicated in altering the healing proc-
ess after balloon angioplasty, increasing the 
potential for positive remodelling,24 arterial 
dilatation, and non-healing dissection. 
It remains uncertain as to whether the 
dissections described represent permanent dis-
ruptions to the vessel wall or merely a retarda-
tion in the healing process. The possible 
inhibitory healing effect of radiation may 
diminish with time such that at a critical point 
there may be a further activation of the resten-
otic process associated with the healing of the 
dissection. 
In an animal model, Farb and colleagues 
showed a reduction in neointimal formation in 
3~P-emitting radioactive stents three months 
after implantation; endothelialisation was in-
complete, however, with only one third of the 
entire intimal surface showing endothelialisa-
tion with poor formation of cell junctions.~5 As 
a result of incomplete or delayed endotheliali-
sation, late thrombosis may also occur among 
the described dissections. It therefore would be 
of considerable interest to repeat rvus assess-
ment of individuals undergoing intracoronary 
radiation treatment at a later date (12-18 
months postintervention) so as to see if there is 
evidence of persisting dissection or of wound 
healinglrestenosis, which may present in a 
delayed fashion.~" 
Although the dissections did not lead to an 
increase of cardiac events in our population, 
Preisack and colleagues recently described a 
higher event rate in patients who suffered cor-
onary dissections after balloon dilatation only.~1 
In this study, the dissection type was highly 
correlated with the probability of a clinical 
event. Other authors have not found a 
difference in sL"( month clinical event rate in 
patients with stable coronary dissections.;>I\ 
We feel that additional stent implantation 
may be justified in patients with dissections 
who are about to receive brachytherapy follow-
ing balloon angioplasty. This approach may be 
warranted even if the dissection is stable. After 
stent implantation in these circumstances, we 
feel that a long term antiplatelet regimen (> 3 
months) may prove helpful in the prevention of 
late thrombotic occlusion, given re-
endothelialisation seems to be delayed in this 
patient cohort. 
There have been no reports on 'Y radiation 
causing interference with the healing of dissec-
tion. Compared with 'Y radiation a higher dose 
of ~ energy is required in the near field to 
deliver the prescribed dose to 2 mm. This 
intrinsic feature of ~ radiation may be causing 
the deleterious effect wimessed. 
The rvus dissection score was created to 
obtain a means of ranking and comparing dis-
section between postprocedural and follow up 
features. Up to this point, there has been no 
system that employs the well described features 
of dissection (arc, length, depth, and presence 
of flap) to create such a ranking. Clearly, the 
fate at six month follow up of rvus proven 
postprocedural dissection is not well described 
and we must rely on evidence that is e..'\."tr'acted 
from angiographic follow up data. An IVUS 
ranking system may be useful to describe the 
fate at follow up of dissection not only in the 
context of normal balloon angioplasty, but also 
after intracoronary radiotherapy. 
Using the prescnbed dose delivered to the 
total treated area there was no difference 
between the dose prescribed and the presence 
of non-healing dissection. On the one hand this 
relation may be genuine, on the other it may be 
argued that this lack of correlation results from 
the use of the measure of radiation received by 
the total vessel; this may not reflect the 
radiation dose received by the specific area of 
dissection,20 or the radiation which is poten-
tially transmitted down the disrupted tissue 
planes of the dissection. It is possible that such 
tissue planes may permit greater passage of 
radiation with deleterious consequences such 
non-healing or aneurysmal change. Equally, it 
is possible that certain tissue characteristics, 
such as heavy calcification, may interrupt 
radiation dosing to the level of the adventitia. 
Clearly, rvus provides superior information to 
angiography in descnoing tissue characteristics 
and is likely to be an integral part in the calcu-
lation of appropriate radiation dose in the 
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furure/" so as to Dl3XllD.lse efficacy and 
minllnise the complications of over- and 
underdosmg. 
The design of the radioactive source delivery 
catheter may also be relevant to its efficacy. A 
non-centred catheter as used in this study may 
lead to inhomogeneous dosing. Alternative 
centred devices are available; however, the 
issue is as yet unresolved and 'Will be the subject 
of further research.)O 
il.'."UTATIONS 
We describe the phenomenon of non-healing 
coronary anery dissection after balloon angio-
plasty in a small group of patients. The 
outcome of dissection in those with flow limit-
ing dissection has not been defined, as these 
individuals all had stents implanted. The 
angiographic dissection control group for this 
study is historical and there is no good descrip-
tion in the literature on the long term outcome 
of those with rvus proven dissection. 
CONCLUSION 
~ Radiation alters the normal healing process, 
resulting in unhealed dissection in certain indi-
viduals. In view of the delayed and abnormal 
healing witnessed, long term follow up may be 
prudent. Although no increase in cardiac 
events at SL-': months following coronary dissec-
tion was seen in this cohort, larger populations 
are needed to confirm this phenomenon. 
Stenting of all coronary dissections and the use 
of prolonged courses of antiplatelet agents may 
be warranted in patients scheduled for brachy-
therapy following balloon angioplasry. 
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ABSTRACT 
Backgronnd Recent trials in humans have given us insight into some of the consequences 
of intracoronary radiation. We describe a new observation noted on intravascular 
ultrasound (IVUS): that of intraluminal echo-lucent tissue, dubbed the 'black hole', 
noted at 6-month follow-up. 
Methods and Results We analyzed 128 consecutive patients enrolled in brachytherapy 
protocols. The control group (C) consisted of individuals who underwent PTCA with 
(n = 48) and without (n = 22) stent implantation. Radiation groups included those who 
underwent low activity (LA) (n = 18), high activity (RA) (n = 26) and cold-end (CE) (n 
= 18) radioactive stenting. The Novoste Betacath (n = 39) and Guidant (n = 27) catheter-
based radiation systems were also employed. At 6 - month follow - up echo-lucent 
tissue was identified in a total of 28 cases (22%). Angiographic restenosis occurred in 
17 cases (61 %). Of those lesions with restenosis echo-lucent tissue comprised 50% of 
the neo-intimal hyperplasia. No echo-lucent tissue was seen in the control group or in 
the LA group. RA and CE radioactive stents were most commonly associated with echo-
lucent tissue (incidence 35% and 39% respectively). All occurred at the proximal or 
distal edges of radiation. Echo-lucent tissue was seen in all groups treated with catheter-
based radiation with and without stenting. Atherectomy was performed on 4 lesions. 
Pathology demonstrated smooth muscle cells scattered in extracellular matrix containing 
abundant proteoglycans and an absence of elastin and mature collagen. 
Conclusions This paper is the first to describe atherectomy samples extracted from 
humans after radioactive stent implantation. Also it is the first to link the IVUS finding 
of echolucency noted after intracoronary radiation with tissue rich in proteoglycans 
while poor in mature collagen and elastin 
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CONDENSED ABSTRACT 
Using IVUS we describe an echo-lucent 'black hole' following intracoronary radiation. 
Radiation groups (n=128) included those who underwent radioactive stenting and 
catheter-based radiation. In total 28 'black holes' (22%) were identified (radioactive 
stents (>6.0~Ci) =37%, catheter-based radiation =17%). Angiographic restenosis was 
a feature in 61 % of these cases. Of those lesions with restenosis echo-lucent tissue 
was on average responsible for 50% of NIH. Atherectomy was performed on 4 lesions. 
Pathology demonstrated smooth muscle cells scattered in extracellular matrix containing 
abundant proteoglycans and an absence of elastin and mature collagen. 
Key words: ultrasonics, radiation, proteoglycan. 
ABBREVIATIONS 
IVUS - intravascular ultrasound 
~Ci - microCurie 
NIH - neointimal hyperplasia 
SMC - smooth muscle cell 
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Intracoronary radiation, a therapeutic modality aimed at decreasing restenosis, has been 
investigated in both animals and humans for several years. With the advent of human 
trials we have started to understand the consequences of this treatment. These include 
non - healing dissection!, late occlusion' and positive remodeling'. We describe a 
further new finding: an echo-lucent area within the lumen of the coronary artery, noted 
using intravascular ultrasound (IVUS). This phenomenon has been dubbed the 'black 
hole'. We describe the finding in terms ofIVUS characteristics and present data on its 
incidence in various subgroups treated conventionally and with radiation. Finally we 
describe the pathological findings of this entity. 
METHODS 
We analyzed 12S consecutive patients enrolled in brachytherapy protocols, who had 
completed 6 - month follow-up that included angiography with IVUS. These protocols 
included individuals who had undergone catheter - based radiation using the "'Sr / 90y 
Betacath™ (Novoste, Norcross, Ga) and 32p Guidant (Santa Clara, CAl systems. The 
radioactive stent group comprised those who received 0.75 - 1.5iJ.Ci (n = IS), 6.0 -
12.0iJ.Ci (n = 26) and 'cold- end' (n = IS) stents (IsostentTM Inc., San Carlos, CA, USA). 
The control group included individuals who underwent PTCA with (n=4S) and without 
stent implantation (n=22). 
Catheter - based radiation 
The Novoste Betacath and the 32 P Guidant ~-radiation systems have been described in 
detail elsewhere 3.4 We followed certain steps to ensure the correct identification and analysis 
of the irradiated segment post intervention and at 6 - month follow - up. First, an angiogram 
was performed after positioning the delivery catheter and the relationship between anatomical 
landmarks and the two gold markers were noted. Typically, the aorto-ostial junction and the 
side branches were used as landmarks. The landmark closest to either of the gold markers 
was used as a guide. During the motorized IVUS pullback, all side branches were counted 
and the guiding landmark was identified. The correct selection of the marker was confirmed 
by visualizing the position of the IVUS probe during a contrast injection. At follow-up, we 
selected the same region of interest and compared it with that after treatment. 
Radioactive stent 
The properties oflow (0.75 - 1.5iJ.Ci) and higher activity (6.0 - 12.0iJ.Ci) radioactive 
stents and procedural characteristics specific to their implantation have been described 
elsewhere5 All stents were implanted with a stent to artery ratio of 1.1:1. 'Cold - end' 
stents were 27.3mm in length and available in diameters of 3.0 & 3.5 mm. The distal 
and proximal5.7mm of the stent was non-radioactive, whereas the central15.9mm had 
an activity of3.0-24.0 iJ.Ci (see Figure 1). 
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5.7mm 15.9mm 5.7mm 
.... --3.0-24.0IlCi--... •
~ 
Figure 1 16~1 
Cold~end stent with central radioactive segment and proximal and distal non-radioactive segments 
Figure 2 
Left coronary angiogram performed at 6-month fonow-up. Proximal in-stent restenosis is seen in a 
6·12J.1Ci stent implanted in the circumilex artery (left frame). 
IVUS performed at 6 month follow-up demonstrating homogeneous black tissue from 6 to 1 o'clock (right frame). 
Figure 3 
a. Baseline longitudinal rvus reconstruction of freshly implanted sterrt. 
b. Longitudinal reconstruction of the same transverse NUS image seen in Fig 2. This 
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IVUS Acquisition 
We used a mechanical 30MHz IVUS system (ClearView, CVIS, Sunnyvale, CAl. 
Motorized pullback was performed at O.5mm1sec. We examined the entire segment 
subjected to radiation, plus the associated 10mm proximal and distal edges. For 
radioactive stents this included 10mm proximal and distal to the final stent strut. Images 
were stored on S-VHS tape for later analysis. Findings were verified by 3 independent 
observers, who were blinded to whether images were from control or radiation cases. 
IVUS definition of echo-lucent tissue 
Lesions with the echo-lucent tissue had the following characteristics: a homogeneous 
black appearance without backscatter. Images with ring-down or other artefacts 
were excluded as were intraluminal echodense structures with associated attenuation. 
Exclusion of other causes of relative echolucency such as contrast", thrombus' or a 
lipid lakeS was performed. Lesions were discrete and readily distinguishable from 
conventional neointimal hyperplasia (Fig. 2, 3). After radioactive stenting all lesions 
were observed adjacent to stent struts. 
Definitions 
The following dimensions were measured in each group: total vessel area (TVA), 
lumen area (LA), the area of echo-lucent tissue and the percentage of neointimal 
hyperplasia (NIH) caused by the echo-lucent tissue in the cross-section of greatest 
stensosis. Restenosis at 6-month follow-up was defined using standard angiographic 
criteria after off-line quantitative coronary angiography (diameter stenosis> 50%). 
Medication 
All patients received clopidogre1 for between I month (conventional stenting) and 3-6 
months (stenting plus catheter - based radiation or radioactive stenting), plus life-long 
aspirin. 
Immunohistochemistry 
For immunostaining, sections were preincubated with 0.3% hydrogen peroxide and 
Protein Block Serum-Free (X0909, Dako Corp, CAl. A mouse monoclonal antibody 
against a-smooth muscle actin (1:5000 dilution, Dako) was used to identify smooth 
muscle cells. Polyclonal antibodies against biglycan (LF-51) and decorin (LF-122) were 
used for identification ofproteoglycans (antibodies kindly provided as a gift from Larry 
Fisher, NIH, Bethesda, Maryland). Before incubating with proteoglycan antibodies, 
sections were first incubated with lUlL chrondroitinase ABC (code # 1003 32, Seikagaku 
Corp., Tokyo, Japan) for 15 minutes at 37°C to detach glycosaminoglycan side chains 
from the protein core; this procedure intensifies staining'. All primary antibodies were 
incubated overnight in a humidified chamber at 4°C. After rinsing in PBS, the primary 
antibody was labeled by a biotinylated link antibody directed against mouse using a 
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peroxidase based LSAB kit (Dako). Positive staining (brown reaction product) was 
visualized with a diaminobenzidine (Dako). After irnmunostaining, the sections were 
counterstained with Gill's hematoxylin, dehydrated in a graded series of alcohols, rinsed 
in xylene and mounted in Pennount (Fisher Scientific). 
RESULTS 
At 6 - month follow - up 28 discrete areas of echo-lucent tissue ('black hole') (22%) 
were identified. No echo-lucent tissue was seen in the control group or in the low 
activity radioactive stent group. Angiographic restenosis was present in 61 % of cases 
where echo-lucent tissue was present. Of those lesions with restenosis, echo-lucent 
tissue was on average responsible for 50% of neointimal hyperplasia. More severe 
stenosis was more frequently observed in the 6.0-12.0/lCi and cold-end radioactive stent 
groups (mean stenosis = 63.1 % ± 24.1) compared with catheter-based techniques (mean 
stenosis = 37.2% ± 20.5), p=0.005. Mean length of the echo-lucent tissue was 4.0mm ± 
1.6mm (range 2-8mm). 
Radioactive stent 
Higher activity and cold-end radioactive stents were most commonly associated with 
echo-lucent tissue (Table I). All occurred at the proximal and distal margins of radiation 
within the stent or at the stent edges. By definition this fall-off in radiation occurred in 
the final 1-2mm of 6.0-12.0/lCi stents and in-stent for cold-end stents. Bilateral echo-
lucent tissue was seen in 5 out of 7 cases that presented with restenosis 6 months after 
cold-end stent implantation. In four of theses cases the proximal edge was more severely 
affected. 
Catheter-based 
Echo-lucent tissue was seen in all groups treated with catheter-based radiation with 
and without stenting. These tended to be smaller lesions than those seen in the 
radioactive stent group (Table I). After catheter-based radiation only one of the echo-
lucent tissues described involved geographical miss (area of injury associated with a falI-
off in radiation)lo. 
Pathology features 
Atherectomy was perfonned on 4 individuals (AtheroCath - Bantam™, DVI, Guidant, 
Temecula, CA, USA). Macroscopic assessment of the tissue samples showed two types 
of tissue: dark yellow, often containing pieces of stent strut and white more fibrotic 
appearing tissue (Fig. 4A). Microscopy revealed tissue containing smooth muscle cells 
in abundant extracellular matrix (myxoid change) with two distinct regions (Fig.4B, C) 
and containing abundant proteoglycans (Fig.4D). Region I (Fig 4E) was more cellular 
in nature, contained collagen and elastin (Fig 4C), and was not distinguishable from 
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Location %BHAofNIH Restenosis (QCA) 
Radioactive 
stent 
6-12 ,"Ci (n=26) 
I Pedge 96 Y 
2 P edge lOa y 
3 D edge 56 N 
4 Pedge 64 Y 
5 Pedge lOa y 
6 P edge 48 Y 
7 D edge 71 Y 
8 Pedge 52 N 
9 D edge 68 N 
cold-end (n= 18) 
10 Pin stent* lOa y 
11 Din stent* 42 N 
12 Pin stent* 50 N 
13 Din stent* 26 Y 
14 PIn stent* 48 Y 
15 Din stent* 38 N 
16 Pin stent* 51 Y 
GuidantCBS 
(n=16) 
17 In-stent 26 Y 
18 In-stent 34 N 
19 Out ofstent 45 Y 
Betacath CBS 
(n=18) 
20 In stent 48 N 
21 In-stent 26 Y 
22 In-stent 26 N 
23 In-stent 56 N 
Guidant: no %BHAofNIH Restenosis 
stent 
(n=l1) 
24 34 Y 
25 90 N 
Betacath: no 
stent (n=21) 
26 27 Y 
27 16 Y 
28 18 Y 
CBS-catheter-based radiation plus stenting. P=proximal. D=distal. * at junction of radioactive 
and non radioactive segment of the stent. NIH=neointimal hyperplasia. 
%BHA of NIH = % of NIH caused by echo-lucent tissue. 
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Figure 4 
Fig. 4A Gross macroscopy of atherectomy specimen, showing that darker more yellow tissue overlies stent 
strut remnants (arrow), with a cover that is white in appearance. 
Fig.4B. Hematoxylin-Eosin stain showing two distinct regions; region 1 being more cellular than region 2. 
Fig.4C. Elastin stain, showing that region 1 consists ofa more elastin and collagen rich tissue as compared 
to region 2. 
Fig.4D. Alcian Blue stain showing that the extracellular matrix contains large amounts of proteoglycans, 
most of which is hyaluronic acid (differential stain, not shown). 
Fig.4E. Detail of region 1, showing tissue that is similar in appearance to nonnal restenotic tissue. 
Fig. 4F. Detail of region 2, showing sparse and pyknotic cells. 
Fig 4G (Movat stain) and Fig 4H (H&E). Porcine model with 3~Ci stent at 6 months. Extensive NIH 
consisting of SMCs in a proteoglycan matrix. 
Figure 5 
Fig SA. Immunoperoxidase stained section showing a-actin positive smooth muscle cells. 
Fig 5B. lmmunoperoxidase stained section showing strong matrix positivity for biglycan. 
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normal restenotic tissue. Region 2 (Fig 4F) was more sparsely populated showing 
pyknotic nuclei, with some of the extracellular matrix having a coagulated or dense 
appearance (fibrinoid change). The latter was thought to be tissue constituting the echo-
lucent tissue. 
The area of the myxoid, proteoglycan rich matrix was thought to constitute the black 
hole. Three of the four biopsies were stained for a-actin (Fig 5A) to confirm presence of 
smooth muscle cells and for biglycan (Fig 5B), which is the dominant proteoglycan in 
restenotic lesions'. All three biopsies were strongly postive for biglycan and one biopsy 
stained for decorin was weakly positive. 
DISCUSSION 
Echo-lucent tissue ('black hole') noted at 6 - month follow-up was uniquely 
associated with intracoronary radiation. More common after radioactive stent (>6.0!J.Ci) 
implantation, it was frequently located adjacent to the stent struts in areas of radiation fall-
off, where it was associated with greater restenosis than the catheter-based techniques. 
Echo-lucent tissue may be a dominant cause of restenosis as seen in 4 patients (1,2,5 and 
10). Overall it appeared to contribute to approximately 50% of the restenotic burden 
associated with NIH seen at 6-month follow-up. The lesion may be missed on IVUS 
examination due to its echolucency, caused by tissue rich in proteoglycans and poor in 
mature collagen and elastin. 
What is unclear is the cause of such lesions. Certainly irradiation is associated with 
proteoglycan accumulation in various tissuesll .l2. Hehrlein has noted that the increase 
in neointimal volume in arteries treated with external beam radiation (EBR) was 
predominantly due to enhanced extracellular matrix production. This study suggested 
that the accumulation of extracellular matrix after stent deployment was augmented by 
external beam radiation and that excessive matrix formation was a determinant of failure 
of radiation therapy to prevent restenosis. The atherectomy samples of the current paper 
reflect changes seen in Carter's porcine modeP2 with radioactive stents (Fig 2G & H). 
Carter has reported myxoid changes in low, intermediate and high activity stents (30%, 
60% and 37% respectively) while no myxoid change was seen in control stents (personal 
communication, 2000). This would indicate that the echo-lucent tissue is a general 
response to irradiation of damaged vascular tissue. 
The matrix seen is rich in biglycan proteoglycan; biglycan secretion by smooth muscle 
cells in culture has been shown to be controlled by TGF_J3l3.l4. Therefore it is likely 
that radiation may induce greater TGF -13 production that results in excessive biglycan 
production and formation of echo-lucent tissue on IVUS. 
O'Brienl' and colleagues suggest that biglycan may bind apoE and apoB in atherosclerotic 
intima. They also raise the possibility that apoE may act as a bridging molecule that 
traps apoA-I-containing HDL in atherosclerotic intima. Taken together these findings 
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are consistent with the hypothesis that biglycan may contribute to the pathogenesis of 
atherosclerosis by trapping lipoproteins in the artery wall. 
Atherectomy samples taken at points where echo-lucent tissue is seen on IVUS shows 
aberrant nuclear morphology, suggesting ongoing cell death. This process continues 
to take place long after stent radioactivity has decreased to background levels. This 
indicates that radiation indeed has long-term effects. The presence of fibrinoid change 
may also be indicative of delayed healing, as was also seen in Carter's report. 
With time the echo-lucent tissue becomes more discernible on IVUS due to its echodense 
cap (Figure 3). This cap is also seen on pathology showing collagen and elastin - rich tissue. 
This may be in keeping with a phenotypic change in the SMCs, allowing them to produce 
collagen and elastin - rich matrix typical of mature NIH with a lack of proteoglycan. 
Conclusion 
This paper is the first to describe atherectomy samples extracted from humans after 
radioactive stent implantation. Also it is the first to link the IVUS finding of echolucency 
noted after intracoronary radiation in various modalities with tissue rich in proteoglycans 
while poor in mature collagen and elastin 
limitations 
Atherectomy was only performed in 4 patients and the findings described here will need 
to be substantiated with greater numbers. The issue of radioaction dosimetry is complex 
and fundamental, however is beyond the scope of this report. 
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Summery and Conclusions 
This thesis assesses issues central to intracoronary radiation and stent implantation. 
Part I addresses factors that affect the angiographic restenosis rate after stent 
implantation. The best predictors of restenosis were post-procedural stent diameter 
stenosis and vessel size. A simple reference chart was devised that defines the probability 
of angiographic restenosis at 6 months. 
Part II considers methodological issues important to the assessment oflesions that have 
undergone intracoronary radiation. These include relocation of the minimum lumen 
diameter (MLD) and geographical miss. Both issues were applicable to radioactive 
stents and catheter-based radiation. Geographical miss was germane to all radioactive 
stenting due to the configuration of the balloon on the stent, which left injured areas 
at the stent edges insufficiently treated with radiation. After catheter-based radiation 
late loss was noted to be significantly greater in edges that had geographic miss, than in 
uninjured edges. Similarly the restenosis rate was greater in these edges. 
Relocation of the MLD was more frequently observed in the catheter-based group. 
Since vessel enlargement frequently occurs at the site of the previous target lesion, the 
MLD may be relocated at follow-up to a different coronary subsegment. As a result 
discrepant results may be obtained depending on the region subject to the analysis. The 
definition and identification of the target segment, irradiated segment, injured segment 
and vessel segment may be helpful in the understanding of the mechanism of action of 
this treatment modality. 
In Part ill we discuss the evolution of radioactive stents through their initial human 
trials to later studies describing different stent configurations. Low activity stents did not 
demonstrate a significant improvement over placebo - a fact verified by clinical, QCA 
and IVUS criteria. By increasing the activity of the stent (6.0-12.0 !lCi), neointimal 
hyperplasia was decreased in-stent at 6-month follow-up, however probably due to a 
combination of sub optimal radiation and injury (geographical miss) there was evidence 
of a new entity descnbed as the edge - effect witnessed at the stent edges in 50% of 
cases. This interesting finding was subsequently also described after catheter - based 
radiation, both with and without stenting. The implementation of cold-end radioactive 
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stents regrettably did not prevent the edge - effect. Instead of restenosis occurring 
outside of the stent at the edges of radiation it occurred in-stent at the edges of radiation. 
Similarly the implementation of hot-end radioactive stents was unsuccessful. 
Although inhibition of neointimal hyperplasia was successful in-stent at 6 months at the 
activity level 6.0-12.0 /-lCi, this was not the case at 1 year. Here there was evidence of 
a late 'catch-up', which was unprecedented after conventional stenting. Consequently 
there was an excessive amount of patients who went onto late revascularization. 
Part IV explores aspects common to both radioactive stenting and catheter - based 
stenting and radiation. Using 3- dimensional rvus, positive geometric remodeling was 
described behind the stent after catheter - based radiation, but not after radioactive 
stenting at 0.75 - 12.0/-lCi. It remains unknown whether this increase in plaque 
became a nidus for subsequent restenosis. Equally one may hypothesize that this 
positive remodeling may leave the stent vulnerable to late thrombosis due to stent 
malapposition. 
The mechanism of edge restenosis was also described - in conventional angioplasty 
there is almost always some degree of edge renarrowing after stenting. This rarely 
is significant and generally accounts for 10-15% oflate lumen loss at the stent edges. 
Mechanistically this is due to negative remodeling at the stent edges with consequently a 
late lumen loss. In contrast the edge effect after radioactive stenting was due to a minor 
degree of negative remodeling and a major increase in plaque. 
In Part V we discuss complications witnessed thusfar. The entity of late thrombotic 
occlusion is extremely important. It occurs more frequently than after conventional 
balloon angioplasty or stent implantation. Several mechanisms are hypothesized as 
being involved in the mechanism: first a delay in stent endothelialization may occur 
after brachytherapy. Furthermore balloon-induced coronary artery dissection may not 
be healed during the follow-up period as witnessed in a substantial proportion of patients 
treated with balloon angioplasty and catheter-based radiation. Finally as discussed in 
previous chapters vascular enlargement may induce late stent malapposition which is a 
well-known substrate for stent thrombosis. 
Hypoechoic tissue, dubbed the 'black hole' was first described at 6-month follow-up 
after radioactive stenting. Such tissue was difficnlt to diagnose initially due to its 
echolucency. We were able to perform the first atherectomy procedures in humans. 
Theses demonstrated that the echolucent tissue was in fact predominantly proteoglycan 
with a paucity of collagenous tissue. Concern has been raised that such tissue may be 
the precursor of atherogenic tissue, explaining the late lumen loss (>6 month) in patients 
that have undergone radioactive stenting. 
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Summery and Conclusions 
Future directions of this treatment modality are uncertain. Certainly radioactive stents 
do not appear to have a clinical application in their current fonnat. Efficacy 
in preventing in-stent re-restenosis has been proven in 5 trials involving catheter-based 
gamma and beta radiation. This may be a niche for this treatment, pending the 
introduction of a more efficacious therapy. 
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Samenvaffing en Conclusies 
Dit proefschrift beschrijft onderwerpen met betrekking tot intracoronaire bestraling en 
stent implantatie. 
Deel! beschrijft faktoren die de angiografische restenose percentage na stent implantatie 
befuvloeden. De beste voorspellers van restenose waren stent lengte en in-stent minimale 
lumen oppervlakte na de index interventie. Een simpe1e referentietabel werd gemaakt, 
welke de waarschijnlijkheid van angiografische restenose na 6 maanden omschrijft. 
Deel II beschouwt methodologische kwesties, welke belangrijk zijn voor de beoordeling 
van lesies, die een intracoronaire bestraling hebben ondergaan. Deze omvatten de 
relokatie van het minimale lumen diameter (MLD) en geografische mis. Beide zijn zowel 
van toepassing op radioactieve stents als catheter-gebaseerde bestraling. Geografische 
mis was obligaat bij alle radioactieve stent implantaties ten gevolge van de configuratie 
van de ballon, waarmee de stent geilnplanteerd weni, welke beschadigde gebieden aan 
de stent randen veroorzaaktten welke onvoldoende behandeld werd met bestraling. Na 
de catheter-gebaseerde bestraling bleek het late lumen verlies significant groter te zijn 
in randen met geografische mis, dan in onbeschadigde randen. Het restenose percentage 
was vergelijkbaar ook groter in deze randen. 
Relokatie van de MLD werd meer frequent geobserveerd in de catheter-gebaseerde 
groep. Aangezien vergroting van het bloedvat vaker optreedt op de plaats van de vorige 
doellesie, kan de MLD bij controle verplaatst zijn naar een ander coronair subsegment. 
Hierdoor kunnen verschillende resultaten verkregen worden, aihankelijk welk gebied 
men in beschouwing nam voor de analyse. De definitie en indentificatie van het doel 
segment, bestraalde segment, beschadigde segment en bloedvatsegment kan nuttig zijn 
in het begrijpen van het mechanisme van werking van deze behandelingsmodaliteit. 
In Deel m bespreken we de evolutie van radioactieve stents vanafhet eerste gebruik in 
patientenstudies tot latere studies met verschillende stent configuraties. Lage activiteit 
stents toonden geen significante verbetering ten opzichte van placebo - een feit bevestigt 
door klinische, QCA en IVUS criteria. Door de activiteit van de stent te verhogen (6-12 
!lCi), werd de in-stent neointimale hyperplasie verminderd bij de 6-maands controle, 
echter waarschijnlijk door een combinatie van suboptimale bestraling en beschadiging 
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(geografische mis) was er een nieuw fenomeen ontstaan, welke werd omschreven als 
randen-effect, welke in 50% van de casussen werd waargenomen aan de randen van 
de stent. Deze interessante bevinding werd vervolgens ook beschreven na catheter-
gebaseerde bestraling, zowel met als zonder stent implantatie. De implantatie van Cold-
Ends radioactieve stents konden helaas niet het randen effect voorkomen. In plaats van 
restenose aan de buitenkant van de stent bij de randen van de bestraling, kwam de 
restenose in de stent aan de randen van de bestraling. De implantatie van Hot-Ends stents 
waren vergelijkbaar onsuccesvol. Alhoewel de inhibitie van neointimale hyperplasie in 
de stent succesvol was 6 maanden na implantatie van een stent met een activiteit van 
6-12 !-lCi, was dit niet het geval na 1 jaar. Er bleek sprake van een late "inhaalslag", 
welke na conventionele stent implantatie niet gezien wordt. Daardoor was een meer dan 
verwachte aantal patienten, welke een late revascularisatie ondergingen. 
Deel IV onderzocht aspekten gemeenschappelijk voor zowel radioactieve stents 
als stent implantatie gevolgd door catheter-gebaseerde bestraling. Met behulp van 
3-dirnensionele IVUS, werd positieve remodelering beschreven achter de stent na een 
catheter-gebaseerde bestraling, maar niet na implantatie van een radioactieve stent met 
een activiteit van 0.75-12 !-lCi. Het is onduidelijk of de geziene toename in plak een 
oorzaak was voor de dooropvolgende restenose. Tevens kan men veronderstellen dat 
deze positieve remodelering de stent vatbaar kan maken voor late thrombose ten gevolge 
van stent malappositie. 
Het mechanisme van randen restenose was ook eerder beschreven - in conventionele 
angioplastiek was er vrijwel altijd enige vernauwing aan de randen na een stent 
implantatie. Dit is zelden significant en speelt een rol voor 10-15% van het late 
lumen verlies aan de stent rand en. Mechanism gezien is dit ten gevolge van negatieve 
remodelering aan de randen met vervolgens een late lumen verlies. In contrast hiermee 
was het randen effect na de implantatie van radioactieve stents, welke ten gevolge van 
een kleine mate van negatieve remodelering is en een grote toename van de plak. 
In Deel V worden de complicaties, welke tot nu toe geobserveerd zijn, besproken. 
Het verschijnsel van late thrombotische occlusie is extreem belangrijk. Het treedt 
vaker op dan na conventionele ballonangioplastiek of stent implantatie. Verschillende 
mechanisme worden verondersteld betrokken te zijn in het mechanisme: Ten eerste 
een vertraging in de stent endothelialisatie kan optreden na brachytherapie. Bovendien 
kunnen de door de ballon veroorzaakte cornarre dissecties niet goed genezen gedurende 
de controle peri ode. Dit is bij een substantiele portie van de patienten waargenomen, 
welke behandeld zijn met een ballonangioplastiek gevolgd door een catheter-gebaseerde 
bestraling. Ten slotte, zoals in de vorige hoofdstukken is besproken, kan vatvergroting 
late stent maloppositie veroorzaken, welke een reeds bekende substraat is voor stent 
thrombose. 
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Samenva!ting en Conclusies 
Hypoechogene weefsel, genaamd het "zwarte gat" werd als eerste beschreven bij 
de 6-maands controle na een radioactieve stentimplantatie. Zulk weefsel was in het 
begin moeilijk te diagnostiseren door het echolucente karakter van dit weefsel. Wij 
hebben v~~r het eerst dit weefsel vanuit coronairen van patienten verkregen met behulp 
van atherectomie. Het verkregen materiaal toonde aan dat dit echolucente weefsel 
voomamelijk bestond uit proteoglycanen met een gebrek aan collageen weefsel. Er 
is bezorgdheid ontstaan dat dit weefsel de voorloper zijn kunnen zijn van atherogeen 
weefsel, welke het late lumen verlies (> 6 maanden) in patienten na een radioactieve 
stent implantatie zou verklaren. 
Toekomst verwachtigen van deze behandelingsmodaliteit blijven onzeker. Zeker 
radioactieve stent lijken geen klinische toepassing te hebben in hun huidige vorm. De 
effectiviteit in het voorkomen van in-stent re-restenose is aangetoond in 5 studies verricht 
met catheter-gebaseerde gamma en beta-bestraling. Dit zou de enige toepassing kunnen 
zijn voor deze behandeling, afhankelijk van de introductie van een meer effectieve 
behandeling. 
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